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Abstract
Activation of sex steroid receptors is a key event in the regulation of uterine function. 
The expression of sex steroid receptors such as Oestrogen and Progesterone have 
been well charaeterised in normal human endometrial tissue. Expression of the 
androgen receptor (AR) has not been well eharacterised. The characterisation of AR 
in human endometrium is important to determine the role of androgens in 
physiological uterine events such as implantation and menstruation.
The teiin “întraerinology” refers to the ability of a peripheral target tissue to 
synthesise sex steroids. The expression pattern of metabolising enzymes determines a 
tissues steroidogenic potential. Key sex steroid metabolising enzymes include the 
17 p-hydroxysteroid dehydrogenases (17P-HSD), 5a-reductases (5aR), 
3 p-hydroxysteroid dehydrogenases (3p-HSD) and Aromatase.
The objectives of this thesis were thus to determine in human endometrium:
1. The spatial and temporal expression of androgen receptor mRNA and protein 
in endometrium aeross the menstrual cycle.
2. The expression of critical androgen metabolising enzymes across the 
menstrual cycle - 17p-HSD type 2 mRNA and protein; 17P-HSD type 5 
mRNA; 3P-HSD type 1 and 2 mRNA; and 5aR types 1 and 2 mRNA.
3. The spatial and temporal localisation, in endometrium exposed to high dose 
intra-uterine levonorgestrel, of AR mRNA and protein; 17p-HSD2 mRNA 
and protein; 17P-HSD5 mRNA; 3p-HSDl and 2 mRNA; and 5aR l and 2 
mRNA.
Endometrial biopsies from both noiinal endometrium and endometrium 
exposed to high dose intra-uterine levonorgestrel were subjected to optimised 
immunohistochemical protocols to detennine the spatial and temporal 
innnunolocalisation of the androgen receptor and 17p~HSD2. hi-situ hybridisation 
(ISH) techniques were employed to localise AR mRNA in full thiclaiess endometrial 
biopsies. Taqman real time RT-PCR examined the temporal variation in mRNA 
expression for AR; 17(3-HSD2 and 5; 3p-HSDl and 2; and 5aR l and 2 in normal 
endometrium and endometrium exposed to high dose intra-uterine levonorgestrel.
The results detennined that AR is expressed in the endometrial stromal 
compartment with down regulation of AR protein and mRNA in the late secretory
phase. This localisation was confirmed with ISH data. Endometrium exposed to high 
dose intra-uterine levonorgestrel exhibits a significant decrease in stromal AR 
protein immunoreactivity when compared with proliferative endometrium.
Temporal variations in expression of steroid metabolising enzymes were 
studied. Significantly elevated levels of 17p-HSD2 are expressed in the glandular 
compartment of mid secretory phase endometrium. Endometrium exposed to high 
dose levonorgestrel exhibited high levels of endometrial 17p-HSD2 protein in the 
first month after insertion of a LNG lUS, associated with high levels of 17p-HSD2 
mRNA expression in endometrial tissue at the three month time point. Thus, 
increased levels of 17p-HSD2 would indicate the potential for lowered intracellular 
oestradiol levels at this time (since this enzyme converts oestradiol to the less potent 
oestrogen, oestrone). Thereafter, levels of 17P-HSD2 protein and mRNA 
significantly decline. 17P-HSD5 mRNA is also significantly increased in the mid 
secretory phase.
The peri-menstrual period is associated with significant elevations in mRNA 
levels for both 3p-HSD enzymes and 5aR  2. 5aR 1 is significantly elevated in the 
mid-cycle phases. In endometrium exposed to high dose intrauterine levonorgestrel, 
an increased expression of 3p-HSD and a reduced expression of 5aR 2 are noted.
In conclusion, AR had been localised to the endometrial stromal compartment 
with a significant down regulation noted in the late secretory phase. The expression 
pattern of metabolising enzymes identified in this study is consistent with the 
secretory phase human endometrium possessing significantly greater steroidogenic 
potential than the proliferative phase. Furthemiore, the available literature suggests 
that secretory endometrium is a significant source of androgen production. Data has 
been published that implicates androgens as having an important role in 
physiological events such as implantation. However, the precise role and regulation 
of androgens, the androgen receptor and the metabolising enzymes in human 
endometrium requires further study.
Novel data is also described here regarding the effect of high local doses of 
progestogen on local tissue androgen receptor and sex steroid metabolising enzymes. 
Such data suggests a potential role for progestogens in influencing the uterine 
enviromnent that may lead to novel interventions for the problematic breakthrough 
bleeding suffered by progestogen only contraceptive users.
Declaration
Except where due acknowledgement is made by reference, the studies undertaken in 
this thesis were the unaided work of the author. No part of this work has been 
previously accepted for, or is currently being submitted in candidature for another 
degree.
Studies investigating the expression of Androgen Receptor (AR) mRNA expression 
in human endometrium using in-situ hybridisation were conducted by Dr Ov 
Slayden. This aspect of the study was performed at the Oregon National Primate 
Research Centre (ONPRC).
Dr Kevin Anthony Burton
Acknowledgements
I would like to thank my principal supervisor Professor Hilary Critchley for her 
consistent support, guidance, and encouragement. I would also like to thank 
Professor Ian Mason, Professor Steve Hillier and Dr Fouad Habib for their valuable 
guidance, insight and diseussions throughout my research. The combined effort of all 
my supervisors is greatly appreciated. Invaluable contributions to discussions were 
also provided by Professor Robert Brenner of the Oregon National Primate Research 
Centre (ONPRC).
The Centre for Reproduetive Biology is a fantastic research community where all 
members of staff were generous with their support and time. I would like them all to 
know this was gratefully appreciated. My thanks also to those who suffered the 
misfortune of sharing a laboratory with me. In particular, the help and friendship 
from Teresa Henderson, Stuart Milne, Deborah Niven, and Susan Brechin 
significantly contributed to the completion of this thesis.
I wish to acknowledge Joan Creiger and Catherine Murray for their assistance with 
patient recruitment and thanlc you to the ward, clinic and theatre staff of Edinburgh 
Royal Infirmary for their help with the recruitment process. Dr A.R.W. Williams also 
provided crucial expertise in the assessment of endometrial biopsies that was greatly 
appreeiated. Many thanks also to Professor Rodney Kelly for his helpful advice with 
quantitative RT-PCR. Thank you also to the staff of the Reproductive Medieine 
Laboratories, Edinburgh for performing oestradiol and progesterone 
radioimmunoassay. The help and tutorials provided in the preparation of graphical 
materials by Ted Pinner were also appreciated. I am indebted to the support provided 
by RCOG/Wellbeing (Ref C2/99) who funded my research enabling me to submit 
my MD thesis.
Finally, I would like to thanlc my family for their support throughout my research and 
completion of my MD Thesis. My wife Joainie and our sons Matthew and Euan 
deserve particular thanlcs for their support and encouragement.
Abbreviations
Analysis of Variance 
Androgen Receptor 
Aromatase
Avidin-Biotin Peroxidase 
BLAST
Breakthrough Bleeding 
Cyclooxygenase 2 
Complementary DNA 
Diaminobenzidine tetra hydrochloride 
Dehydroepiandrosterone 
Dehydro epiandro sterone-sulphate 
Dihydrotestosterone 
Deoxyribonucleic Acid 
Extracellular Matrix 
Follicle Stimulating Hormone 
Glucocorticoid receptor 
Hormone Response Elements 
In-situ Hybridisation 
Immunohistochemistry 
Immunoglobulin
Levonorgestrel Releasing Intra-Uterine 
Luteinising Honnone 
Matrix Metalloproteinases 
Messenger RNA 
Mifepristone 
Oestrogen Receptor 
Oestrogen Receptor alpha 
Oestrogen Receptor beta 
Phosphate-buffered saline 
Polycystic ovarian syndrome 
Polymerase Chain Reaction 
Progesterone receptor
(ANOVA)
(AR)
(P450aroni)
(ABC)
(Basic Local Alignment Search Tool) 
(BTB)
(C0X2)
(cDNA)
(DAB)
(DHEA)
(DHEAS)
(DHT)
(DNA)
(ECM)
(FSH)
(GR)
(HRE)
(ISH)
(IHC)
(IgG)
System (LNG-IUS)
(LH)
(MMP)
(mRNA)
(RU486)
(ER)
(ERa)
(ER(3)
(PBS)
(PCOS)
(PCR)
(PR)
Progesterone receptor A (PR-A)
Progesterone receptor B (PR-B)
Real Time Quantitative Reverse Transcription -  PCR (Q-RT PCR)
Ribonucleic Acid (RNA)
Standard Error of the Mean (SEM)
Tris buffered saline (TBS)
Uterine NIC cells (CD 56 CD 16 ) (uNK)
Vascular endothelial growth factor (VEGF)
3 (3-PIydroxysteroid Dehydrogenases (3P-HSD)
5a-Reductases (5aR)
17 p-Hydroxysteroid Dehydrogenases (17P-HSD)
20a-Hydroxysteroid Dehydrogenase (20a-HSD)
Chapter 1
Literature Review
10
1.1 General Introduction
The endometrium is a dynamic target organ, the development and function of which 
is regulated by the action of sex steroids such as oestrogens and progesterone. The 
other major group of sex steroids are the androgens, and their contribution to 
endometrial function constitutes an under researched aspect of endometrial biology. 
This thesis summarises the published data regarding the role of androgens and the 
androgen receptor in human endometrium and highlights under researched areas 
pertaining to androgen receptor expression and regulation in the human 
endometrium. Furthemiore, new data are presented that will contribute to our 
understanding of the role of androgens in endometrial physiology.
Menstruation signals the end of one ovarian cycle and the initiation of a new 
cycle. Oestradiol levels rise during the proliferative phase of the cycle and are 
responsible for stimulating endometrial growth and proliferation. The combined 
aetivity of oestradiol and progesterone in the secretory phase then prepares the 
endometrium for possible blastocyst implantation. Following the release of an oocyte 
at ovulation, the secretory phase of the cycle commences and there is concun-ent 
lutéinisation of the theca cells to produce the corpus luteum. The corpus luteum is 
then responsible for the production and secretion of progesterone producing the 
elevated levels associated with the secretory phase. The secretory endometrium then 
undergoes functional and morphological differentiation under the influence of 
progesterone, preparing for blastocyst implantation. However, should implantation 
fail to occur then luteolysis of the corpus luteum results in falling progesterone 
levels, initiating a cascade of events that results in shedding of the superficial 
endometrium, menstmation, and thereafter a new cycle begins.
The physiological mechanisms controlling endometrial growth, development 
and menstruation are areas of ongoing research where the precise mechanisms 
remain elusive. Only through establishing the normal physiological events can the 
mechanisms of endometrial dysfunction be better understood. Endometrial 
dysfunction encompasses a range of clinical problems including subfertility, 
menorrhagia, and benign or malignant neoplastic changes. Through understanding 
the normal physiology of endometrial development, we may then be able to target 
and manipulate normal physiological events to achieve therapeutic interventions for
11
endometrial dysfunction. For example, progesterone only contraceptive users may 
benefit from an intervention to prevent the troublesome problem of breakthrough 
bleeding.
Sex steroids (ligands) play a critical role in regulating physiological 
endometrial function. The response elicited will be determined by which ligand binds 
to which sex steroid receptor. Therefore, factors controlling ligand and receptor 
availability are important in determining the response of target organs. Ligand and 
receptor availability may be regulated in endocrine, paracrine and autocrine 
mechanisms but more recently research has highlighted the important role that 
intracrine regulation has to play through influencing ligand availability.
Intracrinology is a term that was first used by Labrie et al in 1988 (Labrie 
1988). In essence it refers to the ability of peripheral target tissues to activate or 
inactivate steroid ligands in the same cell that the steroid action is exerted, without 
release and dilution of the active hormones in the extracellular space or general 
circulation (Labrie 1991). Thus, the rate of formation of each sex steroid ligand 
depends upon the activity of the specific sex steroid metabolising enzymes in each 
cell o f each tissue (Labrie 1991; Stewart et al. 1992). The key enzymes responsible 
for androgen, oestrogen and progesterone interconversion include the 17(3- 
hydroxysteroid dehydrogenases, 3(3-hydroxysteroid dehydrogenases, 5a-reductases, 
and Aromatase. The expression of the different isofoiins for each enzyme family has 
been under researched in part due to the recent determination of human isoforms that 
were previously unlmown.
The temporal and spatial distribution of the oestrogen (ER) and progesterone 
receptor (PR) in human endometrium has been well characterised. In contrast, a clear 
characterisation has not yet been established for the androgen receptor (AR). When 
the temporal and spatial distribution of AR has been established, it may then be 
possible to hypothesise as to its role in human endometrium.
The literature review that follows will expand on the published data, which 
have been summarised in this short introduetion, to illustrate the important role that 
androgens may play in endometrial physiology and where research may be directed.
12
1.2 Steroidogenesis
The uterus and in particular the endometrium are, as previously stated, steroid 
responsive tissues. The classical endocrine organs responsible for steroid production 
in the female are the adrenal gland and the ovary. In particular, the production and 
secretion of sex steroids, such as oestradiol and progesterone, is a major function of 
the ovary.
The hormone secreting component of the ovary is the theca cell-granulosa 
cell unit. Following a brief overview each component shall be described in turn 
illustrating the production of oestrogen and progesterone tlnough the cycle. The 
temporal secretion of sex steroids in the female circulation is illustrated in Figure 1.1.
The primordial follicles of the ovary are single oocytes surrounded by a layer 
of granulosa cells that are in turn suiTounded by stromal cells of the ovary that will 
become the theca interna and externa. The ovary has its highest complement of 
oocytes in-utero where at a gestation of 5 months the number of oocytes is 
approximately 7 million. By birth, this number has declined to 1 million and by the 
menopause to less than 1000. Mathematical models based upon studies examining 
the follicle content of human ovaries at a range of maternal ages have shown this 
decline to be bimodal with a constant rate of decline from birth followed by a rapid 
phase of decline after the age of 37.5 years (Faddy et al. 1992).
Following puberty, the arcuate nucleus of the hypothalamus secretes 
gonadotrophin releasing honnone (GnRH) in a pulsatile mamier. This is then 
transported via and secreted fi'om the hypophyseal portal venous plexus connecting 
the hypothalamus to the anterior pituitary gland. In the anterior pituitary GnRH 
stimulates secretion of Follicle Stimulating Hormone (FSH) and Luteinising 
Hormone (LH). Elevated FSH recruits follicles from the ovary with a dominant 
follicle being selected and the remaining follicles becoming atretic. This dominant 
follicle will then become the major source of oestradiol synthesis. Figure 1.3 
illustrates the two cell two gonadotrophin (Short 1962; Lieberman 1996) mechanism 
of oestradiol synthesis.
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Figure 1.1
Temporal variation in serum oestradiol, progesterone and testosterone levels 
graphically depicted in relation to the menstrual cycle and ovarian follicle/corpus 
luteum development. There is no significant change in serum free testosterone 
through the menstrual cycle (Massafra et al. 2003).
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Under the influence o f LH, theca cells metabolise cholesterol into androstenedione. 
The granulosa cells then metabolise the androstenedione produced by the theca cells 
into oestradiol under the control o f FSH. Thus, both cell types and both 
gonadotrophins are crucial to oestrogen synthesis (McNatty et al. 1980). Figure 1.2 
shows an electron microscope image o f  a graffian follicle with all the components o f  
the follicle labeled.
Following ovulation, lutéinisation o f  the theca-granulosa layers occurs 
commencing production and secretion o f  progesterone. This ovarian region is now  
termed the corpus luteum and is the principal source o f  progesterone production in 
the secretory phase o f  the menstrual cycle.
Serum androgens are abundant in the systemic circulation as the adrenal is 
the major producer o f androgens in the form o f dehydroepiandrosterone (DHEA). In 
addition to being an androgen, DHEA is also an important substrate for the 
production o f oestradiol, progesterone and testosterone.
Figure 1.2 An electron microscopy image o f a graffian follicle with the oocyte O, 
Granulosa cells G, Theca Interna TI, and Theca Externa TE indicated on the image.
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Figure 1.3
Two-cell two-gonadotrophin theory. Steroid synthesis pathways shown in respective 
cells with key enzymes also indicated. Androstenedione produced by the theca cells 
is then converted to oestradiol in the granulosa cells. 3p-HSD -  3p hydroxysteroid 
dehydrogenase, 17P-HSD- 17p hydroxysteroid dehydrogenase
17
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1.2.1 Theca cell Androgen Synthesis
The classic pathway of sex steroid biosynthesis in the ovary (C27 cholesterol -> C21 
progestogen ^  C19 androgen C|g oestrogen) commences with either cholesterol 
that has been synthesised de novo or obtained from the peripheral circulation. 
Cholesterol is then metabolised to pregnenolone by the enzyme cholesterol side- 
chain cleavage (P450scc) (Sasano et al. 1989). 17-hydroxylase/C 17-20-lyase 
(P450cl7) is then responsible within the theca cells for the metabolism of 
pregnenolone to DHEA (Sasano et al. 1989). DHEA is then metabolised to 
androstenedione by 3p-hydroxysteroid dehydrogenase (3p-HSD). 3p~HSD can also 
metabolise progesterone to androstenedione by the sequential actions of P450cl7 and 
3P-HSD (Hillier et al. 1997).
Diffusion of androstenedione then occurs from the theca interna to the 
granulosa cells surrounding the oocyte. Theca cells do not express aromatase and are 
therefore unable to synthesize oestrogens de novo from androgenic precursors such 
as androstenedione.
1.2.2 Granulosa Cell Oestrogen Synthesis
Following diffusion of androstenedione, the granulosa cell is responsible for the 
production of oestrogens. While the granulosa cells do not express the enzymes 
necessary to produce androgens from cholesterol, they do express; members of the 
17P-hydroxysteroid dehydrogenase (17P-HSD) family (Tremblay et al. 1989; Qin et 
al. 2000), 3p-HSD (Sasano et al. 1990), as well as aromatase. Aromatase in particular 
is almost exclusively expressed in granulosa cells (Sasano et al. 1989). Hillier et al. 
demonstrated that 99.9% of aromatase activity was in this cell layer (Hillier et al. 
1981). The association of such enzymes in the granulosa cell allows the 
interconversion of androgens and oestrogens with the main frmction being 
production of oestradiol with FSH playing a key role in production.
In the granulosa cell, androstenedione may be metabolized to oestradiol by 
either of two pathways. Firstly, it may be ai'omatised to oestrone then metabolised to 
oestradiol by the action of 17p-HSD 1 or alternatively androstenedione may be 
metabolised to testosterone by 17p-HSD 1 and then aromatised to oestradiol by 
aromatase (Figure 1.4). The oestradiol produced may then enter the fluid of the antral 
follicle or be secreted into the bloodstream.
19
1.2.3 Corpus Luteum
Following the selection of a dominant pre-ovulatory follicle, it is favoured 
developmentally through the activation of a positive feedback loop. The oestrogen 
produced by the follicle stimulates gi'anulosa cell proliferation, in addition to 
augmenting cellular responsiveness to gonadotrophins, thereby generating additional 
oestrogen fonnation (McNatty 1981). The dominant follicle contributes 95% of the 
serum oestradiol concentrations illustrating its ability to produce oestradiol (Baird et 
al. 1974). Oestradiol augments pituitary LH release, although the mechanism is 
unlmown (Shoham et al. 1996).
Ovulation is triggered by the mid-cycle LH surge, which is itself triggered by 
the sustained high circulatory level of oestradiol produced by the pre-ovulatory 
follicle. The LH surge initiates resumption of meiosis in the oocyte, lutéinisation of 
the granulosa cells, and synthesis of prostaglandins (Shoham et al. 1996).
Following ovulation the gi'anulosa and theca cells undergo angiogenic and 
mitogenic stimulation (McCracken et al. 1999). The luteal cells accumulate lipoid 
vacuoles rich in cholesterol, producing the characteristic yellow appearance. 
Cholesterol acts as a substrate for steroidogenesis with progesterone being the 
principal sex steroid produced. Progesterone secretion peaks about 8  days following 
the LH surge inducing secretory changes in the endometrium, in anticipation of 
possible blastocyst implantation. To maintain the corpus luteum and its attendant 
steroidogenesis, it requires Human Chorionic Gonadotrophin (HCG) secreted from a 
developing placenta. When no blastocyst implantation occurs, the corpus luteum 
undergoes luteolysis.
Luteolysis and the resultant decline in serum progesterone, results in a 
cascade of events leading to endometrial breakdown and menstruation. The role of 
progesterone in menstmation shall be discussed in Chapter 1.8.1.
20
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1.2.4 Adrenal Androgen Steroidogenesis
The adrenal gland is divided into the medulla and cortex with the cortex divided into 
a hirther 3 zones; the outer zona glomerulosa, the zona fasciculata and the inner 
reticularis. Adrenal androgens are thought to arise from the reticularis zone and it 
contains the enzymatic profile that is favourable for DHEA and DHEAS production 
(McKenna et al. 1997).
The onset of adrenal androgen production is termed adrenarche, occurring in 
children from the age of 6  -  8 . 60 -  75% of circulating androgens in women arise 
directly or indirectly from the adrenal glands and 25 -  40% from the ovaries 
(McKenna et al. 1997). Androgens include testosterone, dihydrotestosterone, 
androstenedione, dehydroepiandrosterone (DHEA), and DHEA-sulphate (DHEAS). 
With regards to serum testosterone the adrenal gland is responsible for 25%, the 
ovary for 25% and the remaining 50% from peripheral conversion. The adrenal gland 
is the dominant source of testosterone precursors. The mechanism whereby adrenal 
androgen secretion is controlled is not yet known but it is thought to be related in 
part to adrenocorticotrophin (ACTH) secretion (McKenna et al. 1991). Figure 1.5
Cortisol secretion from the adrenal gland is known to be controlled by ACTH 
from the pituitary gland. During childhood, cortisol and ACTH levels are closely 
correlated but adrenal androgens bear no such close correlation (Cutler et al. 1979). 
However, exogenous ACTH results in elevated cortisol and adrenal androgen 
production. ACTH is Imown to be under very sensitive negative feedback control 
from cortisol, but no such mechanism is thought to exist for adrenal androgens. It 
would therefore appear that ACTH plays a role in the regulation of adrenal androgen 
secretion but other factors are thought to be involved. These factors include 
prolactin, growth hormone, insulin, sex steroids and a cortical androgen stimulating 
hormone has been proposed (McKenna et al. 1997).
23
Figure 1.5.
Fligher control of ovarian and adrenal androgen production via luteinising hormone 
(LH) and adrenocorticotrophin (ACTH). The predominant androgen produced by 
each tissue is indicated, with the uterus shown as an example target organ. The 
ovarian and adrenal contribution to serum androgen secretion is also shown with red 
figures inset between the illustrations.
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1.3 Sex Steroid Hormones Mechanism of Action
Having established in broad terms the sites of sex steroid hormone synthesis and the 
temporal variation of the endocrine levels of hormone tlii'ough the menstrual cycle it 
remains to describe their mechanism of action in target tissues. The steroid ligands 
classically bind to nuclear receptors, initiating a genomic response. In essence the 
nuclear receptors are ligand-inducible transcription factors whose primary function is 
to mediate the transcriptional response in target cells to hormones such as the sex 
steroids (androgens, oestrogens and progestins), adrenal steroids (glucocorticoids, 
mineralocorticoids), vitamin D3, thyroid hormones and retinoid honnones, in 
addition to a variety of other metabolic ligands. These protein receptors constitute the 
Nuclear Receptor Superfamily (Evans 1988; Soontjens et ah 1996; McKenna et ah 
1999). More recently a fuither, Non-Genomic, mechanism of action for sex steroids 
has been recognised. Non-Genomic responses are in contrast to genomic responses, 
rapid and their response is not inhibited by agents that inlaibit transcription or 
translation, e.g. actinomycin-D or cycloheximide.
1.3.1 Genomic Mechanism of Action
Phylogenetic studies in the mid to late 80’s determined that the members of the 
family were evolutionarily related (Amero et ah 1992; Laudet et ah 1992). They are 
subdivided into 3 subclasses: Type 1, Type II and Orphan receptors. Type 1 or 
“Classical” receptors includes the AR, PR, ER, Glucocorticoid receptor (GR), and 
Mineralocorticoid receptor. Type II receptors encompass the thyioid receptor, 
retinoic acid receptors, and vitamin D3 receptors. Orphan receptors are a relatively 
new class of receptors. Cloning studies have identified a large number of previously 
unknown genes that have sequence homology to the steroid homione receptor 
superfaniily, however the ligands for these proteins (Orphan Receptors) are not 
known and are currently being characterised (Soontjens et ah 1996; McKenna et ah 
1999).
The receptors share a common domain structure with the regions of the 
receptor being subdivided into regions A -  F. The A/B domain contains a 
transactivation function that allows the activation of target genes and presumably 
detemiines target gene specificity. The C region is the DNA binding domain and is
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responsible for DNA site recognition and dimérisation. The variable hinge region, D 
domain, allows the protein to change shape or alter conformation. The complex 
ligand binding domain, E region, also possesses a number of functions including 
Ligand binding, HSP binding, dimérisation, nuclear localisation and transactivation 
(Soontjens et al. 1996; Podczaski et al. 2001). No specific function has been assigned 
to the F domain. An illustration of the domain structure is shown in Figure 1.6
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Figure 1.6
Domain Structure of the “Classic” Nuclear Receptor.
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Type I receptors in the absence of ligand binding are bound to heat shock proteins (HSP) 
and in this state are unable to effect changes in cellular transcription. However, once 
ligand binds to the receptor the HSP dissociate, the receptor-ligand complex translocates 
to the nucleus, and the activated complex is now able to undergo dimérisation with other 
steroid receptors. The dimers fonned are then able to bind to specific regions of DNA 
termed homione response elements (HRE). Once bound to the HRE the receptor can 
alter transcription of genes aided by the recruitment of co-regulators with resultant 
activation or suppression of function (McKemia et al. 1999). Type II receptors are able 
to bind to the HRE of DNA in the absence of ligand. If a type II receptor binds to DNA 
in the absence of ligand then it may repress the hinction of that gene, “silencing”. The 
receptor must still undergo dimérisation and unlike type I receptors, that usually fomi 
homo-dimers, the type II receptors may Ibrni hetero-dimers with other type H receptors 
and this may modulate the amplitude of the tianscriptional response to ligand binding 
(McKemia et al. 1999).
If a gene is activated, RNA polymerase transcribes the infomiation from the gene 
into messenger RNA (niRNA). Initially the ti*anscribed product contains the intron and 
exon infomiation but prior to fransport from the nucleus the introns are spliced out 
joining the exons in a continuous sequence. This molecule then traiisfers the iiifoimation 
decoded fr om the gene into the cytoplasmic conipai tment of the cell. The infomiation is 
then decoded (translated) by the ribosomes of the rough endoplasmic reticulum to 
produce the protein appropriate to the gene. Finally, post translational modifications may 
occur prior to the protein producing its fruiction within the cell.
Gene activation can also be modulated by coregulators wliicli may be coactivators 
or corepressors. Coregulators are, by definition, rate limiting for nuclear receptor 
activation and repression, but do not significantly alter basal transcription(McKenna et 
al. 1999). This field is vastly complex and a comprehensive overview is out with the 
scope of this thesis. However, in general tenus the initiation of transcription by steroid 
hormones requires the assembly of a complex of general ti'anscription factors. 
Ultimately, it is by influencing the rate of assembly of such complexes that nuclear 
receptors, in association with their coregulators, acliieve transcriptional regulation. The 
precise physiological role of nuclear receptor coregulators has yet to be determined. 
McKemia et al. provide a comprehensive review of this field (McKemia et al. 1999). 
Figure 1.7 illustiates the genomic mechanism of action.
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1.3.2 Non-Genomic Mechanism of Action
Unlike classical genomic steroid responses, non-genomic steroid responses are rapid, 
within minutes, and are not sensitive to inhibitors of translation and transcription. 
The ability of steroids to initiate second messenger signaling cascades, including 
Phospholipase C; Phosphoinositide turnover; intracellular pH; intracellular free 
Calcium concentration; and Protein Kinase C, have been described for all classes of 
steroids (Falkenstein et al. 2000).
The precise mechanism of non-genomic steroid action is currently not Icnown. 
Several possibilities have been suggested and if non-genomic progesterone action is 
used as an example, the suggestions are:
1. High concentrations of progesterone may insert into the plasma membrane of 
the cell and affect membrane fluidity that will elicit an intracellular response.
2. Direct progesterone activity with a subset of classic intracellular receptors 
bound to the cell membrane.
3. Progesterone interaction with a partner ligand via a non-progesterone 
receptor.
4. Direct progesterone action via a non-classical cell membrane bound receptor.
Recent data from Harding et ah have described the presence of membrane progestin 
receptors in the membrane fraction from endometrial fibroblasts (Harding et al. 
2003).
Rapid effects of androgens on cells such as human granulosa-lutein cells, prostate 
cancer cells, adult rat brain and human breast cancer cells have been described 
(Falkenstein et al. 2000). The data indicated the response was not initiated via a 
classical genomic response, as androgen receptor antagonists did not prevent a 
response. Furthennore, in some of the studies, the use of a plasma membrane 
impermeable testosterone conjugate elicited a response, suggesting action via cell 
surface receptors (Falkenstein et ah 2000).
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1.4 Intracrinology
Humans have a sophisticated, stratified regulatory system for the control of 
steroidogenesis and steroid hormone activity. The stratification of control includes 
endocrine, paracrine, autocrine and most recently described intracrine regulation. 
Classical endocrine systems secrete steroid hormones fiom endocrine glands into the 
systemic circulation whereby they are transported to target cells in peripheral tissues. 
Paracrine activity refers to the influence of hormone secreted into the extracellular 
space upon adjacent/proximal cells. Autocrine activity is the influence of hormone 
secreted into the extracellular space upon the cell from which it was secreted. 
Intracrine activity is described as the influence exerted by hormones within the same 
cell where synthesis occurred without release into the extracellular space. Figure 1.8
The term “Intracrinology” was first described by Labrie et al. (Labrie 1991). 
The importance of this concept is that peripheral target tissues have autonomous 
control over their sex steroid formation and metabolism according to the 
requirements of the target tissue (Labrie 1991). Figure 1.4 details the metabolic 
pathways in the production of sex steroids and the enzymes responsible for each step. 
In the female, oestradiol and progesterone have long been considered the biologically 
active sex steroids with a lesser contribution from the androgen, testosterone. The 
main source of all is ovarian steroidogenesis under the control of FSH and LH 
secretion. They are not however the most abundant sex steroids in the systemic 
circulation, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate 
(DHEA-S) are both synthesised in large quantities by the adrenal gland under the 
control of ACTH.
The secretion of DHEA and DHEA-S in the adrenal gland first commences 
with adrenarche, which occurs in the region of 6-8 years of age. From this point 
forward elevated levels of both are maintained tlrrougli adulthood. In comparative 
terms the levels of DHEA-S is 1000 -10 000 higher than those of Oestradiol in the 
adult female (Labrie et al. 2000). Such elevated levels of this inactive steroid 
precursor provides a large reservoir of substrate that may later be converted into 
alternative biologically active sex steroids such as oestradiol, progesterone and 
testosterone within peripheral target tissues. The importance of intracrinology was 
first realised in a clinical context in the treatment of prostate cancer.
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Prostate eancer is an endocrine responsive cancer with prognosis related in 
part to serum and tissue levels of androgens. Endocrine modulation is an important 
element in the treatment of prostate cancer where surgical or medical castration 
(GnRH agonists) were shown to reduce serum testosterone levels by 90-95%, 
however tissue levels of dihydrotestosterone (DHT) were only 50% of normal. As 
the main pathway of DHT production is the 5 alpha reduction of testosterone this 
suggested another source of androgens - the adrenal -  persisted following castration 
that could be 5 alpha reduced to DHT in the prostate(Labrie et al. 1996). This 
important discovery has now altered the treatment of prostate cancer with therapy 
now aimed at blocking the effect of both adrenal and testicular androgens -  
combined androgen blockade. This combined androgen blockade in essence inhibits 
both the androgen receptor and the enzyme 5a reductase which are both expressed in 
the prostate. Prospective randomized control trials have now shown that this 
approach improves survival in patients with prostate cancer (PCTCG 2000).
The role of peripheral intracrine sex steroid formation is also seen in post­
menopausal females affected by breast cancer, a condition that is also endocrine 
responsive. In the postmenopausal female, oestradiol production is via extra-ovarian 
aromatisation of oestrone. Inhibition of oestradiol action has been targeted by 
blockade of aromatisation with aromatase inhibitors (Buzdar et al. 1996) and the 
oestrogen receptor with selective oestrogen receptor modulators (SERM’S) 
(Cummings et al. 1999). Both interventions were shown to improve outcomes in 
patients diagnosed with breast cancer.
The target cell responses to steroid hormones are dependent on the target cell 
concentration of steroid and their binding affinity to their respective receptors. 
Through ligand binding, gene transcription is activated to express steroid hormone 
actions. Apart from receptor concentration, another key regulatory factor in steroid 
action is the intracellular steroid concentration. The enzymes that play a key role in 
regulating intracrine sex steroid metabolism include the isoenzymes of 
17|3-hydroxysteroid dehydrogenase (17p-HSD), 5a-reductase (5aR), 
3 p-hydroxysteroid dehydrogenase (3|3-HSD) and Aiomatase.
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Figure 1.8
Illustration of endocrine, paracrine, autocrine and intracrine secretion. Classically, 
endocrine activity includes the hormones secreted in specialized glands, called 
endocrine glands, for release into the general circulation and transport to distant 
target cells. Alternatively, hormones released from one cell can influence 
neighboring cells (paracrine activity) or can exert a positive or negative action on the 
cell of origin (autocrine activity). Intracrine activity describes the formation of active 
hormones that exert their action in the same cells where synthesis took place without 
release into the pericellular compartment.
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1.4,1 17 beta hydroxysteroid dehydrogenases
The 17(3-hydroxysteroid dehydrogenases (17(3-HSD) are enzymes involved in the 
formation of activation and inactivation of sex steroids, including testosterone (T), 
oestradiol (E2), 5-androstenediol (5-diol) and dihydrotestosterone (DHT). They 
catalyse the last and key step in the formation of all oestrogens and androgens, the 
reduction of the 17-keto gi'oup to the 17(3-hydroxyl on the steroid nucleus, increasing 
the affinity of the steroids to their cognate receptors (Peltoketo et al. 1996).
There are currently eight known isoforms in the 17 (3-HSD family with seven 
human isoforms having been identified (Luu-The 2001), Each member of the 17 [3- 
HSD family is a separate gene product from a different chromosome making it a 
multi-gene family. The enzymes play an important role in the control of active sex 
steroids with a wide distribution in tissues tliroughout the body. As well as being 
localised to classical steroidogenic tissues such as the human placenta (Luu-The et al. 
1990), ovary (Luu-The et al. 1990), and testis (Inano et al. 1986; Geissler et al.
1994), the 17 p-HSDs are found in peripheral intracrine tissues (Martel et al. 1992), 
such as adipose tissue (Bleau et al. 1974), endometrium(Casey et al. 1994), ilemn (Inano 
et al. 1986), liver (Brener et al. 1966), and vaginal mucosa (Weinstein et al. 1968).
Despite catalysing similar reactions often with the same substrates, the 
various 17 p-HSDs only share in the region of 20% homology in their gene sequence 
(Peltoketo et al. 1999; Luu-The 2001). In keeping with other dehydrogenases the 17 
[3-HSDs were thought to facilitate reversible interconversion between substrate and 
product. However, transfection studies without exogenous co factors to drive 
reactions have shown that within an intracellular environment the direction of 
reaction is unidirectional and is likely to depend upon the intracellular ratio of NAD+ 
to NADPH (Luu-The et al. 1995; Luu-The 2001). It is noteworthy that all the 
enzymes catalyzing the reduction reaction prefer a phosphorylated cofactor 
(NADPH) while the enzymes that catalyze the oxidative reaction prefer NAD (Luu- 
The 2001). The enzymes, except 17 p-HSD 5, are all members of the short-chain 
alcohol dehydrogenase/reductase family (SDR). 17 (3-HSD 5 is a member of the 
aldoketoreducatse (AKR) protein family (Deyashiki et al. 1995). The seven human 
isoforms are 17 (3HSD types 1, 2, 3, 4, 5, 7 and 8. The substiate preference, function 
and tissue distribution of the enzymes are detailed in Table 1.1.
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Type/Protein Family Subceliular Localisation Tissue Distribution
1/SDR Cytosolic Ovary
Placenta
Breast
2/SDR Microsomal Placenta, Liver 
Gastrointestinal tract, 
Kidney Uterus, Breast, 
Prostate
3/SDR Microsomal Testis
4/SDR Peroxisomal Widely distributed
5/AKR Cytosolic Liver, Kidney 
Testis, Prostate 
Adrenal, Bone
6/SDR (Rat) Membrane bound Prostate, liver
7/SDR (Rat and mouse) Membrane bound Ovary 
Placenta 
Mammary gland
8/SDR Unknown Liver, Pancreas, Kidney 
Skeletal Muscle, Liver 
Ovary, Testis, Spleen
Table 1.1 List of the cloned 17 HSD/KSR enzymes (Peltoketo et al., 1999).
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1.4.1.1 17P-HSD1
The molecular stmcture of a human typel 17P-HSD cDNA and its corresponding 
gene encodes a predicted protein of 327 amino acids with the gene consisting of 6 
exons and 5 introns within a genomic DNA fi*agment of 3.2 kb. IVp-HSD 1 enzyme 
is a protein that catalyzes predominantly the conversion of oestrone to oestradiol 
using NAD (H) or NADP (H) as cofactor (Labrie et al. 1997; Labrie et al. 2000).
The typel 17P-HSD enzyme plays an active role in the regulation of 
oestradiol production in the ovary. It is exclusively expressed in granulosa cells 
being at low levels in antral follicles, up regulated during follicular maturation, and 
highest in Graffian follicles. These data suggest that typel 17P-HSD is the principal 
17-HSD isoenzyme involved in ovarian oestradiol production. Similarly, to P450 
aromatase, 17P-HSD 1 expression is regulated by gonadotrophins, and the effects of 
gonadotrophins are modulated by oestrogens, androgens and growth factors. 
Moreover, 17P-HSD 1 is also expressed in human coi-pus luteal, as well as in human 
granulosa luteal cells and is involved in the production of significant amounts of 
oestrogens (Poutanen et al. 1995; Zhang et al. 1996).
In addition to the ovary, I7p-HSD 1 participates in oestradiol biosynthesis in 
the human placenta (Fournet-Dulguerov et al. 1987). Northern blotting experiments 
show that 17p-HSD 1 is highly expressed in the placenta and the enzyme has been 
immunolocalised to the syncytiotrophoblast cells of the human placenta (Labrie et al. 
1997; Takeyama et al. 1998; Bonenfant et al. 2000). Two niRNA species have been 
cloned for 17p~HSD 1, a major RNA species of about 1.3 kb and a minor RNA 
species of 2.3 kb being detected. The 1.3 kb and 2.3 kb mRNA species are also 
detected in other tissues. The 1.3 kb mRNA is very abundant in placental and ovarian 
tissues. It has been suggested that the 1.3 kb mRNA is present only in tissues 
producing oestrogens, whereas the 2.3 kb mRNA has been found in steroid-forming 
tissues and some target tissues of steroid hormone action, such as prostate and breast 
tissue, as well as in breast and endometrium cancer cell lines (Vililco et al. 1991; 
Poutanen et al. 1995).
Until recently there has been a lack of clarity in the literature regarding the 
expression of 17p-HSD 1 and 2. It appears from reviewing the literature that, before 
cloning of a separate enzyme for 17p-HSD 1 and 2, 17p-Oestradiol Dehydrogenase
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was generally referred to as the enzyme responsible for the conversion oestrone to 
oestradiol, in keeping with IVp-HSD 1 activity as is now understood (Luu The et al. 
1989; Vihko et al. 1991). However, a series of papers was published by Maentausta 
et al. that referred to 17p-Oestradiol Dehydrogenase as the enzyme responsible for 
the inactivation of oestradiol to oestrone, in keeping with 17P-HSD 2 activity as it is 
now understood (Maentausta et al. 1990; Maentausta et al. 1991; Maentausta et al. 
1993). Maentausta et al. described the progesterone up regulation of the enzyme, 
lyp-HSD 2, and subsequent papers misquoted this reference as meaning up 
regulation of the enzyme responsible for catalysing the conversion of oestrone to 
oestradiol (Miettinen et al. 1996; Peltoketo et al. 1996; Mustonen et al. 1998).
In summary, typel 17P-HSD is involved in the endocrine and intracrine 
production of oestradiol in females, in classical steroidogenic cells and in some 
peripheral, oestrogen target tissues, respectively. This suggests a central role for the 
enzyme in regulating the circulating oestradiol concentration, as well as its local 
production in oestrogen target cells.
1.4.1.2 17P-HSD2
The type2 17p-HSD cDNA encodes a predicted protein of 387 amino acids with a 
molecular mass of 42,782 Da (Wu et al. 1993). The gene is comprised of seven 
exons, which give rise to the 387-amino acid type IIA 17P-HSD and a predicted 291- 
residual type IIB 17P-HSD proteins through alternative splicing. Cloning of the 
human type 2 17p-HSD gene confirmed that type IIA and IIB 17p-HSD transcripts 
originate from a single gene. Sequencing of the exons and of the adjoining intron 
sequences revealed that the 17P-HSD IIA protein is encoded by exon 1-3 and 6-7, 
whereas type IIB protein is encoded by exon 1-7 inclusively (Labrie et al. 1995). 
Sueh detail is important for the design of molecular probes to allow distinction 
between the active and inactive gene products.
The type IIA 17(3-HSD, but not type IIB, has been shown to catalyse the 
conversion of oestradiol into oestrone, testosterone into androstenedione and 
androstenediol into DHEA. It also demonstrates 20cx-hydroxysteroid dehydrogenase 
activity, i.e. the conversion of 20a-dihydroprogesterone to the more active progestin, 
progesterone (Wu et al. 1993). The function of the type IIB 17(3-HSD protein is
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unknown but it is hypothesized that the type IIB protein might regulate type IIA 17(3- 
HSD activity by fonning heterodimers with type IIA 17(3-HSD (Labrie et al. 1995). 
Future reference to 17(3-HSD 2 in this text will refer to type IIA 17(3-HSD.
The enzyme is a member of the short-chain alcohol dehydrogenase super 
family, sharing in the region of 20% sequence identity with the enzyme encoded by 
the 17(3-HSD1 gene, typical of the 17(3-HSD multigene family. The type2 17(3-HSD 
isoenzyme utilizes NAD as a cofactor and preferentially catalyzes the oxidative 
reaction (Andersson et al. 1997; Labrie et al. 2000).
17(3-HSD 2 is principally expressed in the placenta (Casey et al. 1994; 
Moghrabi et al. 1997; Takeyama et al. 1998; Bonenfant et al. 2000), 
endometrium(Maentausta et al. 1990), and liver(Wu et al. 1993) with lower levels in 
the prostate(Wu et al. 1993), kidney, colon and pancreas(Casey et al. 1994; 
Andersson 1995). Virtually undetectable levels are found in testis, ovary, skeletal 
muscle, brain, heart, spleen and thymus(Casey et al. 1994; Andersson 1995).
In human placenta, both immunohistochemistry and northern blot analysis 
have shown that 17(3-HSD 2 is expressed in the endothelial cells of capillaries and 
sinusoids in the chorionic villi (Moglwabi et al. 1997; Takeyama et al. 1998; 
Bonenfant et al. 2000). Gurpide et al demonstrated that 90% of the oestradiol and 
oestriol produced by human placental trophoblast enters the maternal circulation 
(Gurpide et al. 1966) and it is generally agi'eed that both oestradiol and oestriol, but 
not oestrone are secreted directly via the intervillous space to the maternal circulation 
(Moghrabi et al. 1997). Investigators have also established that oestrone is the major 
oestrogen product in foetal umbilical veins(Walsh et al. 1981; Guipide et al. 1982). 
Following trophoblast synthesis of oestradiol, the oestrogen must first cross the 
intervillous space prior to traversing the fetal capillary wall. The localisation of 17p- 
HSD 2 in the endothelial cells lining this space will therefore be in a position to 
metabolise oestradiol to oestrone. One proposed physiological role of 17(3-HSD 2 
may therefore be the protection of the fetus from excess placental and maternally 
derived bioactive oestrogens and androgens that are produced by the 
syncytiotrophoblast cells (Moglu'abi et al. 1997). Such a catabolic role would also be 
consistent with the expression of 17(3-HSD 2 in the liver
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Human endometrium also expresses 17 [3-HSD 2. Temporal variation in the 
expression of 17|3-HSD 2 was first shown by Gurpide and colleagues. They 
demonstrated oestradiol conversion to oestrone in human secretory endometrium that 
was up-regulated by the action of progestins both in vivo and in vitro (Tseng et al. 
1975; Gurpide et al. 1976; Guipide et al, 1977; Tseng et al. 1977; Tseng et al. 1979; 
Gurpide et al. 1981; Holinka et al. 1981). Further, the activity was localised to 
secretory glandular epithelium (Scublinsky et al. 1976; Satyaswaroop et al. 1982). 
Following on from these early reports of enzyme activity, the protein has been 
immunolocalised using a polyclonal antibody. Highest levels were noted in the mid- 
secretory endometrium and the progesterone regulation was also demonstrated in 
vivo (Maentausta et al. 1990; Maentausta et al. 1991; Maentausta et al. 1992; 
Maentausta et al. 1993). Higher levels of the 17|3-HSD 2 mRNA were also 
demonstrated in the mid- to late-secretory phase endometrium in contrast to 
relatively low levels in proliferative phase endometrium (Casey et al. 1994; 
Mustonen et al. 1998).
The precise role of 17[3-HSD 2 in human endometrium is not known. It is 
hypothesized that the effect of increasing oxidative activity during the luteal phase of 
the cycle is to not only down-regulate oestrogen action, but to also up-regulate 
progesterone action in the endometrium during this phase of the cycle in keeping 
with the enzyme’s ability to catalyse the formation of progesterone (Wu et al. 1993; 
Mustonen et al. 1998). The immunolocalisation of 17|3-HSD 2 with a monoclonal 
antibody is now possible following the characterisation of a novel monoclonal 
antibody (Moghrabi et al. 1997). This should enable further characterisation of the 
enzyme in a spatial and temporal context within the endometrium. The role of 17[3- 
HSD 2 in androgen and androgen receptor metabolism within human endometrium 
also remains to be determined.
1.4.1.3 17P-HSD3
17p-HSD 3 is expressed predominantly in the testis (Geissler et al. 1994). It has also 
been detected in the brain (Stoffel-Wagner et al. 1999) and in both tissues it catalyses 
the conversion of androstenedione to testosterone. In addition it can also catalyse 
DHEA to androstenediol and oestrone to oestradiol (Geissler et al. 1994). 17p-HSD
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3 cDNA was cloned in 1994 also belongs to the short chain alcohol dehydrogenase 
super family (Geissler et ah 1994; Andersson 1995).
Testosterone is synthesized by the Leydig cells of the testis and is the main 
hormone of the male gonad. Testosterone is required for the development of internal 
male reproductive structures (epididymis, vas deferens, seminal vesicles and 
ejaculatory ducts) derived from the Wolffian ducts while its 5a reduced form, 
dihydrotestosterone, induces fonnation of the male external genitalia (penis and 
scrotum) and prostate gland (Andersson et ah 1997; Twesten et ah 2000). A failure in 
testosterone biosynthesis or a failure in conversion of testosterone to 5a 
dihydrotestosterone can lead to insufficient differentiation of the male external 
genitalia, and hence to defective virilisation. This may result in genotypic males with 
female phenotypes, male pseudohennaphroditism.
Molecular defects in the 17P-HSD 3 enzyme are among the genetic defects 
that cause this syndrome (Andersson et ah 1997; Twesten et ah 2000). The defect 
was first described by Saez et ah (Saez et ah 1971; Saez et ah 1972). It is inlierited in 
an autosomal recessive pattern producing a characteristic phenotype of 46 XY with 
testis, Wolffian duct-derived male internal genitalia, but an absence of prostate 
gland, and with female external genitalia (Andersson et ah 1997).
Attempts were made to localise 17P-HSD 3 in human endometrium but 
northern blotting failed to detect this isofoim of the enzyme in human endometrium 
or endometriotic tissue (Zeitoun et ah 1998).
1.4.1.4 17P-HSD4
Human 17p~HSD 4 was cloned by Adamski et al in 1995(Adamski et ah 1995) and it 
catalyses the conversion of oestradiol to oestrone and androstenediol to DHEA. 
Human mRNA encoding type4 17P-HSD is expressed in virtually all human tissues 
examined. The highest mRNA level of human 17P-HSD 4 was observed in liver, 
followed by heart, prostate and testis. Moderate expression occurred in lung, skeletal 
muscle, kidney, pancreas, thymus, ovary, intestine, and tenn placenta. Weak signals 
were observed in brain, spleen, colon and lymphocytes(Adamski et ah 1995). I f  s 
expression has now been demonstrated in endometrial epithelial cell cultures (Husen 
et ah 2000). It has not however been demonstrated in intact human endometrium.
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17p~HSD 2 also catalyses the same reaction but there is only 16% amino acid 
identity between the two enzymes (Labrie et al. 1997). It is likely to play a role in 
inactivation of oestrogens in peripheral tissues, although its activity is low and its 
physiological importance remains to be established in human (Labrie et al. 2000).
1.4.1.5 17P-HSD5
17P-HSD 5 differs from the other 17-hydroxysteroid dehydrogenases in that it 
belongs to the aldo-keto reductase family. Identification of the enzyme was 
confusing as it has also been recognised as dihydrodiol dehydrogenase and 3a- 
hydroxysteroid dehydrogenase type 2 (3a-HSD 2) which is also known as AKR1C3. 
3a-HSD 2 was originally cloned by Klianna et al. from human liver (Klianna et al.
1995). They localised the enzyme mRNA using RT-PCR to liver, kidney, placenta, 
brain and testis (Klianna et al. 1995). Subsequently it has been demonstrated in 
human prostate by northern blotting and in this same study northern blotting also 
identified the mRNA in leukocytes, colon, small intestine, ovary, thymus, spleen, 
pancreas, skeletal muscle, and heart (Lin et al. 1997). The enzyme was also known to 
possess reductive 17p-HSD activity but the 3a-HSD 2 activity was thought to be the 
predominant activity of the enzyme. However, Dufort et al. established that human 
3a-HSD 2 was not the predominant activity and a higher percentage conversion of 
androstenedione to testosterone and progesterone to 20a-hydroxyprogesterone 
occurred when a stably expressed enzyme was studied. It was felt from this and prior 
studies that homogenization protocols had destroyed much of the 17p-HSD activity 
of the enzyme, suggesting that it was highly labile (Dufort et al. 1999). It is therefore 
now recognised as 17p-HSD 5.
The 17P-HSD 5 activity of the enzyme catalyses androstenedione to 
testosterone (Penning 1997; Dufort et al. 1999). The 20a-hydroxysteroid 
dehydrogenase activity will inactivate progesterone to 20a-hydroxyprogesterone 
(Dufort et al. 1999). The 3a-HSD 2 activity will catalyse the inactivation of DHT to 
androstenediol (Penning et al. 2000).
Active androgens in the male are formed mainly within the testis under the 
control of 17p-HSD3, an enzyme that in humans is functional mainly within the male 
(Geissler et al. 1994). The enzyme may be subject to mutations with the affected 
male individuals suffering male pseudohennaphroditism, to date no females with
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similar mutations have been shown to suffer an equivalent condition (Mendonca et 
al. 1999). As the ovary is the main source of serum androgens in the female, studies 
were carried out to localise 17(3-HSD3 in the ovary but it was not found (Zhang et al.
1996). However, 17p-HSD3 shares the same substrate specificities as 17p-HSD5, 
catalysing the conversion of androstenedione to testosterone (Pemiing 1997), and 
17P-HSD5 has been localised in the ovary (Luu-The et al. 2001). It would therefore 
appear that 17p-HSD5 is the hydroxysteroid dehydrogenase responsible for androgen 
production in the female. However, in the male 17p-HSD5 is also present in 
peripheral target tissues such as the prostate. In this tissue its role is thought to be a 
combination of androgen formation and progesterone inactivation via its 20a- 
hydroxysteroid dehydrogenase (20a-HSD) activity, protecting the prostate from the 
action of progesterone (Dufort et al. 1999).
In the female 17p-HSD5 has now been localised to the ovary, breast and 
uterus (Pelletier et al. 1999). Uterine 17P-HSD5 was localised to glandular and 
surface epithelium; however the stage of the cycle in which it was detected was not 
stated (Pelletier et al. 1999). As endometrial AR localisation is thought to be 
predominantly stromal, it may be that local 17P-HSD5 androgen production 
produces a paracrine effect in the stroma. Alternatively, its role may relate to its 20a- 
HSD activity, inactivating progesterone. To elucidate its role, more details regarding 
the immunolocalisation of 17p-HSD5 in endometrium tlnough the menstrual cycle 
would be required.
1.4.1.6 17P-HSD6
17p-HSD 6 selectively catalyzes the oxidation of 3a-androstanediol to androsterone. 
Additionally it may catalyse DHT to androstanedione and testosterone to 
androstenedione but at an approximately 50 to 100 fold lower rate. This enzyme 
belongs to the retinol dehydrogenase family. Northern blotting analysis shows high 
expression of 17p-HSD 6 in rat liver and prostate. The human counterpart has not yet 
been described, and a human clone that possesses the characteristics of rat 17p-HSD 
6 has not been found (Labrie et al. 2000; Luu-The 2001)
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1.4.1.7 17P-HSD7
17P-HSD 7 was first cloned in a rat corpus luteum cDNA library and was identified 
as prolactin receptor associated protein (Duan et al. 1997). It efficiently and 
selectively catalyzes oestrone to oestradiol (Nokelainen et al. 1998). A human type7 
17p“HSD has been cloned and using RT-PCR the enzyme was detected in the ovary, 
breast, prostate, placenta, liver and brain (Ki'azeisen et al. 1999). As present, the 
endometrium has not been examined.
1.4.1.8 17P-HSD8
17P-HSD 8 catalyses oestradiol to oestrone most efficiently and to a lesser extent 
the oxidation of androgens. The conversion of testosterone to 4-dione is about 25% 
of that oestradiol into oestrone. It was cloned in humans by Kikuti et al (Kikuti et al. 
1997) and determined to have 17P-HSD activity by (Fomitcheva et al. 1998). This 
enzyme is expressed abundantly in the kidney, liver, gonads and spleen. In the ovary, 
typeS 17p-HSD is present in cumulus cells but not in granulosa or luteal cells, unlike 
typel and type? 17p-HSD, respectively (Peltoketo et al. 1999; Labrie et al. 2000).
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1.4.2 3 beta liydroxysteroid dehydrogenase
3[3-hydroxysteroid dehydrogenase/A5-A4 isomerase (3p-HSD) isoenzymes are 
essential for the biosynthesis of all classes of hormonal steroids, namely 
progesterone, glucocorticoids, mineralocorticoids, androgens and oestrogens 
(Lachance et al. 1990; Labrie et al. 1992). Additionally they catalyse the formation 
and/or degradation of 5a-androstanes and 5a-pregnanes such as 5 a- 
dihydrotestosterone and 5a-dihydroprogesterone respectively (Mason et al. 1993; 
Mason et al. 1997). Two isoenzymes are present in humans with the type 2 gene 
coding for the 3p-HSD isoenzyme predominantly expressed in the adrenal gland, 
ovary and testis, whereas expression of the type 1 gene appears to account for the 3^- 
HSD activity found in peripheral target tissues (Simard et al. 1996; Mason et al.
1997). Type 1 encodes a protein of 372 amino acids and was first sequenced by Luu- 
The et al. (Luu-The et al. 1990) with type 2 encoding a protein of 371 amino acids 
being sequenced by Rlieaume et al. (Rlieaume et al. 1991). The two isoenzymes are 
highly homologous sharing 93.5% identity of amino acids (Simard et ah 1996). The 
type 1 displays a higher substrate affinity than the type 2 (Rlieaume et al. 1991) that 
may facilitate steroid formation from relatively low concentrations of substrate 
usually present in peripheral target tissues (Simard et al. 1996).
As a clinical entity this enzyme is important as it is a cause of congenital 
adrenal hyperplasia (CAH). CAH is the commonest cause of ambiguous genitalia 
and adrenal insufficiency in newborns (Simard et al. 1996). 3|3-HSD deficiency is 
included with 21-hydroxylase and 11 (3-hydroxylase deficiencies as specific enzyme 
defects that impair cortisol biosynthesis that in turn increase ACTH secretion from 
the anterior pituitary as cortisol negative feedback is absent. This produces a 
compensatory hypertrophy of the adrenal cortex. 3(3-HSD deficiency affects both the 
adrenal and gonads with consequent impairment of sex steroid biosynthesis. A range 
of phenotypes are noted with 3p-HSD deficiency suggesting a range of complete to 
partial inlribition of activity. As such 3p-HSD deficiency may present as late onset 
CAH at the time of expected puberty (Rosenfield et al. 1980).
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The role of 3p-HSD expressed in the human ovary is to produce C l9 steroids 
in the thecal cells that can be aromatised to oestrogens in the granulosa cells of the 
ovary. The enzyme is also expressed in the luteal cells of the ovary following 
ovulation where its role is extended to the production of both progesterone and 
oestrogens (Doody et al. 1990; Sasano et al. 1990). Towards menstruation expression 
of 3p-HSD in the ovary declines presumed due to a loss of response to LH (Benyo et 
al. 1993) as it has been demonstrated that the primate corpus luteum requires LH for 
continued 3p-HSD expression (Ravindranath et al. 1992).
In the placenta 3p-HSD is expressed principally within the 
syncytiotrophoblast from as early as 6 weeks gestation (Riley et al. 1992). At this 
point the source of progesterone is still the corpus luteum. However, with advancing 
gestation there is an increase in the expression of 3p-HSD that conesponds to the 
increase in plasma progesterone during this time (Riley et al. 1992). This suggests 
that the placenta synthesises progesterone with 3P-HSD expression being a key 
factor in the steroidogenesis.
3p-HSD activity has also been demonstrated in human (Tang et al. 1993) and 
rhesus macaque endometrium (Martel et al. 1994). Tang et al. suggested that 
expression may be progesterone regulated following an increase in enzyme 
expression following culture of endometrium with medroxyprogesterone acetate. A 
recent publication by Rhee et al. have now imniunolocalised expression of the 
enzyme in the endometrial glandular epithelium with higher expression in the 
secretory phase than the proliferative phase (Rlree et al. 2003). The role that 3(3-HSD 
may play in endometrial function is not yet known.
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1.4.3 5 alpha reductase
5a-reductase (5aR) is multifunctional and catalyses the reduction of many steroid 
substrates (Wilson 1975) such as testosterone to the more potent dihydrotestosterone 
and progesterone to the inactive 5a-pregnan-3,20-dione (Fisher et al. 1978). Two 
isoenzymes have now been cloned and characterised (Russell et al. 1994) and are 
designated 5aR 1 and 5aR 2 according to the order in which they were cloned. They 
play an essential role in the development of the male phenotype where there are 
differential roles for testosterone and the more potent androgen of 
dihydrotestosterone (DHT). DHT possesses an affinity for the AR four times higher 
than that of testosterone (Kovacs et al. 1984; Grino et al. 1990; Poletti et al. 1998). 
Moreover, the activated AR is also stabilized by DHT and DHT exhibits a fivefold 
slower dissociation rate from the hormone binding domain of the receptor than its 
precursor testosterone (Kovacs et al. 1984; Grino et al. 1990). Consequently, DHT 
activates transcription of androgen-dependent genes at concentrations significantly 
lower than testosterone. This ability would enable androgens to contribute to a local 
intracrine enviromnent tlirough fonnation of DHT in target tissues. To date little is 
known regarding the expression of 5aR in human females and what role it may play.
The Salpha-reductase type 1 gene (SRD5A1) encodes an isoenzyme with an 
alkaline pH optimum (Jenkins et al. 1991; Jenkins et al. 1992) whereas the Salpha- 
reductase type 2 gene (SRD5A2) encodes an isoenzyme with an acidic pH optimum 
(Andersson et al. 1991; Thigpen et al. 1992). The two Salpha-reductase isoenzymes 
can also be distinguished by their 4-azasteroid inliibitor, finasteride, 
pharmacokinetics as 5aR 2 is inliibited by this compound (Liang et al. 1984; 
Vermeulen et al. 1989). Tissue distribution of the isoenzymes has been described 
with 5aR 1 localised to the hair follicles, sebaceous glands and liver predominantly 
and SaR 2 localised to genital skin, seminal vesicles, epididymis, liver as well as 
being the only isoenzymes detected in the prostate (Thigpen et al. 1993). The use of 
finasteride as a 5aR 2 inhibitor has significantly improved the outcome for patients 
with pro static carcinoma, an androgen responsive carcinoma, whereby in 
combination with anti-androgens it will provide suppression of intra-pro static DHT 
formation to inhibit androgen stimulation of the carcinoma (Prostate Cancer Triallist 
Collaborative Group2000. 2000).
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In physiological terms, androgens play an important role in the expression of 
the male phenotype with Testosterone and DHT having specific roles. Testosterone 
is required for differentiation of the Wolffian ducts, speiinatogenesis and it provides 
feedback control for the secretion of Luteinising hormone. DHT is required for 
differentiation of the urogenital sinus and external genitalia as well as playing a role 
in sexual maturation at puberty (Wilson et al. 1993). The role of DHT in 
differentiation of the external genitalia is another area where 5aR 2 has a direct 
clinical relevance. 5aR gene mutations result in the failure of 5aR 2 enzyme 
expression, contributing as one cause of the androgen insensitivity syndrome or male 
pseudohermaphroditism as the condition is alternatively called (Imperato-McGinley 
et al. 1974; Wilson et al, 1974; Brinlmiann et al. 1996). The external genitalia require 
the more potent action of dihydrotestosterone (DHT) for the development of the male 
external genital phenotype during organogenesis and development whereas the 
internal genitalia, Wolffian ducts, are able to utilise testosterone for adequate 
differentiation. Within the families identified with 5a-reductase gene mutations a 
group of females homozygous for the defect have been studied. In this small group 
the females were noted to have delayed menses and a higher than expected twin 
pregnancy rate (Katz et al. 1995). The authors suggest the delay in menarche implies 
a regulatory role for 5aR 2 in the initiation of puberty at the hypothalamic/pituitary 
and/or gonadal level and in view of the twin pregnancy rate there may be a role for 
5aR 2 or DHT in ovarian follicular maturation (Katz et al. 1995). As yet no defect in 
5aR 1 gene expression has been published but murine studies suggest this enzyme 
has an important contribution for fertility and parturition (Mahendroo et al. 1999).
On the basis of tissue distribution and biochemical properties 5aR lis thought 
to mainly act as a catabolic agent whereas 5aR 2 is essentially an anabolic agent 
(Andersson et al. 1990; Normington et al. 1992; Wilson et al. 1993). No naturally 
occurring mutations have been described in the 5aR 1 gene (Mahendroo et al. 1999). 
Therefore, to explore the physiological role of 5aR 1 Mahendroo et al. generated mice 
with a null mutation in the 5aR 1 gene. Male mice with this defect appeared to virilise 
normally and appeared to suffer no adverse consequences from the loss of this gene. It 
is thought the male compensates by utilising its 5aR 2 activity. In humans and mice 
with SaR 2 gene defects the males fail to virilise properly but the female expresses a 
normal phenotype with no apparent consequences (Mahendroo et al. 1999).
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Mahendroo et al. in their review show that mice affected by the null mutation in 5aR 
1 suffer adverse reproductive outcomes and hypothesise that 5aR 1 is the important 
isoenzyme in females whereas 5aR 2 is the important isoenzyme for males 
(Mahendroo et ah 1999).
An adverse reproductive outcome has been noted in the 5aR 1 knockout 
mouse. 70% of 5aR 1 knockout mice died in utero (Mahendroo et ah 1997). 
Fertilisation, implantation and early fetal development were normal but at the time of 
5aR 1 gene induction in the decidua an increased rate of intrauterine death occurred. 
At this time an increase in the serum oestradiol levels was also noted, correlating 
with a surge in placental androgens at this gestation (Mahendroo et ah 1997). 
Mahendroo et ah hypothesis that this increase in androgenic substrate, that may have 
been metabolised by 5aR l, would now alternatively be metabolised by aromatase 
leading to the increase in serum oestradiol at this time resulting in an intrauterine 
environment that was toxic to the fetuses (Mahendroo et ah 1997). hi support of this 
hypothesis an oestrogen receptor antagonist and an aromatase inliibitor were able to 
prevent the intrauterine deaths (Mahendroo et ah 1997).
While not directly exploring the role of 5a-reductase in the endometrium 
these studies have indicated that 5a-reductase may have an important role to play in 
female reproductive biology. The only study to examine 5aR expression in female 
reproductive tissues was published very recently by Ito et al (Ito et ah 2002). They 
described the immunolocalisation of 5aRl and 5aR2 in the glandular epithelium of 
the endometrium with no temporal variation. Their sample numbers were small 
which may have precluded the demonstration of significant differences. In addition 
to normal endometrium, they examined 44 cases of endometrial carcinoma and 
determined that 5aR was expressed in 80% of specimens. This would appear to 
confirm that 5aR is present in normal cycling endometrium but the paper does not 
provide answers as to the role of 5aR in normal or malignant endometrium.
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] .4.4 Aromatase
The primary source of oestrogen biosynthesis in the non pregnant pre-menopausal 
female is the ovary. Aromatase is the enzyme complex that catalyses the synthesis of 
oestrogens from androgens, and therefore it has unique potential to influence the 
physiological balance between the sex steroid hormones (Conley et al. 2001). The 
balance between androgen and oestrogen production is not only essential for normal 
sexual development and reproduction, but also for nomial physiological well being. 
Abnormalities in female aromatase expression have been associated with disease 
processes such as breast cancer, endometrial cancer, and endometriosis.
Aromatase is the product of the CYP19 gene (Means et al. 1989; Harada et al. 
1990) which is a member of the cytochrome P450 superfamily of genes (Simpson et 
al. 1997). Regulation of aromatase (P450arom) expression in humans is controlled by 
tissue specific promoters and alternative splicing tecluriques (Simpson et al. 1997; 
Simpson et al. 2002). Consistent with its fundamental biological importance, 
P450arom is highly conserved especially among mammals (Conley et al. 2001). 
Androstenedione and testosterone are the commonest and physiologically perhaps 
most important substrates for aromatase, being converted to oestrone and oestradiol 
respectively. However, in pregnancy 16 hydroxy-androstenedione arising Rom 
hepatic hydroxylation of foetal adrenal dehydroepiandrosterone sulphate (DHEAS), 
is an important substrate for placental oestriol synthesis (Siiteri 1982).
Extra-gonadal oestrogen biosynthesis has been identified in mesenchymal 
cells of the adipose tissue and skin (Simpson et al. 1997), osteoblasts (Bruch et al,
1992), aortic smooth muscle cells (Sasano et al. 1999) as well as a number of sites in 
the brain (Naftolin et al. 1975). In postmenopausal women these extra-gonadal sites 
become the main contributors to serum oestrogen (Simpson et al. 1997). In support 
of the observation that post menopausal oestrogen levels are primarily the product of 
extra-gonadal oestrogen biosynthesis and adipose tissue in particular, Bulun et al. 
demonstrated increasing P450arom mRNA expression in adipose tissue with 
advancing age (Bulun et al. 1994). hr pre-menopausal women the role of extra- 
gonadal aromatase will primarily be the provision of local oestrogen biosynthesis. 
This will allow high tissue concentrations that will likely exert a significant local 
influence in keeping with the principles of intracrinology (Labrie 1991).
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Aberrant P450arom expression in tissues that do not nomially have high 
concentrations of the enzyme is associated with many pathological conditions in 
humans. These include breast cancer (Bulun et al. 1997; Sasano et al. 1998), 
endometrial cancer (Bulun et al. 1997; Sasano et al. 1998), and endometriosis (Noble 
et al. 1996; Bulun et al. 1997; Kitawaki et al. 1997). Understanding what turns ‘on’ 
the expression of aromatase in disease or what causes a ‘switch’ in promoter usage is 
currently an area of intense investigation (Conley et al. 2001). The power of local 
oestrogen biosynthesis is illustrated in the case of postmenopausal breast cancer. It 
has been determined that the concentration of oestradiol present in breast tumours of 
postmenopausal women is at least 20-fold greater than that present in the plasma 
(Pasqualini et al. 1996). Overall, it is thought that about half of the oestrogen is 
produced locally within the tumour or suiTounding tissue (Miller 1999). With 
aromatase inliibitor therapy, intra-tumoural concentrations of oestradiol and oestrone 
drop precipitously, together with a corresponding loss of intra-tumoural aromatase 
activity, consistent with this activity being within the tumour and the surrounding 
breast adipose tissue and being responsible for these high tissue concentrations (de 
.long et al. 1997).
Initial studies investigating aromatase activity in human endometrium 
suggested that it may indeed possess such activity (Tseng et al. 1982; Neulen et al. 
1987). However, the presence or absence of the enzyme in endometrium was still 
thought to be controversial with Bulun et al. unable to demonstrate aromatase 
activity nor mRNA using sensitive RT-PCR in normal endometrium, decidua or 
endometrial stromal cell culture (Bulun et al. 1993). The latter findings by Bulun et 
al. have been subsequently substantiated by other studies suggesting that aromatase 
is not expressed in normal human endometrium but is expressed in endometrium 
associated with pathological conditions such as endometrial cancer and 
endometriosis (Bulun et al. 1994; Noble et al. 1996; Kitawaki et al. 1997).
The expression of aromatase in pathological conditions, benign and 
malignant, affecting the endometrium is an important finding that may have 
important implications for the management of endometriosis and endometrial cancers 
with aromatase inhibitors (Sasano et al. 1999; Berstein et al. 2002).
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1.5 The human uterus and endometrium
The uterus is a hbro-musculai* taiget organ that is essential for hiunan reproduction. 
Embryologically it is derived horn the imillerian duct and it is composed of a smooth 
muscle outer layer lined by endometrimn and is grossly divided in three anatomical 
portions; the body of the uterus, the istlmiic portion and the cervix.
The body of the uterus constitutes the tliickest layer with the largest proportion 
being smooth muscle. The smooth muscle cells are steroid responsive, imdergoing 
hyperplastic and hypertroplric changes at key points in a women’s reproductive life. Pre­
puberty the body of the uterus is in equal proportion to tire cervix and following puberty, 
under the influence of ovarian oestr ogens, the body of the uterus becomes twice as large as 
the cervix. Plohn et al. have demonstrated pubertal maturation of the uterus using 
ultrasound. They determined that uterine and ovarian volume increased before the onset of 
clinical puberty and continues several years after the menarche (Hohn et al. 1995).
A significant change in uterine size occurs in pregnancy where the cells undergo 
extensive hyperplasia, hypertrophy, and remodelling under the influence of placental 
steroidogenesis; allowing the growing foetus to develop within the uterus.
The body of the uterus tapers towards its lower pole where the isthrnic portion is 
in essence a transition zone that in late pregnancy forms the lower uterine segment. 
Through this zone the composition of the tissue grudually changes to become increasingly 
fibrous in nature as it becomes the cervix.
The endometrium lines the body of the uterus and is a dynamic steroid responsive 
tissue that must undergo rapid regeneration and remodelling each menstrual cycle to 
prepare for possible conceptus implantation. Human endometrium can be identified as 
tluee distinct layers: the superficial zona compacta, the intermediate zona spongiosa and a 
basal layer. The tenn functional layer refers to the compacta and spongiosa layers and it 
responds to the temporal variations in serum sex steroid levels as secreted by the ovary. 
Oestradiol initially drives proliferative change prior to progesterone mediating secretory 
phase differentiation. Following luteolysis and withdrawal of progesterone, menstruation 
occurs, shedding the firnctional layer (Cameron et al. 1996). The basal layer is in contact 
with the myometrium and undergoes little cyclic change tlrroughout the menstrual cycle 
and is not sloughed during menstruation but provides the platform for regeneration of the 
functional layer following rnerrstruation.
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1.6 Endometrial Morphology during the Menstrual Cycle
The menstrual cycle is divided into a pre-ovulatory proliferative phase and a post­
ovulatory secretory phase that precedes menstmation. The proliferative and secretory 
stages are further divided into early-, mid-, and late- categories classically based 
upon the seminal work by Noyes et al. A number of researchers had produced papers 
detailing histological changes in endometrium through the menstrual cycle in both 
monkeys and human. Noyes et ah, recognizing the need for a quantitative 
interpretation, reviewed papers produced regarding endometrial morphology in 
addition to their depth of experience to produce a guide for the dating of endometrial 
biopsies that is still referred to this day. The following is a brief description of the 
characteristics for each stage of the cycle (Noyes et al. 1950; Buckley et al. 1989).
1.6.1 Proliferative Phase
Early proliferative phase (day 4-day 7).
Identified by a regenerating surface epithelium, especially between the mouths of the 
glands. Most of the straight, short, narrow glands are of proliferative type, as shown 
by epithelial mitosis. Some still show cuboidal, ragged, inactive epithelium in 
keeping with involution. The stroma is compact with stellate or spindle-shaped cells 
with scanty cytoplasm and anastomosing processes making the nuclei appear 
relatively large.
Mid-proliferative phase (Day 8-Day 10)
This phase is recognizable by columnar surface epithelium, longer, curving glands, 
and a variable amount of stromal oedema, which tends to regress. Mitosis are 
numerous in the stroma.
Late-proliferative phase (Day 11-Day 14)
Characterised by an undulant surface with tortuous glands and pseudostratification of 
epithelium. There is a moderately dense, actively growing stroma.
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1.6.2 Secretory Phase
Early Secretory Phase (Post Ovulation Day (P.O.D) 1-Day 4)
Siibniiclear glycogen-rich vaciiolation of the glandular epithelium becomes 
prominent in at least 50% of cells, lasting for up to 6 days post ovulation (Buckley et 
al. 1989). The nuclei lose the pseudostratified configuration with an accompanying 
increase in the diameter and tortuousity of the glands. Mitoses cease to be seen.
Mid Secretory Phase (post ovulation Day 5-Day 9)
Acidophilic intra-luminal secretions reach a peak. Stromal oedema is 
characteristically marked in the mid-secretory phase, peaking about day 8-9. The 
stroma at this phase looks like small, dense, nuclei with only filamentous cytoplasm. 
The spiral arterioles, previously somewhat difficult to distinguish in the oedematous 
stroma, become much more prominent peaking at day 9-10. These findings constitute 
the earliest visible pre-decidual change.
Late Secretory Phase (post ovulation Day 10-Menses)
Eosinophilic pre-decidual cells may be identified around the arterioles and stromal 
proliferation recurs, as evidenced by mitosis. The differentiation of pre-decidua is 
accompanied by a sharp increase in lymphocytic infiltration. Also accompanying the 
pre-decidual change there is stromal regression and loss of endometrial height 
(Buckley et al. 1989). In the absence of pregnancy, gland secretion diminishes to a 
variable extent, and involution of gland epithelium occurs. The glands are dilated and 
tortuous, and the epithelium is thrown into tufts causing the characteristic saw­
toothed effect; but the previously tall columnar epithelium is now low, the nuclei are 
shrunken, and the cytoplasmic edges are ragged and indistinct.
1.6.3 Menstrual Phase
The menstrual cycle commences with the first day of blood flow. The upper two 
thirds of the endometrium, the superficial layer, are shed. Endometrium in the early 
menstrual phase exhibits focal areas of sub-epithelial necrosis with subsequent 
glandular collapse and necrosis. As the menses cease a typical shallow dense 
endometrium remains that is composed of the basal layer and residual deeper 
functional layer. From the third day of the cycle regeneration commences in glands 
and stromal elements (Buckley et al. 1989).
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1.7 Endometrial Sex Steroid Receptor Expression.
The important role of oestrogen and progesterone in endometrial growth, 
differentiation and function has been long recognised. Their spatial and temporal 
distribution within the endometrium has been well characterised as researchers have 
attempted to unravel the field of endometrial biology. Other members of the 
classical nuclear receptor super family such as AR and GR have not been so 
intensely researched and hitherto their spatial and temporal localisation have not 
been well characterised in normal endometrium. In recent years it has also become 
apparent that even the well characterised ER and PR distribution will require further 
refining as subtypes and variants of the receptors are recognised and their 
localisation determined using monoclonal antibodies.
1.7.1 Oestrogen and Progesterone Receptor Expression
The development of specific monoclonal antibodies to ER and PR in addition to 
improved antigen retrieval tecluriques has advanced immunohistochemical 
localisation. Immunohistochemistry has therefore been employed to determine 
receptor distribution in human endometrium. The ER and PR are immunolocalised to 
the nuclear compartments of cells with the description of their spatial localisation in 
broad teims divided between the superficial layer and basal layer of the 
endometrium. The layers are further categorised into stromal, glandular, endothelial, 
and perivascular regions. The following summary of receptor localisation will keep 
within this convention and will also cover the factors thought to regulate sex steroid 
receptor expression.
There are two isofonns of human PR known, PR-A and PR-B, which arise 
from the same gene (Clarke et al. 1990). The A isoform 779 amino acids (aa) in 
length is a truncated version of the B isoform that is 933 aa in length, the truncation 
of 164 aa being from the N temhnal end of the protein (Tung et al. 1993). There are 
also two distinct subtypes of ER that arise from two different genes: ERa (Kuiper et 
al. 1996) and ER(3 (Enmark et al. 1997). ERp was originally cloned from rat 
prostate(Kuiper et al. 1996)and later in the human (Mosselman et al. 1996), with the 
classical ER now designated ERa.
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Temporal variation in the expression of the ER and PR was initially detailed 
through studies by Lessey et al. comparing monoclonal antibody immunolocalisation 
with ligand binding studies (Lessey et al. 1988). These data revealed an increase in 
ER concentrations throughout the proliferative phase peaking in the early secretory 
phase of the cycle; thereafter the ER concentrations decline. A parallel but delayed 
increase in the PR was also described with a decline in the secretory phase of the 
cycle. Further immunohistochemical studies have demonstrated the nuclear 
localisation of the ER and PR in the endometrial compartments. In the stromal and 
glandular compartments, ER expression was maximal in the late proliferative phase. 
In the secretory phase, ER expression declined in the glandular and stromal 
compartments, with the ER decrease in the glandular compartment being more 
gradual. The PR also exhibits marked immunoreactivity in the nuclei of glands and 
stroma during the proliferative phase. In the secretory phase this immunoreactivity 
declines in the glandular compartment with a modest persistence of stromal 
immunoreactivity (Lessey et al. 1988; Snijders et al. 1992; Critchley et al. 1993).
With the development of two anti-progesterone receptor antibodies, a specific 
polyclonal raised against PR-B and the other a commercially available monoclonal 
raised against PR subtype A+B, it has been possible to refine the cellular localization 
of PR subtype A and B in the noimal endometrium throughout the menstrual cycle. 
As PR-A is a shorter splice variant it was not possible to raise an antibody specific to 
it alone, all immunohistochemical analysis of PR subtype A has further to been 
determined by subtractive inference (Wang et al. 1998). Using subtractive inference 
it was determined that the isoform of PR that mainly persists in the secretory phase 
stroma is PR-A (Wang et al. 1998). hr addition, both PR-A and -B are present in a 
perivascular location in the secretory phase, but not in the proliferative phase. Their 
expression supports a role of progesterone action either directly or indirectly 
influencing growth, development and function of the spiral arterioles in this phase of 
the menstrual cycle (Wang et al. 1998; Brosens et al. 1999).
It is also now possible to localise ERa and ER(3 using monoclonal antibodies. 
ERa and ER(3 are both immunolocalised in the nuclei of the glandular epithelial and 
stromal cells of functional and basal endometrium in the proliferative phase. The 
expression of ERa declines in the glandular and stromal of the functional layer while 
expression of ERp declines in the glandular cell nuclei, but not stroma, during the
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secretory phase. Levels of expression of ERa and ERp in all cellular compartments 
remain unchanged in the basal layer (Critchley et al. 2001).
Interestingly, unlike ERa, ERp was present in the nuclei of the endothelial 
cells of most blood vessels, including spiral arteries, capillaries, and veins. The 
intensity of immunoreactivity of ERp in the endothelial cells shows little change 
tlu'oughout the proliferative and secretory phases. These data supported the 
hypothesis that oestrogen action for regulation of the vasculature and angiogenesis is 
mediated via binding to ERp (Critchley et al. 2001).
1.7.2 Androgen Receptor Expression
Data available describing the immunolocalisation of AR has been conflicting 
reflecting the variety of antibodies and immunohistochemical techniques employed. 
The presence of an androgen receptor in human endometrium was initially shown 
with ligand binding studies (Muechler 1987; Fujimoto et al, 1994). However, 
subsequent immunolocalisation studies using the mouse monoclonal antibody 
(F39.4) localised AR in a variety of human tissues, but no receptors were localised to 
the uterus (Ruizeveld de winter et al. 1991). Horie et al., using rat anti-human 
monoclonal antibody, then reported the presence of the receptor in the ovary 
throughout the menstrual cycle (Horie et al. 1992). Using the same monoclonal 
antibody, this group found the androgen receptor to be present in endometrial glands 
and stroma throughout the menstrual cycle. The endometrial immunoreactivity was 
mainly in the functional layer with less in the basal layer (Horie et al. 1992). Kimura 
et al, and Takeda et al. also found immunoreactivity in endometrial stroma and 
glands but Takeda et al. less so in the glands (Takeda et al. 1990; Kimura et al. 
1993). Further contradiction arose when Chadha et al. also used the mouse 
monoclonal antibody, F39.4, to compare the endometrium of transsexual women on 
testosterone with the endometrium of pre-menopausal women to look for evidence of 
AR up-regulation. This study indicated absent or focal areas of AR immunoreactivity 
in the endometrium of pre-menopausal women compared with more intense and 
diffuse immunoreactivity in the testosterone treated patients, hi both groups the 
glandular epithelium was negative for AR (Chada et al. 1994). Recently Mertens et 
al. has localised the receptor to stromal cells with the most profound 
immunoreactivity in the basal layer and only minimal immunoreactivity in the
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glandular epithelium. This study also found no immunoreactivity in the late secretory 
phase indicating there may be temporal variation in expression within the menstrual 
cycle (Mertens et al. 1996). Mertens et al followed this study with further work in 
2001 confirming their previous findings (Mertens et al. 2001).
Most studies confirm the presence of AR in the uterus. The description of a 
stromal distribution of AR is not consistent but the more recent studies suggest that 
the most abundant immunoreactivity is within the stromal areas of the basal layer. 
The glandular epithelium appears to stain only very weakly for AR. As stated earlier 
the differences between these studies may be due to variations in 
immunohistochemical protocols and the different antibodies used.
Unlike the functional variants for ER and PR, AR has not yet been shown to 
have functional variant isoforms. Wilson et al. identified A (87k) and B (110-112IC) 
isoforms of the androgen receptor. Both isoforms were distributed widely in the body 
with the longer AR-B isoform being the more common. The isoform pattern is 
similar to the progesterone receptor, which also has two isoforms derived hom the 
same gene producing a longer B isoform, and a shorter N terminal truncated A 
iso form. The presence of two isoforms suggests that each may effect a different 
function depending upon the tissue or cell where it is sited (Wilson et al. 1996). 
However, the possibility that the AR-A isoform might be a proteolysed product of 
AR could not be ruled out. As no follow-up studies were reported about the N- 
temiinally truncated isoform of AR, the concept of AR isoforms is not widely 
accepted (Lee et al. 2003).
With improvements in immunohistochemical techniques it would be hoped 
that a greater consistency in the localisation of AR may emerge. Further work is 
necessary to characterise the spatial and temporal variation in expression of the AR 
in human endometrium through the menstrual cycle in addition to confimiing that 
protein expression is substantiated by evidence of AR mRNA production.
67
1.7.3 Regulation of Endometrial Sex Steroid Receptors
1.7.3.1 Oestrogen and Progesterone Receptor Regulation
The PR is controlled by both oestrogen and its own ligand progesterone. In the 
oestrogen dominated proliferative phase PR is up regulated secondary to the 
oestradiol up regulation of PR mRNA via an oestrogen response element that results 
in increased PR protein synthesis (Clarke et al. 1990). In the progesterone dominated 
secretory phase it’s own ligand, progesterone, initiates down regulation at both the 
transcriptional, via the same oestrogen response element (Savouret et al. 1991), and 
post transcriptional levels (Chauchereau et al. 1992).
In keeping with the regulation of PR, ER is controlled by its own ligand, 
oestrogen, and progesterone. In the proliferative phase, oestradiol interacts with the 
oestrogen response element up regulating the production of ER mRNA with resultant 
increase in receptor levels. In the secretory phase, progesterone initiates down 
regulation of ER at the ER mRNA level via interaction with its hormone response 
element resulting in reduced ER (Clarke et al. 1990).
1.7.3.2 Androgen Receptor Regulation
While the functional significance of the androgen-AR receptor pathway in the male 
reproduction system is well studied, that in the female has been little understood due 
to the lack of a proper model system. The generation of an AR knockout (ARKO) 
female mouse model has long been hampered, because the AR gene is located on the 
X clu'omosome (Lee et al. 2003). However, recently ARKO female mice have been 
successfully generated (Yeh et al. 2002). The study demonstrated that homozygous 
ARKO female mice produced a smaller number of pups per litter with an average of 
four, whereas the counteipart wild-type female mice produced an average of eight 
pups per litter. This result indicates that AR may play a role in female fertility and/or 
ovulation (Yeh et al. 2002). Further study indicated that homozygous ARKO female 
mice suffer Eom defective folliculogenesis due to poor follicular maturation and 
defective implantation due to subnormal uterine development (Lee et al. 2003).
In human endometrium data regarding the regulation of the AR is, similar to 
its immunolocalisation, conflicting and lacking in clarity. Research has been earned 
out to determine possible mechanisms regulating the androgen receptor expression
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with many studies being ligand binding studies and only a few immunohistochemical 
studies. No quantitative methods of detemiining mRNA have been employed.
Fujimoto et al. studied women given an intramuscular injection of oestradiol 
dipropionate (ED) with or without testosterone cypionate (TC) 1 week prior to 
hysterectomy. ED alone significantly increased AR mRNA and testosterone binding 
sites but when administered with TC the testosterone binding sites were significantly 
reduced and the AR mRNA level showed a non significant increase. Suggesting that 
while TC significantly reduced testosterone binding sites it had no significant effect 
on AR mRNA levels(Fujimoto et al. 1995).
Iwai et al experimenting on endometrial stromal cell cultures found that 
progesterone and testosterone independently were able to decrease ER mRNA, PR 
mRNA, and AR mRNA levels in a dose dependant maimer (Iwai et al. 1995). It is 
difficult to compare the Fujimoto et al. results with those of Iwai et al. as the patients 
in Fujimoto’s study were part of an in-vivo study and the patients received ED as 
well as TC. However, the Iwai et al. study did show a decrease in AR mRNA levels 
occurred after 9 days in culture. This finding may explain the difference with 
Fujimoto’s results as these patients were operated upon only seven days after their 
testosterone injections.
Studies regarding AR regulation in endometrium have been carried out in 
Rhesus monkeys. In 1999 Adesanya-Famuyiwa et al. showed a non-significant 
increase in AR mRNA with oestradiol treatment alone but significant increases were 
seen in stromal, glandular and myométrial compartments when oestradiol was given 
in combination with progesterone or testosterone (Adesanya-Famuyiwa et al. 1999).
More recent immunohistochemical data is available from Mertens et al. and 
Chadha et al. Mertens et al., while not examining regulation directly, described 
temporal variation in expression of the AR with a down regulation of the receptor in 
the late secretory phase (Mertens et al. 1996; Mertens et al. 2001). As the reduction 
in receptor expression occurs during the progesterone dominated secretory phase, it 
may be suggested that the down regulation is secondary to a progesterone regulated 
mechanism. Chada et al. were able to obtain the uteri of patients receiving 
testosterone supplementation as a component of treatment to become a transsexual. 
In this situation where testosterone was administered in a continuous regimen the
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patients exhibited more intense AR immunoreactivity compared with controls 
suggesting possible androgen mediated up-regulation (Chada et al. 1994).
In summary, a consistent increase in AR mRNA is seen when estrogen is 
given with progesterone or testosterone. When oestradiol is given alone a significant 
increase may occur in AR mRNA in addition to increasing testosterone binding sites. 
When progesterone is administered alone, a decrease in AR mRNA is noted. 
However, when testosterone is administered alone a decrease or increase in the AR 
has been observed. In some aspects it would appear to parallel the pattern of 
progesterone receptor regulation. PR is up regulated by oestradiol and is down 
regulated by its own ligand, progesterone. There is yet no clarity in this field with 
further work required to establish the mechanism of AR regulation.
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1.8 Menstruation
Menstruation is a physiological event involving shedding of the superficial layer of 
the endometrium producing cyclical uterine bleeding. Normal menstruation occurs 
with the fall in progesterone levels secondary to luteal regression. The mechanisms 
regulating menstruation continue to be the subject of intense research despite the 
gross physiological events being known for over sixty years.
Classic studies unlikely to be reproduced were conducted by Markee in the 
rhesus monkey. Endometrial explants were transplanted into the anterior chamber of 
the eye allowing direct visualisation of stromal and vascular events following 
progesterone withdrawal. The events noted include stromal shrinlcage, increased 
coiling of spiral arterioles and vascular stasis. Subsequently there was a period of 
vasodilatation and perivascular bleeding followed 24 hrs later by intense 
vasoconstriction, tissue necrosis and menstruation (Markee 1940).
The sequence of events resulting in menstruation is initiated if the oocyte 
released at ovulation is not fertilised. The failure of HCG secretion in the absence of 
a conceptus leaves no drive for the corpus luteum to continue steroidogenesis, 
resulting in luteal regression and a fall in serum progesterone. Following 
progesterone withdrawal in the secretory phase there is an increase in the stromal 
density of a unique population of leukocytes named uterine NIC cells (CD 56 
CD 16" ) associated with an increase in local cytokine production (Loke et ah 1995; 
King 2000)and MMP expression. The association of leukocyte invasion, cytokine 
release and MMP expression has led to menstmation being described as an 
inflammatory event (Finn 1986; Kelly 1994; Critchley et al. 2001).
It is hypothesised by Kelly et al. (Kelly et al. 2001) that menstruation is a 
biphasic event with an initial progesterone dependant phase followed by a 
progesterone independent phase. In the initial phase up-regulation of inflammatory 
mediators such as cytokines, prostaglandins and vasoconstriction are potentially 
reversible progesterone dependant mechanisms. The subsequent phase is then 
inevitable with the changes at this point occurring independently of progesterone 
withdrawal and likely secondary to endometrial hypoxia. Figure 1.12 provides an 
illustrative overview of the induction of menstruation.
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Figure 1.12
Illustration summarising the effects of progesterone withdrawal and hypoxia on the 
mechanisms that may be involved with induction o f menstruation. Progesterone 
withdrawal results in an up-regulation of inflammatory mediators, production of 
MMPs, a leukocyte influx and expression o f stromal KDR in the upper endometrial 
zones. There is coincident hypoxia and an up-regulation of VEGF. VEGF binds to its 
type 2 receptor, KDR and there is a paracrine/autocrine action on the up-regulation 
of MMP production in the same endometrial upper zone stromal cells. Menstrual 
sloughing takes place from the functional layers o f the endometrium (Critchley et al. 
2001).
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1.8.1 Progesterone dependant mechanisms in menstruation
In the initial phase, the withdrawal of progesterone modulates factors that will 
encourage leukocyte recruitment and activation in the endometrium in addition to 
factors that induce changes in vascular permeability, such as prostaglandins.
Leukocyte influx during the secretory phase consists of uterine NIC cells, 
neutrophils, mast cells, macrophages and other haematopoietic cells. It is likely that 
this influx will represent a combination of in-situ proliferation and migration horn 
the peripheral circulation (Salamonseii 2000). Regulation of leukocyte proliferation 
and migration is not yet clear. Factors that have been examined include sex steroids, 
cytokines and prostaglandins.
In a hormonally driven target organ such as the endometrium it would be 
anticipated that sex steroids would play a key role in events such as leukocyte 
migration. However, ERa and PR have not been immunolocalised in the major peri- 
menstrual leukocyte, the uterine NK cell (King et al. 1996; Stewart et al. 1998), 
suggesting these sex steroid receptors have no direct role. The PR is however 
prominent in a perivascular location (Perrot-Aplanat et al. 1988; Perrot-Aplanat et al. 
1994; Wang et al. 1998) with an absence of endothelial cell immunoreactivity 
(Kolnien et al. 2000) suggesting that indirect mechanisms for progesterone action 
may exist within the perivascular region. A role for AR, the other major sex steroid, 
has not as yet been examined.
The cells that compose the perivascular region are heterogeneous (Roberts et 
al. 1992) with the main type appearing to myofibroblasts, they express smooth 
muscle a -actin and the fibroblast marker vimentin (Kohnen et al. 2000), a quality 
shared by decidual cells. The perivasculai" region is known to be a rich source of 
inflammatory mediators such as prostaglandins and cytokines. Key inflammatory 
mediators such as Cyclooxygenase 2 (COX-2), Interleukin-8 (IL-8) and Monocyte 
Chemotactic Peptide-1 (MCP-1) have all been localised to the perivascular region 
with significant up regulation in the late secretory phase (Jones et al. 1997). 
Prostaglandins are also up regulated in the secretory phase of the menstrual cycle 
(Smith et al. 1981) with PGE in particular expressed in a perivascular location 
(Cheng et al. 1993). Progesterone stimulation of the perivascular region may be 
responsible for the prostaglandin and cytokine production.
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Evidence for progesterone regulation of these inflammatory mediators is 
available. All are up regulated in the late secretoiy phase, a point when progesterone 
levels are in decline, coincident with leukocyte accumulation in the endometrium 
(Jones et al. 1997). In vivo administration of the anti-progestogen RU486 
(Mifepristone) when decidualised endometrium is present results in significantly 
increased expression of PGE in the perivascular region of the decidua (Cheng et al.
1993). Similarly, up regulation of IL-8 is also noted in endometrium (Critchley et al. 
1999) and decidua (Critchley et al. 1996) following administration of mifepristone.
The up-regulated cytokines and prostaglandins are believed to act 
synergistically in the proposed mechanisms of menstruation (Kelly et al. 2002). IL-8 
is chemotactic for both neutrophils and NK cells. It is produced by monocytes and 
fibroblasts and in endometrium it has been localised to the perivascular region 
(Critchley et al. 1994; Jones et al. 1997; Milne et al. 1999). MCP-1 is also produced 
by monocytes, fibroblasts and additionally by epithelial cells. It has been localised to 
the perivascular region in human endometrium (Jones et al. 1997; Critchley et al. 
1999)and is chemotactic for both monocytes and NK cells. An in-vivo experimental 
model of progesterone withdrawal demonstrated up-regulation of IL-8 and COX-2 
mRNA and protein 48 hours following progesterone withdrawal (Critchley et al. 
1999).
The peri-menstrual influx of haematopoietic cells releases more cytokines 
providing further signals for leukocyte migration. The leukocytes release enzymes 
that play direct and indirect roles in menstruation. Secretory products of leukocytes 
such as elastase digest elastin or certain collagen types (Salamonsen et al. 2000). 
Indirect mechanisms involve the activation of Matrix Metalloproteinases (MMP). 
MMP’s are enzymes that can degrade the extracellular matrix (ECM) and basement 
membranes of tissues but are not usually synthesised in nomial connective tissue 
(Birkedal-Hansen et al. 1993). However, they have been reported as key enzymes in 
the breakdown of the endometrial ECM with a focal distribution in the peri- 
menstrual phase (Salamonsen et al. 1999). The focal MMP expression suggested 
local regulation and due to the spatial and temporal distribution of leukocytes within 
the endometrium they must be considered as a possible mechanism of regulation. 
Leukocytes may directly release MMP’s and indirectly via paracrine interactions
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they can induce endometrial cells to produce MMP or activate MMP’s secreted by 
local cells (Salamonsen et al. 2000).
In-vitro experiments have shown sex steroids to be regulators of MMP 
expression with up-regulation of MMP’s following progesterone withdrawal. The 
action of progesterone upon the oestrogen primed endometrium inliibits MMP-1, a 
collagenase, preventing degradation of the ECM but upon its withdrawal the up 
regulation of MMP-1 allows ECM degradation which is thought to be a key element 
of menstruation (Lockwood et al. 1998). Evidence also exists for progesterone 
regulation of MMP-2, a gelatinase, in-vitro data showing up-regulation following 
withdrawal of progesterone (Irwin et al. 1996).
Other inflammatory mediators that are regulated by progesterone include the 
prostaglandins (Abel et al. 1980). Elevated levels of which are found in the 
endometrium (Pickles 1957; Downie et al. 1974). Indeed prostaglandin synthetase 
inhibitors remain a component of the management strategies for the treatment of 
menorrhagia (Cameron et al. 1990; Fraser 1992) and their role in menstruation is 
reviewed by Baird et al (Baird et al. 1996). Prostaglandin synthetase has an isofomi, 
Cyclooxygenase 2 (C0X2), which is expressed in human endometrium. The enzyme 
is inducible by a variety of factors and inliibited by progesterone and glucocorticoids 
(Baird et al. 1996). Highest levels of C0X2 have been shown in the menstrual phase 
(Jones et al. 1997) in keeping with the secretory phase decline in serum progesterone 
levels. Further evidence of its progesterone regulation is shown data from 
Hapangama et al. where administration of mifepristone in the mid luteal phase 
produced a significant increase in the expression of COX2 (Hapangama et al. 2002). 
In addition, this study also showed that a significant decline in the luteal phase 
expression of Prostaglandin dehydrogenase (PGDH) following administration of 
mifepristone (Hapangama et al. 2002), PGDH is responsible for the inactivation of 
prostaglandins and its down regulation will therefore result in elevated levels of 
prostaglandins. C0X2 products that appear to be of particular importance are PGE-2 
and PGF-2a. PGE-2 is a vasodilator that acts synergistically with bradykinin to 
increase oedema and pain (Williams 1979). PGF-2a is a vasoconstrictor that 
stimulates myométrial and other smooth muscle contractility; and intrauterine 
administration induces menstruation (Lundstrom 1977; Martin Jr et al. 1978).
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A number of key events in the peri-menstrual phase are under the influence of 
progesterone. Progesterone withdrawal, as first described by Markee, induces 
vasoconstriction of the spiral arterioles and up-regulates an inflammatory response. 
The prostaglandins up-regulated in the inflammatory response may also be the 
mechanism of vasoconstriction. This however has yet to be determined with other 
candidates having been proposed, such as endothelins (O'Reilly et al. 1992) and 
angiotensin II (Almied et al. 1995). Of particular interest the perivascular stromal 
cells are reported to be intensely immunoreactive for angiotensin II, a region that 
also expresses the progesterone receptor. Slayden et al. also provide data to support 
this hypothesis. In their paper if  progesterone is “added back” within 36 hours of 
progesterone withdrawal, menstruation can be prevented. If progesterone is added 
back more than 36 hours following progesterone withdrawal then menstruation is 
inevitable (Slayden et al. 1999). It is therefore after this period that progesterone 
independent mechanisms are important in the menstrual process.
1.8.2 Progesterone Independent mechanisms in menstrnation
Progesterone dependent events include mechanisms that produce hypoxic conditions 
within the endometrium. In the premenstmal phase, constriction of the spiral arteries 
after progesterone withdrawal induces a local endometrial hypoxic injury. In this 
phase it has been shown that prior to the onset of bleeding there is degeneration in 
the tissue architecture supporting the decidualised endometrial cells and the 
endothelium of the endometrial blood vessels (Roberts et al. 1992). The degradation 
of the extracellular matrix (ECM), as previously noted, is likely to involve the 
MMP’s. A close association between menstruation and MMP activity has been 
shown (Salamonsen et al. 1996; Hulboy et al. 1997; Rudolph-Owen et al. 1997). The 
greatest MMP activity was noted in the pre-menstrual and menstrual phases with 
activity confined to the functional layer of the endometrium which is shed during 
menstruation. Progesterone has a role to play in the control of MMP activity but P 
withdrawal is a generalised endocrine action and MMP up regulation in endometrium 
is focal (Salamonsen et al. 1996). It has been hypothesised that the hypoxia produced 
by spiral artery constriction, which is greatest in the superficial functional layer, may 
be the event that initiates the cascade culminating in MMP up-regulation and ECM 
degradation.
77
Hypoxia also stimulates local mediators including cytokines and Vascular 
endothelial growth factor (VEGF). VEGF is present in human endometrium tlnough 
the menstrual cycle (Shifren et al. 1996) with up-regulation noted in the menstrual 
phase (Charnock-Jones et al. 1993; Sharkey et al, 2000). In addition to being up- 
regulated under hypoxic conditions (Popovici et al. 1999; Sharkey et al. 2000) VEGF 
has also been shown to up-regulate MMPs (Unemori et al. 1992; Wang et al. 1998). 
The close spatial (functional layer) and temporal association (premenstrual phase) of 
VEGF and MMP’s was described by Nayak et al. (Nayak et al. 2000).
Nayak et al described the up-regulation of the VEGF receptor type2 (KDR) in 
the stromal cells of the functional layer o f the endometrium following progesterone 
withdrawal. KDR is normally found only in endothelial cells but in this case was 
significantly up-regulated in stromal cells of the upper endometrial zones. Hypoxia is 
not thought to directly induce such effects (Gerber et al. 1997). It was therefore 
hypothesised that the up-regulation of KDR may be as a consequence of hypoxia 
induced VEGF up-regulation (Sharkey et al. 2000) indirectly up-regulating KDR. 
Therefore, as VEGF can affect MMP expression the up-regulation of KDR is a 
possible mechanism whereby VEGF can produce such a ligand binding effect.
Hypoxic induction of the VEGF-MMP pathway contributes to other proposed 
factors where expression is influenced by the premenstrual phase. These other factors 
include tumour necrosis factor (TNF)-a (Tabibzadeh 1996), prostaglandins (Baird et 
al. 1996) and tissue plasminogen activator (Schatz et al. 1995). The role of, and 
interplay between, these mechanisms with regards to menstruation remain to be 
resolved.
Progesterone does appear to have an important role to play as its withdrawal 
following luteal regression initiates a cascade of factors that are implicated in the 
mechanism of menstruation. Hitherto a role for the androgens has not been suggested 
or investigated. Chapter 1.7.2 describes the expression of the AR in human 
endometrium and there is evidence to suggest that it may be temporally expressed 
with a down regulation in the late secretory phase. If the reduced availability o f AR 
is confirmed in the late secretory phase, androgens will have a diminished ability to 
influence endometrial function which may be of significance with regards to 
menstruation.
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1.9 Deddualisation
In humans, the ability of the endometrium to undergo the morphological changes that 
result in decidualisation is a key event to allow blastocyst implantation. Despite 
decidualisation being an important intrauterine event, little is known regarding the 
exact mechanisms involved (King 2000).
The precise role of decidualisation in allowing blastocyst implantation and 
successful placentation is unknown. A possible role may be to control the extent of 
maternal spiral arteriole invasion by trophoblast cells (Osteen 1998; Pijnenborg 
1998). The importance of such a control mechanism is exhibited in patients where 
trophoblast invasion exceeds the limit of the decidua and becomes morbidly adherent 
to the myometrium (Placenta Accreta) or invades through the entire myométrial wall 
of the uterus (Placenta Percreta). Such clinical problems are potentially life 
threatening due to hemorrhage and are more common when implantation occurs at 
sites where there may be defective decidualisation such as the uterine cornu or at the 
site of a caesarean section scar. Decidual trophoblast interaction may therefore alter 
matrix metalloproteinase (MMP) expression, cytokine production, surface amounts 
of integrin and major histocompatability complex (MHC) molecules (Loke et al. 
1995). While the mechanisms that initiate decidualisation are not yet understood, the 
key role of progesterone acting upon oestrogen primed tissue is well recognized 
(Maslar 1988). Key morphological and functional changes occur in endometiial 
stromal cells, glandular epithelium, spiral arterioles and endometrial leukocyte 
population.
1.9.1 Stromal Cells
Stromal cells enlarge mainly due to an increase in cytoplasm that stains pale pink 
with haemotoxylin and eosin. The stromal cells produce prolactin (Jones et al. 1998), 
insulin-like growth factor binding protein 1 (IGFBP-1) (Pekonen et al. 1992; 
Rutanen et al. 1997), and tissue factor among other substances. The exact role that 
this change in function plays is not yet known. An additional functional change that 
is also not fully understood is the fomiation and deposition of extracellular matrix 
proteins, such as fibronectin, in a peri-cellular manner. A proposed function is that 
this provides a framework for trophoblast cells to maneouvre towards spiral
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arterioles and myometrium. Progesterone does however appear to play a critical role 
in such functional changes (Loke et a l 1995).
1.9.2 Glandular Epithelium
The glands in decidualised endometrium, in contrast to their late secretory saw tooth 
appearance, continue to produce glandular secretions especially in the lower third of 
the endometrium where stromal cells are not so evident (Decidua Spongiosa). The 
upper two thirds of the decidua (Decidua Compacta) stops secretion and the glands 
become attenuated (King 2000).
1.9.3 Spiral arterioles
The spiral arterioles, in keeping with other endometrial components, undergo 
dynamic changes tlnough the menstrual cycle. From thin walled vessels in the 
proliferative phase they obtain actin rich thicker walls as the menstrual cycle 
advances also increasing in tortuousity (Kam et al. 1999). While the arterioles may 
become more prominent, there is no angiogenesis on the same level as visualised in 
the placentation of other species. Instead, human placentation involves the 
destruction of existing arterial walls and subsequent dilation of the vascular space.
1.9.4 Endometrial Leukocytes
Endometrial leukocyte populations vary tlrroughout the menstrual cycle. However, 
standard morphological stains such as haemotoxylin and eosin will not reveal 
leukocytes, therefore Immunohistochemical localisation with leukocyte markers is 
necessary (King et al. 1998).
In the human endometrium, spatial differences in leukocyte populations are 
noted. The basal layer contains lymphoid aggregates populated by mainly T cells 
with occasional B cells. The functional layer contains a scattering of uterine Natural 
Killer (uNK) cells, T cells and B cells. Of this group the macrophages show an 
increase pre-menstrually and significant increase at the implantation site. The uNK 
cells are present in low numbers during the proliferative phase but during the 
secretory phase they increase significantly in number until the pre-menstrual phase, 
in the absence of pregnancy (King et al. 1989).
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In decidua, uNK cells remain in significantly increased numbers if pregnancy 
occurs and in particular in the basal decidua where trophoblast cells are also greatest 
in number. The uNK cells appear to be a distinct cell type different from those NK 
cells found in the systemic circulation. Other terms for this unique cell type include 
large granular lymphocytes (LGL) (King et al. 1991), endometrial granulocytes 
(Hamperl et al. 1958), K cells (Spornitz 1992), endometrial granulated lymphocytes 
(Buhner et al. 1991), or decidual granulated lymphocytes (Deniz et al. 1996). To 
encompass all ternis this cell type is now called the uterine NK cell and this cell is 
the predominant leukocyte at the time of decidualisation(King 2000). The uNK cells 
are distinguished from systemic NK cells by their surface cluster determination (CD) 
markers. Uterine NK cells express high levels of the universal NK cell marker CD 56 
and do not express CD 16 (CD 56 CD 16") whereas systemic NK cells have low 
concentrations and do express CD 16 (CD 56 CD16^)(King 2000).
High levels of uNK cells at the time of decidualisation suggest that they may 
have an important role to play in the process. uNK cells increase in number during 
the early secretory phase, particularly around both arteries and glands. The 
proportion o f uNK cells in the stromal compartment reaches 30-40% by the late 
secretory phase. Despite their rise and persistence in decidua occurring at the time of 
progesterone dominance, in addition to studies showing that progesterone can 
increase CD 56 cell numbers (Inoue et al. 1996), it would not appear to be an event 
directly regulated by progesterone. uNK cells have not been shown to express classic 
genomic sex steroid receptors (King et al. 1996; Stewart et al. 1998). Recently, 
Henderson et al. have described the expression of ERp and Glucocorticoid receptor 
in uNK cells(Henderson et al. 2003). However, it may be that progesterone has an 
important paracrine influence in suiTounding stromal cells, which may in turn 
influence uNK cell function, as the stromal cells express PR at this time.
The role that uNK cells play in the decidualisation process is unknown. Their 
importance may be inferred from studies in patients with recurrent miscarriage 
(Lachapelle et al. 1996) or failed implantation with in vitro fertilisation therapy 
(Fukui et al. 1999). In both groups, mid secretory endometrium revealed altered 
leukocyte profiles when compared with normal. The endometrium had fewer CD 56 
Bngiii QjQ 26" and more CD 56 CD 16^ cells. This suggests that the altered profile
produces a hostile implantation environment, leading to fetal loss. Further data to
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support a role for CD56 cells in decidualisation are available from murine studies 
where similar cell types are noted. Mice lacking these cell types showed a failure of 
decidualisation and a lack of spiral arteriole development (Aslilcar et al. 2001).
The increase in uNK cells in the progesterone dominated secretory phase in 
addition to their persistence in decidualised endometrium would tend to suggest they 
are likely to play an important role but the precise nature of their regulation and the 
role played in endometrial physiology is yet to be determined.
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1.10 Implantation
Blastocyst implantation is the initiating event in a 9-month long complex, highly 
coordinated and controlled maternal-embryonic interaction. Among the initial events 
important for implantation is ovulation allowing release of an oocyte and formation 
of the corpus luteum that will drive the progesterone dominated secretory phase. As 
discussed in Chapter 1.9 the endometrium undergoes morphological and functional 
differentiation in the presence of progesterone that is termed pre-decidual and 
following conception decidual formation is stimulated to facilitate implantation.
To establish implantation of the blastocyst there must be initial apposition to 
the maternal epithelium, intrusion of trophoblast, and then invasion of the 
endometrial compartments (Lessey 2000). The embryo enters the uterine cavity 72- 
96 hrs after fertilisation. Hatching of the embryo by day 5 allows release of the zona 
pellucida exposing receptors, cell adhesion molecules (CAMs), MMPs and 
extracellular matrix components (ECM) that are likely to be involved in the next 
stage of implantation (Lessey 2000).
The initial step of blastocyst attacliment is thought to involve the extraction 
of fluid from the uterine lumen by specialized endometrial apical protrusions called 
pinopods. Pinopods are thought to be progesterone-dependent cellular organelles 
appearing between days 19 and 21 of the cycle and could therefore be markers of the 
implantation window. The maximum life span of these pinopods is only 48 hours. As 
pinopods extract fluid from the uterine lumen, the blastocyst is drawn towards the 
uterine epithelium. This process is termed blastocyst apposition (Sunder et al. 2000).
In the next stage, adhesion of the blastocyst, trophectodeiinal cells establish 
close contact with the apical surface of the uterine epithelium. Adhesion molecules 
are thought to be important in modulating adhesion with MUC-I being the most 
extensively studied to date. MUC-1 has been localised to human endometrium, is an 
oestrogen responsive cell membrane glycoprotein that appears to have anti-adhesive 
properties and is expressed at the luminal endometrial surface in the mid-secretory 
phase (Meseguer et al. 1998). This observation suggests the existence of a barrier to 
the implanting embryo and the need for a locally acting mechanism for the removal 
of inliibition. It is possible that, as in rabbits, the local down-regulation of maternal 
MUC-1 is in response to a paracrine signal from the embryo. Murine studies have
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shown that high levels of MUC-1 create a non-receptive endometrium but this role 
has not yet been demonstrated in humans (Carson et al. 1998; Meseguer et al. 1998). 
The role of MUC-1, it’s hormonal regulation and its properties as an anti-adhesion 
molecule are controversial in humans but animal studies suggest that it may be an 
important factor for successful adhesion (Simon et al. 2000).
Other adhesion molecules that appear to play a role include Trophinin (Aplin 
2000; Sunder et al. 2000) and integrins (Sunder et al. 2000), both of which are 
expressed in the implantation window of endometrium, hi particular, the integrins 
may have a role in integrating trophoblast with decidua, embryo attachment and 
initial invasion of the embryo into the extracellular matrix. Some of the integrins 
facilitate the expression of MMP-like collagenases, gelatinases and stromeolysins 
that play a major role in trophoblast invasion(Sunder et al. 2000).
The next stage of implantation is invasion of the trophoblast into the uterine 
epithelium. Uterine NK cells interact with invading trophoblast to generate leukemia 
inhibitory factor (LIF). LIF is thought to induce urokinase plasminogen activator 
(uPA) and gelatinase enzymes that play a role in trophoblast invasion. NK cells may 
also have an important role to play through their interactions with HLA-G and HLA- 
C class antigens, antigens expressed by the invading trophoblast. This response may 
in part explain the successful interactions between tissues of disparate immunogenic 
sources, the embryo and the endometrium, in implantation (Loke et al. 2000; Sunder 
et al. 2000).
While other factors have been suggested to play an important role in 
blastocyst implantation, they are too expansive for inclusion in this thesis. However, 
specific data pertaining to a potentially important role for androgens exists.
Most recently murine studies carried out in androgen receptor laiockout mice 
revealed impaired fertility compared to wild type mice, possibly related to subnormal 
uterine development(Lee et al. 2003). In human females with elevated semm 
androgens low levels of glycodelin-A (previously known as placental protein 14 -  
PP14) have been shown in uterine flushings (Okon et al. 1998). Another factor 
important for endometrial receptivity that has been negatively correlated with 
androgens is H OX A-10 (Cennik et al. 2003).
Glycodelin-A is a major protein secreted by the secretory endometrium and 
gestational decidua that can be found in uterine flushings(Li et al. 1993). Its role in
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implantation is thought to be mediated tltrough inliibition of the maternal immune 
system. Specifically it inhibits uterine NK cell cytotoxicity (Okamoto et al. 1991) 
and diminishes the IL-2 enhanced cytotoxicity of the NK cells (Seppala et al. 2001). 
Secretory phase levels of glycodelin-A in the plasma and uterine flushings of women 
who have recurrent miscaniages are lower than those of normal fertile women 
(Dalton et al. 1995; Tulppala et al. 1995).
Endometrial development and receptivity requires transcriptional regulation 
by HOX genes (Cermik et al. 2003). Specifically, H OX A-10 is essential for the 
development of the uterus during organogenesis (Block et al. 2000) and it is also 
essential for allowing uterine receptivity to implantation (Taylor 2000). Female mice 
deficient in FlOXA-10 are viable but have infertility caused by uterine defects, 
unable to support implantation (Satokata et al. 1995). In women, HOX A -10 
expression varies during the menstrual cycle, with a dramatic rise in the mid-luteal 
phase (Taylor et al. 1998). This rise corresponds to the time of implantation and 
remains elevated throughout the rest of the luteal phase. Regulation of maternal 
HOX A-10 expression is essential to blastocyst implantation and reproductive 
success. HOXA-10 is up regulated by oestrogen and progesterone in 
endometrium(Taylor et al. 1998). However, recent work by Cermik et al. has shown 
that testosterone will diminish endometrial expression of HOXA-10(Cermik et al. 
2003). Such data would be consistent with elevated androgens, associated with 
PCOS and recurrent miscarriage, producing an endometrial environment unreceptive 
to implantation, resulting in impaired fertility.
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1.11 Effects of Levoiiorgestrel on the Endometrium
Levonorgestrel is a potent progestogen which also has a binding affinity for the 
androgen receptor (Kloosterboer et al. 1988). The Levonorgestrel Releasing Intra­
uterine System (LNG-IUS) was initially developed as a contraceptive with the Pearl 
index (a measure of pregnancy rate) varying from 0.0-0.2 per 100 women-years with 
its 5-year contraceptive duration (Luukkainen et al. 1990). Additionally the LNG- 
IUS will significantly reduce menstmal blood loss (Andersson et al. 1990), menstmal 
pain and is associated with a low rate of infection (Limklcainen et al. 1990). The 
contraceptive effect of the LNG-IUS, the reduction in menstrual blood loss, and 
amenorrhea in some cases, are thought to be due to local effects on the endometrium 
(Nilsson et al. 1984). Ovarian function appears to be unaffected with studies 
confirming ongoing ovulation with LNG-IUS treatment (Nilsson et al. 1984; Xiao et 
al. 1995).
The LNG-IUS has a T-shaped body (32 x 32 mm) made of polyethylene. An 
elastomer sleeve is mounted around its vertical part. This sleeve consists of a 1 to 1 
mixture of polydimethylsiloxane and 52 mg of levonorgestrel. The sleeve is covered 
with a drug release controlling membrane of medical grade polydimethylsiloxane. 
This system releases levonorgestrel over an extended time of up to 5 years at a 
practically constant rate. The initial release rate of levonorgestrel is 20 pg per 24 h. 
At the end of 5 years, the release rate is still above 10 pg per 24 h. The LNG-IUS 
was first introduced in Finland in 1990 (Lahteenmaki et al. 2000).
The histological appearances after an insertion time of 1 month are uniform 
suppression throughout the thickness of the functional layer of the endometrium. The 
histological picture is independent upon the distance from the intrauterine device. 
Typical findings are a 1 to 3 mm endometrium with a swollen stroma and enlarged 
cells consistent with a pseudo-decidual appearance. The endometrial glands are 
scarce, extremely narrow, and atrophic and lined by inactive, flattened cuboidal 
epithelium with no signs of mitotic activity or iiTegularity. No difference could be 
seen between specimens obtained during the luteal phase and those obtained during 
the follicular phase or those obtained from subjects not ovulating during treatment 
(Nilsson et al. 1978; Silverberg et al. 1986; Critchley et al. 1998). The changes in
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endometrial morphology return to normal within 1-3 months following removal of 
the LNG-IUS (Silverberg et al. 1986).
The endometrial tissue concentrations of LNG are much higher with the 
LNG-IUS, far exceeding the tissue levels found with high systemic doses of LNG. 
Indeed endometrial LNG tissue levels are 1,000 times greater than serum 
concentrations (Nilsson et al. 1982). Therefore, the endogenous, systemic 
progesterone effect on the endometrium would be masked, despite circulating 
progesterone concentrations remaining in the nonnal follicular-luteal phase range 
(Critchley et al. 1998). Additionally, there is no reduction in oestrogen 
concentrations because women using an LNG-IUS as a rule have normal ovulatory 
cycles.
Sub-dermal LNG administered as a long term contraceptive exhibits an 
increase in immunoreactivity of the stromal progesterone receptor when compared 
with control endometrium at all stages across the menstrual cycle (Critchley et al. 
1993). Endometrial treatment with the LNG-IUS providing continuous high local 
LNG levels, down regulates oestrogen and progesterone receptors in both glands and 
stroma with suppression being maintained until the 12 month time point (Critchley et 
al. 1998). Similar findings were also published by Zhu et al where again after 12 
months treatment with the LNG-IUS a down regulation of oestrogen and 
progesterone receptors in both glands and stroma was noted (Zhu et al. 1999). 
However, progesterone receptor A levels appear to increase in the stroma by the 12 
month time point (Critchley et al. 1998). This finding for the progesterone receptor 
subtype expression in LNG pseudo-decidualised endometrium is consistent with the 
observations in first trimester decidua (Wang et al. 1998). The lack of endometrial 
sensitivity to oestradiol during intra-uterine exposure to LNG is likely reflected in 
the down regulation of endometrial ER. However, the presence of LNG-IUS also 
disrupts oestradiol mediated proliferation of the endometrium by the stimulation of 
Insulin-like growth factor (IGF) binding protein production in endometrium. This 
prevents IGF-1 from perfomiing its normal mediation of oestradiol activity to induce 
endometrial proliferation (Pekonen et al. 1992; Rutanen 2000).
Other endometrial factors that have been shown to be affected by intra­
uterine LNG-IUS administration treatment are prolactin receptors, granulocyte- 
macrophage colony stimulating factor (GM-CSF) and uterine NK cells. There are
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significant increases in prolactin receptors and granulocyte-macrophage colony 
stimulating factor (GM-CSF) immunoreactivity in the glandular epithelial and 
pseudo-decidual stromal cells. GM-CSF is an activating growth factor for 
granulocytes and monocytes whereas prolactin is an immune regulation agent and 
may play a role in leukocyte function. As a result, there is a significant increase in 
the endometrial leukocyte population, the majority of which are CD56+ uterine NK 
cells (Critchley et al. 1998).
LNG is Imown to bind to both the androgen receptor and the progesterone 
receptor (Kloosterboer et al. 1988). It does not possess any binding affinity for the 
oestrogen receptor. It can be metabolised by the same enzymes responsible for sex 
steroid metabolism and this can influence the binding affinity of LNG. Lemus et al. 
examined tissue metabolism of LNG in rats and demonstrated that following 5a 
reduction it will have a greater binding affinity for androgen receptor (AR) but 
diminished binding for progesterone receptor (PR) (Lemus et al. 1992).
Users of a LNG-IUS often report breakthrough bleeding (BTB). Indeed this 
complaint is the commonest reason for discontinuation of the method. The manner in 
which it affects mechanisms involved with vascular control such as VEGF, tissue 
factor, vessel density and vessel size has been the subject of much research. These 
findings will be discussed at greater length in Chapter 1.12.
The precise role of altered sex steroid receptor expression in the formation of a 
pseudo-decidualised endometrium, contraception, reduced menstrual blood loss and 
the clinical problem of breakthrough bleeding associated with the LNG-IUS remain 
to be resolved. As yet data relating to the expression of the androgen receptor and the 
enzymes responsible for the metabolism of sex steroid ligands in LNG-IUS treated 
endometrium have not been published.
1.12 Endometrial Breakthrough Bleeding
All progesterone only contraceptives are associated with the clinical problem of 
breakthrough bleeding (BTB) (Critchley et al. 1998). BTB is spotting between 
periods that may become prolonged. It is most likely to occur in the first 6 months 
following insertion of the LNG-IUS (Lahteenmaki et al. 1998). BTB is commonest 
in the early months following insertion and improves with duration of use. In a study 
by Zalel et al. the incidence at 2 months was 44%, subsequently falling to 8% by 6 
months (Zalel et al. 2003). Over this same time the cessation o f menstrual bleeding 
increased from 5% at 2 months to 66% by 6 months.
The LNG-IUS is increasingly being used as a contraceptive and as a method 
of treating menstrual dysfunction. Patient acceptability is high but many patients will 
discontinue therapy due to the adverse effect of breakthrough bleeding (BTB) 
(Anderson 1992; Findlay 1996). The aetiology of BTB is unknown at present but is 
likely to involve angiogenic factors, matrix metalloproteinase activation, and altered 
haemostatic factors that result in increased endometrial vessel fragility (Hickey et al. 
2000).
The presence of unscheduled breakthiough bleeding and reduction in 
menstrual blood loss suggests that progestogens might affect the endometrial 
vascular system directly (Roopa et al. 2003). A broad range of molecules identified 
as angiogenic growth factors are present in the endometrium. These polypeptides, 
which have been implicated in angiogenesis, include vascular endothelial growth 
factor (VEGF) (Charnock-Jones et al. 1993), epidermal growth factor (Nelson et al. 
1991), basic fibrobroblast growth factor (Feniani et al. 1993) and transforming 
growth factor-beta (Roberts et al. 1986). These angiogenic factors promote 
endothelial cell proliferation, migration and tube formation, and also facilitate the 
changes in extracellular matrix needed to permit new vessel formation. VEGF has 
also been shown to be produced by endometrial stromal cells in culture following 
stimulation by oestradiol and progesterone (Perrot-Applanat et al. 2000). Further, 
Roopa et al. have demonstrated that treatment with LNG-IUS increases VEGF 
expression at 3 and 6 months following insertion (Roopa et al. 2003). VEGF 
stimulates plasminogen activators which could be involved in the proteolytic 
degradation of the basement membrane of blood vessels, thereby leading to increased
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vascular fragility (Roopa et a l 2003). Superficial vascular dilatation is seen in the 
endometrium exposed to low dose progestogens (Hickey et al. 1998) and similar 
findings have also been described in endometrium exposed to high dose LNG 
following treatment with the LNG-IUS (McGavigan et al. 2003). VEGF is also 
Imown to stimulate the potent vasodilator, nitric oxide from endothelial cells which 
would be expected to promote vasodilatation (Papapetropoulos et al. 1997).
Additional molecular factors, implicated in BTB, reported in the endometrium of 
levonorgestrel users includes activation of matrix metalloproteinases 1, 3 and 9 to a 
level consistent with that seen in menstrual phase endometrium (Galant et al. 2000; 
Rodriguez-Manzaneque et al. 2000; Vincent et al. 2000). This may explain the 
features of focal stromal breakdown and collagen lysis noted in endometrium from 
users of Norplant, sub-demial LNG delivery (Galant et al. 2000). Other factors 
reported that relate to vessel fragility include a decrease in endometrial perivascular 
alpha smooth muscle actin in Norplant users (Rogers et al. 2000) and decreased 
endothelial cell proliferation (Goodger et al. 1994; Rodriguez-Manzaneque et al. 
2000; Hague et al. 2002). Haemostatic factors may also play an important role as a 
decrease in tissue factor protein and mRNA has been reported in levonorgestrel 
exposed endometrium (Runic et al. 1997). The aforementioned factors all suggest a 
disruption in the mechanisms that control vessel growth and haemostasis.
While the knowledge base regarding local mechanisms that may be involved with 
BTB (experienced by progesterone only contraceptive users) is ever expanding, the 
precise mechanisms are not yet fully understood. The data thus far would support an 
important role for the factors summarised above that are important for angiogenesis 
and the maintenance of vascular integrity. The role of sex steroids and their 
respective receptors and the influence they exert on the above local factors requires 
further research. In particular, despite LNG demonstrating a binding affinity for AR, 
the role of androgens and androgen metabolising enzymes in LNG-IUS treated 
endometrium has to date not been elucidated.
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Chapter 2 
Hypothesis and Aims of Thesis
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2 Hypothesis and Aims of Thesis
Sex Steroids and their cognate receptors play a critical role in the regulation of 
normal endometrial physiology. Well studied regulators of endometrial function are 
oestradiol and progesterone, acting via their respective receptors. The foregoing 
literature review highlights an under researched area of endometrial physiology, 
namely the role of androgens and the androgen receptor (AR) in endometrial 
physiology.
To date there have been inconsistent data reporting the spatial and temporal 
localisation of AR messenger RNA (AR mRNA) and AR protein in human 
endometrium tlmoughout the menstrual cycle. Therefore, the role of androgens in 
physiological processes such as implantation and menstruation is currently unknown. 
Furthermore, the role that androgens play in endometrial dysfunction has received 
little attention. Androgens have been implicated in defective implantation in the 
hyper-androgenic polycystic ovarian syndrome.
The availability of sex steroids to bind to sex steroid receptors, and in 
particular the AR, will also determine the predominant sex steroid regulated 
physiological events at any particular point in the menstrual cycle. The key 
determinants of sex steroid availability in endometrium are metabolising enzymes 
that include the 17 |3-hydroxysteroid dehydrogenases, 3 p -hydroxysteroid
dehydrogenases, 5a-reductases, and Aromatase. The expression of the 
aforementioned enzymes will allow a target tissue/cell autonomous control over its 
sex steroid requirements.
Furthermore, progestogenic agents are commonly employed in gynaecology 
and they possess androgenic activity. Knowledge of the effect of progestogens, such 
as levonorgestrel, on endometrial biology will contribute to our understanding of the 
role of androgens in endometrial biology and their mode of action.
Thus the based upon the available evidence to date the following hypotheses 
are proposed:
1. Normal endometrial function requires a stable ratio of intracellular androgens 
and 0 estrogens that favours lower intracellular oestrogen concentrations at 
specific times in the menstrual cycle, for example, during the secretory phase. 
Low intracellular oestrogen concentrations are maintained by the sex steroid
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metabolising enzymes; 17(3-hydroxysteroid dehydrogenases, 3p- 
hydroxysteroid dehydrogenases, and the 5a-reductases.
2. Raised local concentrations of androgens are deleterious for normal 
endometrial function. Hence, aberrant menstrual bleeding patterns and 
defective implantation may be a consequence of abnonnalities in endometrial 
AR expression and/or expression of 17[3-hydroxysteroid dehydrogenases, 3[3- 
hydroxysteroid dehydrogenases, and the 5a-reductases.
3. Exposure of human endometrium to high doses of intra-uterine levonorgestrel 
influences the expression patterns of AR and/or the sex steroid metabolising 
enzymes. Altered expression of such factors may be relevant to the 
problematic bleeding patterns seen during treatment with the levonorgestrel 
releasing intrauterine system
The aims of this thesis were thus to establish in human endometrium:
1. The spatial and temporal expression of androgen receptor mRNA and protein 
in endometrium across the menstmal cycle.
2. The expression of critical androgen metabolising enzymes across the 
menstrual cycle - 17(3-hydroxysteroid dehydrogenase type 2 and 5; 3[3- 
hydroxysteroid dehydrogenase type 1 and 2; and 5a-reductase type 1 and 2.
3. The spatial and temporal localisation, in endometrium exposed to high dose 
intra-uterine levonorgestrel, of AR mRNA and protein; 17(3-hydroxysteroid 
dehydrogenase type 2 mRNA and protein; 17 p -hydroxysteroid 
dehydrogenase type 5 mRNA; 3p-hydroxysteroid dehydrogenase type 1 and 2 
mRNA; and 5a-reductase type 1 and 2 mRNA.
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Chapter 3 
General Methods
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3.1 Human Endometrial Tissue Collection.
Human endometrial tissue samples were obtained from patients attending the Royal 
Infimiary of Edinburgh Gynaecology department, histitutional ethical approval was 
obtained and all women provided written informed consent.
3.1.1 Endometrial Specimens
The first group consisted of fertile women (n=53) with regular menstrual cycles 
lasting between 25 and 35 days who had not been using hormonal preparations for 
the preceding 3 months. Samples were obtained at the time of hysterectomy for 
benign indications. Subjects with significant uterine pathology (for example, 
fibroids) were excluded. Endometrial tissue was collected from women during the 
proliferative phase (n=29), early secretory (n=6), mid secretory (n=8) and late 
secretory phase (n^lO) of the menstrual cycle.
The following specimens were collected immediately following removal of 
the uterus:
1. A fu ll  thickness biopsy of the endometrium (including adjacent endometrial- 
myometrial junction) was obtained and fixed in 4% paraformaldehyde.
2. A separate endometrial sample was snap frozen in liquid nitrogen at 
collection and subsequently stored at -80°C.
3. In addition, venous blood samples were collected at the time of tissue 
collection for determination of circulating oestradiol and progesterone 
concentrations.
The full thiclmess endometrial biopsy extended from the uterine lumen continuously 
tlu'ough to the myométrial layer, therefore including the superficial and basal 
endometrium in addition to the adjacent myometrium (Figure 3.1). Following 
fixation in paraformaldehyde at 4°C the specimen was embedded in paraffin blocks. 
Histological dating according to the criteria o f Noyes et al (Noyes et al. 1950) was 
performed to confirm the stage of the menstmal cycle was consistent with the 
patients reported last menstrual period. Venous blood samples were centrifuged at 
3000 rpm for 7 min to separate serum allowing oestradiol and progesterone 
concentrations to be detemiined by radioimmunoassay (RIA) again to confirm levels 
were consistent with the designated cycle stage. Figure3.2
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The second group consisted of fertile women (n=30) with regular menstrual 
cycles lasting between 25 and 35 days that had not been using hormonal preparations 
for the preceding 3 months. Samples were obtained at the time of laparoscopic 
sterilisation using an endometrial aspirating curette (Pipelle de cornier, Laboratoire 
CCD, Paris, France). Subjects with significant uterine pathology (for example, 
fibroids) were excluded. Endometrial tissue was collected from women during the 
early proliferative phase (n= 5), mid proliferative phase (n= 5), late proliferative 
phase (n= 5), early secretory (n=5), mid secretory (n=5) and late secretory phase 
(n=5) of the menstrual cycle. At collection, samples were divided and collected in 
4% paraformaldehyde and snap fiozen in liquid nitrogen and stored at-80^C. 
Parafoimaldehyde fixed specimens were embedded in paraffin blocks. Histological 
dating according to the criteria of Noyes et al (Noyes et al. 1950) was performed to 
confirm the stage of the menstrual cycle was consistent with the patients reported last 
menstrual period. Serum oestradiol and progesterone levels were consistent with the 
designated cycle stage. Figure 3.3
3.1.2 Endometrial Specimens from Women Using a Levonorgestrel Releasing 
Intra-Uterine System
This patient group consisted of fertile women (n=10) with regular menstrual cycles 
lasting between 25 and 35 days and who had not been using hormonal preparations 
for the preceding 6 months. The patients were to have a LNG-IUS inserted as a 
method of long-term hormonal contraception. All patients underwent a pre-insertion 
endometrial biopsy immediately after which a LNG-IUS (Mirena, Schering HC, UK) 
was inserted as an outpatient procedure. The stage of the cycle prior to insertion of 
the LNG-IUS was determined by reference to histological dating by the criteria of 
Noyes at al. (Noyes et al. I950)and reported date of last menstrual period. Further 
endometrial samples were collected at I (n-2), 3 (n=5), 6 (n=5) and 12 months (n=5) 
following insertion of the LNG-IUS. Specimens were divided into portions that were 
either fixed in 10% neutral buffered formalin at 4°C then embedded in paraffin for 
immunohistochemical analysis or snap frozen in liquid nitrogen at collection and 
subsequently stored at -80°C. An additional cohort of women using a LNG-IUS also 
consented to endometrial biopsies being performed. These patients were attending a
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menstrual problems clinic with regular periods but suffering hom heavy menstmal 
blood loss and were managed with a LNG-IUS. Endometrial samples were collected 
from patients attending the clinic with an LNG-IUS in-situ for 3 months, 6 months, 
or greater than 1 year. Endometrial samples were frozen immediately upon collection 
in liquid nitrogen and stored at -80°C.
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Figure 3.1
Images illustrate the bisection o f the uterus enabling identification of the uterine 
cavity. A biopsy incorporating the endometrium and a portion of the myometrium is 
then dissected free. Sample is then divided into separate portions for subsequent 
processing as detailed in 3.1.1.
The diagram illustrates the layer architecture for the full thickness endometrial 
biopsy with the functional layer adjacent to the uterine lumen and the basal layer 
adjacent to the myométrial layer.
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Figure 3.2
Bar charts illustrating serum oestradiol levels and serum progesterone levels from 
full thickness endometrial specimens used for immunohistochemical analysis. The 
table indicates mean serum values for oestradiol and progesterone for each cycle 
stage, standard error of the mean is shown in brackets. A significant decline in serum 
progesterone is noted in the late secretory phase of the menstrual cycle.
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a, p<0.05
200—
a, p<0.05
b, p<0.05
Mean Serum E2 (±SEM) 
omoi/L
Mean Serum P4 (±SEM) 
mmoi/L
Proliferative Phase
Early 533.4 (± 97.5) 2.8 (±0.41)
Mid 252 (± 66.9) 2.8 (± 0.42)
Late 737.2 (± 2551 5.5 (± 3.9)
Secretorv Phase
Early 232.7 (± 38.9) 28.5 (± 7.8)
Mid 352 (± 44.6) 28.8 (± 7.3)
Late 294 (± 63.0) 12.0 (±5.2)
101
Figure 3.3
Bar charts illustrating serum oestradiol levels and serum progesterone levels from 
endometrial specimens used for real time RT-PCR analysis. The table indicates mean 
serum values for oestradiol and progesterone for each cycle stage, standard error of 
the mean is shown in brackets. A significant decline in serum progesterone is noted 
ill the late secretory phase of the menstrual cycle.
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"2 700—
r
a,b p<0.05
5 10
Mean Serum E2 (±SEM) 
omol/L
Mean Serum P4 (±SEM) 
mmol/L
Proliferative Phase
Early 721 (±337) 2.7 (± 0.44)
Mid 713 (±512) 1.5 (±0.27)
Late 624 (±191) 2.3 (± 0.33)
Secretorv Phase
Early 452 (± 13) 15.9 (±7.1)
Mid 524 (± 54) 23.9 (±1.1)
Late 342 (± 73) 10.7 (±3.0)
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3.2 Immunohistochemistry.
Immimohistochemistry (IHC) was perfoiiiied for localisation of the Androgen 
Receptor (AR), 17p-hydroxysteroid dehydrogenase (HSD) type 2 enzyme, and 
Aroinatase enzyme. No commercially available antibodies were available to 
determine the immnnolocalisation of other IVp-HSD iso-enzymes or the 5 alpha 
reductase iso-enzymes. All protocols were optimised to determine the best conditions 
for maximal immunostaining. The protocols are summarised in Table 3.1.
3.2.1 General Immunoliistochemistry Protocol.
Paraffin block specimens were cut to 5 micron width sections and mounted on 
superfrost glass slides (BDH, Merck House, Poole, Dorset, England). Slides were 
placed in histoclear for 10 minutes, then rehydrated tlu'ough graded alcohols, 100% 
ethanol (2 min), 95% ethanol (2min), 70% ethanol (2min), and then into distilled 
water for 10 minutes. Thereafter the slides were washed in phosphate buffered saline 
(PBS, Sigma-Aldrich Ltd. Poole, Dorset, England) for 10 minutes.
The next step in the protocol involved an antigen retrieval step. 
Formaldehyde fixation primarily involves its reacting with the basic amino acid 
lysine to form cross-linked ‘methylene bridges’. This means that there is relatively 
low pemieability to macromolecules and that the structures of intracytoplasmic 
proteins are not significantly altered. This generally allows good cytoplasmic 
preservation and immunolocalisation with a minimum of antigen masking. However, 
some epitopes are difficult to expose in formalin-fixed paraffin-embedded tissues. 
Therefore, an antigen retrieval step such as pressure cooking, microwaving, or 
proteolytic digestion is used to umuask the antigenic site hidden by cross-linlced 
proteins. When pressure cooking antigen retrieval is required, sections are heated in 
boiling O.OIM Na Citrate (pH 6.0) for 5 minutes, then left to cool for 20 minutes. 
Thereafter the sections are washed in O.OIM PBS for 10 minutes before the next step 
of immunohistochemical procedure.
To reduce background staining, further steps may also be included. 
Endogenous peroxidase activity is quenched by immersion in 3% hydrogen peroxide 
solution (Merck, Poole, UK) for 10 minutes followed by a 10 minute wash in PBS. 
Next endogenous biotin and avidin activity is blocked with a 15 minute incubation 
period with each in turn. A 5 minute PBS wash follows each incubation. Finally, to
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reduce non-specific background binding the slides are incubated with a non immune 
serum block diluted in buffer that is from the same species as the biotinylated 
secondary antibody.
Next, a standard Avidin-Biotin Peroxidase immunohistochemical protocol 
was followed (Figure 3.4). The ABC complex method utilized the high affinity of 
avidin for biotin. Avidin has four binding sites for biotin (dissociation constant 10 
M). The sequence of reagent application is primary antibody (e.g. mouse), 
biotinylated secondary antibody (biotin is covalently linked to the antibody, e.g. 
Biotinylated horse anti-mouse) specific for the primary antibody and diluted in serum 
as a second concurrent non immune block. Then preformed avidin-biotin enzyme 
complex is added. This prefomied avidin-biotin complex has open sites on avidin to 
allow binding to the biotin on the secondary antibody. The peroxidase substrate 
Diaminobenzidine tetra hydrochloride (DAB) is employed as the chromagen. The 
peroxidase enzyme causes oxidation of DAB, which results in a stable enzyme- 
substrate complex and a brown precipitate allowing visualization o f the stain (Figure 
3.4). Sections were counterstained with Harris’ haemotoxylin, dehydrated in 
ascending grades of alcohol and mounted from xylene in Pertex.
To improve the detection of antigens the ABC-Elite system can be employed. 
ABC-Elite is the most sensitive peroxidase-based detection system, providing about 
5-10 times more sensitivity than the regular ABC in immunohistochemical staining. 
When the avidin and biotinylated peroxidase in the ABC-Elite kits are combined, a 
smaller, very uniform and highly active complex is formed which allows a greater 
number of enzyme complexes to diffuse through a tissue section and bind to a 
biotinylated target.
Primary
Antibody
Antigen Retrieval 
Step Dilution Incubation
Androgen
Receptor a F 39.4 Pressure Cooking 1:480
Overnight
4°C
17P-HSD2 MabC2-12 Pressure Cooking 1:20
Overnight
4"C
Aromatase In House Not Required 1:50
Overnight
4°C
Table 3.1 Summary of Immunohistochemical Protocols.
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Figure 3.4
Diagrammatic representation of the ABC immunohistochemical method as referred 
to in 3.2.1. Sequential addition of primary antibody, biotinylated secondary antibody 
and Diaminobenzidine allows visualisation o f antigen detection by the primary 
antibody.
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3.2.2 Androgen Receptor (AR) Immunohistochemistry.
5 micron paraffin sections were de-waxed and re-hydrated as in the general protocol. 
Following the washing steps detailed in the general protocol an antigen retrieval step 
was included. This step involved heating the sections in a pressure cooker containing 
O.OIM sodium citrate at pH 6 for 5 minutes, then cooling the sections in the mixture 
for 20 minutes. The blocking steps included were the same as detailed in the general 
protocol with normal horse semm as the 20 minute non immune blocking step in a 
humidified chamber. The antibody raised against the AR was a commercially 
available monoclonal antibody called aF39.4 (IgG];Biogenex Laboratories, Inc., San 
Ramon, CA, USA). Tissue sections were incubated overnight at 4°C in the 
humidified chamber with 50 pi of aF39.4 diluted 1:480 in PBS/Bovine Serum 
Albumin (BSA) - employed as an additional method to minimise background 
staining. The primary antibody was substituted with equimolar concentration of 
mouse immunoglobulin (IgG) in negative control sections. After the primary 
antibody incubation, sections were washed between each stage for 10 minutes with 
PBS/Tween buffer solution. Sections were incubated with horse anti-mouse 
biotinylated secondary antibody and then with ABC-Elite detection system 
(Vectastain, Vector Laboratories, Inc., Peterborough, UK), both for 60 minutes at 
room temperature. DAB (DAKO Liquid, DAKO Corporation, California, USA) was 
then added to the sections allowing visualization of the stain. Sections were 
counterstained with Harris’ haemotoxylin, dehydrated in ascending grades of alcohol 
and mounted from xylene in Pertex.
3.2.3 17 Beta-Hydroxysteroid Dehydrogenase Type 2 (17(3-HSD 2)
Immimohistochemistry.
This protocol was identical to that for androgen receptor immunolocalisation. The 
primary antibody, Mab C2-12, detected 17(3-HSD 2. This is a monoclonal antibody 
that was a kind gift from Stefan Andersson (University of Texas, Dallas, USA). 
Details regarding antibody production and specificity have been previously published 
(Moghrabi et al. 1997). It was diluted 1:20 in normal horse serum and applied 
overnight at 4 °C in a humidified chamber. Negative control sections were incubated 
under the same conditions with equimolar mouse IgG.
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3.2.4 Aromatase Immunohistochemistry.
This protocol differed from previous protocols as Tris buffered saline (TBS) was 
used for washes tlu'oughout and no antigen retrieval step was required. The anti 
Aromatase antibody was a mouse monoclonal antibody and details regarding its 
production and specificity have been previously published (Turner et al. 2002). The 
antibody was a kind gift from Dr P. Saunders (Human Reproductive Sciences Unit, 
University of Edinburgh, UK), a co-author for the paper describing the new antibody. 
The first non immune block was performed with nomial rabbit serum diluted in 
TBS/BSA (Diagnostics Scotland, Edinburgh, Midlothian, UK) for 30 minutes at 
room temperature. Primary antibody incubation was at a 1:50 dilution overnight at 
4°C. Rabbit anti-mouse biotinylated secondary antibody was employed diluted with 
normal rabbit serum as above and incubated at room temperature for 60 minutes. The 
ABC complex used was ABC-HRP (Vectastain, Vector Laboratories, Inc., 
Peterborough, UK) and this incubation step was also at room temperature for 45 
minutes.
3.2.5 Immunohistochemical Analysis and Statistics.
An objective quantitative scoring system was employed for the analysis of AR 
immunoreactivity in nomial human endometrium. A semi-quantitative scoring 
system was employed for the analysis of all other IHC experiments
3.2.5.1 Quantitative image analysis
Quantitative image analysis involved capturing images at x20 magnification via a 
Zeiss microscope that was in turn connected to an Apple McIntosh G3 computer. 
Images were captured using a real time digital video camera connected to the Zeiss 
microscope. Analysis was performed on the Apple McIntosh G3 using image 
analysis software - openlab 3.0 (Improvision inc., Lexington, MA.). 12 random 
images were captured from the functional and basal layers of each tissue section. 
After 12 fields were captured the running mean stabilised, ensuring inter-image 
variance is <5% (Lowrey et al. 1995).
To allow sepaiate analysis of the stroma and epithelial glands, the glands were 
interactively removed from each of the 12 images for each tissue seetion. This 
allowed later, separate analysis of the epithelium. Using hue, saturation and intensity
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values to determine optimal colour discrimination, the automated software generated 
a mask that calculated the total number of DAB positive brown cells and 
subsequently the total number o f negative blue cells in each of the stromal and 
glandular epithelial compartments. Calculation of the percentage of chromagen 
positive cells in each compartment could then be performed. Knowing the value for 
each of the 12 random images per section allowed a mean percentage of positive 
cells for each compartment of each section to be calculated.
A one way analysis of variance (ANOVA) with least significant difference 
(LSD) analysis was used to evaluate statistical differences in compartments tluough 
the menstrual cycle. Results with a p value <0.05 were considered to be significant 
differences.
3.2.5.2 Semi-quantitative analysis
Semi-quantitative analysis was employed for assessment of intensity and localisation 
of immunoreactivity in entire tissue sections. Scoring was performed by two 
independent observers blinded to the stage of the menstrual cycle. A score of 0 = 
absent immunoreactivity; 1 = faint immunoreactivity; 2 = strong immunoreactivity; 3 
= very strong immunoreactivity. This scoring system was previously validated in a 
study that compared semi-quantitative and quantitative scoring systems as described 
above (Wang et al. 1998). In this study a high correlation, with a regression 
coefficient of 0.963 was found between the two methods. This provides a high level 
of confidence in the semi-quantitative scoring system and takes much less time to 
perform than quantitative analysis.
Due to the discontinuous nature of the semi-quantitative data the non 
parametric Kmskall-Wallis test was perfomied in addition to Dumas multiple post 
test to evaluate statistical differences between sections. Results with a p value <0.05 
were considered to be significant differences.
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3.3 Real Time Quantitative Reverse Transcription -  PCR 
(Q-RT PCR).
3.3.1 RNA Extraction
Tissue was collected as specified above whereupon it was immediately frozen in 
liquid nitrogen at collection and stored at -80 °C. Endometrium was easily 
homogenised and the extraction method is detailed below. All tissue handling was 
conducted to minimise the possibility of RNAse contamination. All instruments and 
disposables used in the procedure below were autoclaved or were certified RNAse 
free and used sterile.
Trizol reagent (Invitrogen Life teclmologies Ltd, Paisley, UK) was used for 
RNA isolation from endometrial tissues. This reagent is a monophasic solution of 
phenol and guanidine isothiocyanate. During sample homogenization, Trizol reagent 
maintains the integrity of the RNA while disrupting cells and dissolving cell 
components. Addition of chlorofoiin followed by centrifugation separates the 
solution into an aqueous phase and an organic phase. RNA remains exclusively in 
the aqueous phase. After transfer of the aqueous phase, the RNA is recovered by 
precipitation with isopropyl alcohol.
Tissue samples were homogenized in 1 ml of Trizol reagent per 50-100 mg of 
tissue using a hand-held homogenizer. Then each homogenized sample was placed in 
a phase-lock gel heavy tube and incubated for 5 minutes at 15 to 30°C to peiinit the 
complete dissociation of nucleoprotein complex. After adding 0.2 ml of chloroform 
per 1 ml of Trizol reagent, sample tubes were capped and mixed by inversion for 15 
seconds, and incubated at room temperature for 3 minutes. Then the samples were 
centrifuged at no more than 13,000 rpm for 15 minutes at 4^C for separation of the 
mixture into two portions, the aqueous RNA containing phase above and the 
DNA/protein content was contained below the gel in the phenol red layer.
The aqueous phase, the top portion, was transferred to 2ml eppendorf tube. 
Then 0.5 ml of 100% isopropyl alcohol per 1 ml of Trizol reagent used for the initial 
homogenization was added to allow precipitation the RNA from the aqueous phase. 
After that, samples were incubated at room temperature for 10 minutes and 
centrifuged at no more that 13,000 i*pm for 10 minutes at 4 ^C. The resulting 
supernatant was removed leaving a pellet containing RNA precipitate. The RNA
111
pellet was washed once with 75% ethanol by adding at least 1 ml of 75% ethanol per 
1 ml of Trizol reagent used for the initial homogenization, mixing the samples by 
vortexing. Samples were then centrifuged at 7,500 ipm for 10 minutes at 4^C. At the 
end of the procedure, the RNA pellet was briefly air dried, and then resuspended in 
RNA storage solution (Anbion, Austin, Texas, USA) and stored at -80^C until 
required for Taqnian PCR analysis.
3.3.2 RNA Quantitation
To quantify the concentration of RNA, optical density measurements were performed 
using the Genequant machine. This machine automated the calculation of the 
concentration of RNA. A 1:10 dilution of RNA was made by dilution of 2 pi of RNA 
in 8 pi of nuclease free H2O. A ratio of the optical density at a wavelength of 260mn 
to a wavelength of 280nm (260:280) was calculated. If the ratio was less than 1.6 the 
sample was considered not to have sufficient purity for use in the studies. The 
concentration was then recorded.
3.3.3 Reverse Transcription
The reverse transcription polymerase chain reaction (RT-PCR) is a sensitive method 
for detection of low-abundance niRNA. RT-PCR assays are the most common 
method for comparing niRNA levels in different sample populations (Orlando et al. 
1998). As RNA camiot serve as a template for PCR, the first step in an RT-PCR 
assay is the reverse transcription of the RNA template into cDNA, followed by its 
exponential amplification in a PCR reaction. An advantage of the RT step being 
earned out separately from the PCR step is that the generated pool of cDNA can be 
stored for later use.
Taqman primers and probes were designed to span an intron where possible 
as this should prevent amplification of contaminant genomic DNA. Where Taqman 
primers and probes did not span an intron samples were DNAse treated prior to 
reverse transcription to prevent the risk of genomic DNA contamination. The initial 
Taqman primers and probe to detect androgen receptor spanned an intron and 
samples were not DNAse treated. All subsequent reverse transcriptions were 
performed with DNAse pre-treatment as the Taqman primers and probes did not span
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an intron with each design due to specific criteria that had to be followed in Taqman 
primer probe design.
DNAse pre-treatment of RNA stock solutions was carried out as follows. 1 pg 
of each RNA was added to individual mixtures containing 1 pi of DNAse buffer and 
Ipl of DNAse with the remaining volume being made up to 10 pi with nuclease free 
water. The mixture was incubated at room temperature for 15 minutes at which point 
1 pi of 25 niM EDTA was added to stop the digestion reaction. Then the mixture was 
incubated on a PCR block for 5 minutes at 99®C to denature the DNAse. The mixture 
was then cooled on ice and samples given a pulse centrifuge to collect any sample 
condensed on the eppendorf wall. Samples could then be stored at -80^C until 
required for cDNA preparation.
The following is the protocol for reverse transcription. The RT-PCR reaction 
was performed in a 10 pi volume of reaction solution. 2 pi of DNAse treated mixture 
containing 200 ng of RNA or RNA stock was diluted in nuclease free HiO to prepare 
the concentration of 100 ng/pl from which 200 ng (2 pi) of each sample RNA, 
including a positive control, were added into 8 pi of master mix solution. Master mix
solution contained lOx Taqman buffer, MgCb (5.5 mmol/1), deoxyNTP’s, random 
hex amers (2.5pmol/l), multiscribe reverse transcriptase (1.25 lU/pl), RNAse 
inhibitor (0.40 lU/pl), and nuclease free water (Perkin-Elmer, Applied Bio systems, 
Warrington, UK). Each tube was mixed by vortexing, pulse centrifuged and over­
layered with mineral oil. PCR reactions were carried on a Hybaid Omn-E thermal 
cycler (Hybaid, Ashford, U.K.). Reverse transcription reaction was conducted at 
25°C for 60 minutes, 48°C for 45 minutes, and 95°C for 5 minutes for 1 cycle. 
Thereafter samples were stored at -20*^ C.
3.3.4 Real Time Quantitative RT-PCR
The Taqman assay (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA) is a 
real time RT-PCR assay. It requires the use of the ABI Prism 7700 - a combined 
thermal cycler/detector (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA) 
which utilises sequential laser stimulation of its 96 reaction wells to detect 
fluorescence between 500 nni and 660 nm. Detected fluorescence is then analysed to
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quantify the amount of amplicon of interest in the samples being analysed. A 
summary of this process is shown below.
PCRSamplepreparation
Fluorescence
DetectionReverseTranscription
Quantification
Following reverse transcription the assay requires the annealing of specific 
oligonucleotide sequences to the cDNA under examination to be successful. Two 
specific oligonucleotide primers define the endpoints of the amplicon providing the 
first level of specificity with additional specificity from the use of an oligonucleotide 
probe that hybridises to the amplicon during the annealing/extension phase of the 
PCR. To avoid amplification of contaminant genomic DNA the primers should be 
designed to span an intron. This is sometimes not possible and in such cases the 
RNA to be quantified should be DNAse treated with RNAse free DNAse to minimise 
the potential for genomic contamination of the cDNA.
The assay utilises the 5’-3’ nuclease activity of the DNA polymerase, Taq 
polymerase, to hydrolyse a hybridisation probe that is bound to its amplicon. The 
probe used for Taqman assay is a 5’labelled FAM (6-carboxyfluorescene; a 
fluorophore) 3’labelled TAMRA (6-carboxytetramethylrhodamine; a quencher) 
FRET (Fluorescence Resonance Energy Transfer) probe. In FRET probes, the 
fluorophore donor transfers its energy to the quencher suppressing fluorescence due 
to its close proximity. If no amplicon complementary to the probe is amplified during 
the PCR, the probe remains unbound and its fluorescence cannot be emitted for 
reporting. If the correct amplicon has been amplified, the probe can hybridise to that 
amplicon after the dénaturation step. It remains hybridised while the polymerase 
extends the primers until it reaches the hybridised probe, when it displaces its 5’ end 
to hold it in a forked structure. The enzyme continues to move from the now free end 
to the bifurcation of the duplex, where cleavage takes place. This separates the FAM 
reporter and TAMRA quencher dyes meaning the quencher can no longer suppress 
the reporter. Hence, the fluorescence is increased allowing measurement of the 
amount of PCR product (Bustin 2000).
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Figure 3.5
Diagrammatic representation of Taqman real time RT-PCR process.
Polymerisation
During PCR, if the target of interest is present, the probe specifically anneals 
between the forward and reverse primer sites. When the probe is intact, the proximity 
of the reporter dye to the quencher dye results in suppression of the reporter 
fluorescence.
Strand Displacement
As polymerization of the strand continues, the probe fi-agments are displaced from 
the target sequence.
Cleavage
During the reaction, cleavage of the probe separates the reporter dye and the 
quencher dye, resulting in increased fluorescence o f the reporter. Accumulation of 
PCR products is detected directly by monitoring the increase in fluorescence of the 
reporter dye. Taq DNA Polymerase cleaves the probe only if  it hybridises to the 
target.
Polymerisation Complete
The 3 '-end of the probe is blocked to prevent extension of the probe during PCR. 
This process occurs in every cycle and does not interfere with the exponential 
accumulation of product. The increase in fluorescence signal is detected only if  the 
target sequence is complementary to the probe and is amplified during PCR. Because 
of these requirements, any nonspecific amplification is not detected.
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3.3.4.1 Primer/Probe Design and Validation
The primers and probes for use in the Taqman system need to be designed to very 
exacting specifications. The Taqman system incorporates its own design program, 
Primer Express, to facilitate adherence to the design specifications for the Taqman 
oligonucleotides that will in turn ensure successful hybridisation with the template 
cDNA and efficient amplification. BLAST (Basic Local Aligmnent Search Tool) 
searches were also conducted to determine the presence of sequences in the scientific 
databases that are similar to those amplified by each set of primers.
In the experiments, a multiplexing strategy was utilised to allow relative 
quantitation of cDNA between samples. Multiplexing is the use of more than one 
primer pair in the same tube. In relative quantitation, one primer pair amplifies the 
target and the other amplifies an endogenous reference in the same tube. The details 
of multiplexing shall be explained later in this Chapter.
An endogenous reference is employed as there may be difference in the 
amount of starting material between samples. The accepted method for minimising 
these eiTors and correcting for sample-to-sample variation is to amplify, 
simultaneously with the target, a cellular RNA that serves as an internal reference 
against which other RNA values can be normalised (Karge et al. 1998). The ideal 
internal standard should be expressed at a constant level among different tissues, at 
all stages of development, and should be unaffected by any experimental treatment. 
Three references are currently used; (3-Actin, GAPDH, and ribosomal RNA (rRNA). 
The endogenous reference used in these experiments was rRNA. It was used as it 
constitutes 85-90% of cellular RNA, their levels are unlikely to vary under 
conditions that may affect expression of inRNA (Barbu et al. 1989), and it has also 
been shown to be more reliable than the other two normalisation genes in a 
comparison study of human malignant cell lines (Zhong et al. 1999).
VIC-labeled ribosomal 18s RNA probe and primers were used for 
normalisation in this research project (Perkin-Elmer, Applied Biosystems, 
Warrington, UK). VIC is an alternative fluorescent probe that is detected at a 
different wavelength from FAM hence allowing discrimination between the two 
different labeled probes. To prevent consumption of reagents by the abundant 18s 
within tissue samples, the concentration of 18s primers and probes were limited to
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the same degree in all samples in accordance with the suggested protocol by applied 
bio systems.
Prior to using the primers and probe for quantitation, the linearity of the 
response was determined by serial dilutions of both measuring primer probe 
amplification against a standard pool of RNA (cDNA) that expresses the target gene. 
The dilutions were up to 1/64. The log of the ng total RNA was plotted against the 
ACt. The Ct is the cycle number at which the PCR signal crosses a designated 
threshold; and the ACt is the difference between the Ct values for the specific 
amplicon and 18s. The gradient o f the best fit line through these points should be < 
0.1. An example is shown in Figure.3.6.
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3.3.4.2 Taqman Protocol
Real-Time relative quantitative RT-PCR was used to measure the levels of Androgen 
Receptor, 17 p-HSD 2, 17p-HSD 5, 5 alpha-reductase type 1, 5 alpha reductase type 
2, and 3 p-HSD types 1 and 2 in the cDNA samples. A reaction mixture was made 
containing Stratagene Taqman buffer, MgCl^ (5.5mmol/l), Sure Start Taq DNA 
polymerase (0.025 lU/pl; Stratagene, Amsterdam, Netherlands), dATP (200 pmol/1), 
dCTP (200 pmol/1), dGTP (200 pmol/1), dUTP (200 pmol/1), specific target 
amplicon forward and reverse primers (300nmol/l; Biosource, Nivelles, Belgium), 
and specific probe (200nmol/l; Biosource, Nivelles, Belgium). Additionally specific 
primers and probe for ribosomal 18S were also added at 50mnol/l (Perkin-Elmer; 
Applied biosystems, Warrington, UK).
The mixture was then aliquoted into separate tubes for each cDNA sample. 
An amount of 2,5 p 1/rep lie ate o f 1: 2.5 dilution cDNA was added to each tube. After 
mixing, 23 pi of each sample were added to the wells on a PCR reaction plate with 
each sample being added and analysed in triplicate. Wells were sealed with optical 
caps and the PCR reaction run on the ABI prism 7700 using standard conditions.
To assess if genomic DNA contamination was present, two negative controls 
were added to the plate in triplicate. A no template (containing water) control and no 
reverse transcriptase (containing RNA) control.
3.3.5 Taqman Analysis and Statistics
PCR data was analysed using the formula (as described above the Ct is the
cycle number at which the PCR signal crosses a designated threshold). The ACT is 
the difference between the Ct value at the threshold for the target amplicon and the 
internal normalisation control, 18S. A ACT is the difference between the ACT and the 
internal reference control, which all samples are compared to thus providing a 
relative value to the reference. As each cDNA sample was analysed in triplicate the 
mean ACT was used for each.
Statistical analysis was conducted using SPSS 11.0 for Windows. One-way 
analysis of variance (ANOVA) with Least Significant Difference (LSD) post testing 
used to evaluate whether there were significant differences in mean target mRNA 
expression between samples with error bars signifying the standard error of the 
mean. Results with a p value of <0.05 were considered statically significant.
122
Chapter 4
Androgen Receptor Expression in 
Human Endometrium
123
4.1 Introduction
The role of the androgen receptor (AR) in endometrial biology has been subject to 
limited study to date. Immunolocalisation of the AR in human endometrium has 
failed to reveal a consensus regarding its expression and no studies have exhibited its 
expression at the messenger RNA levels in human endometrium. However, studies 
do agree that the AR is expressed in human endometiium.
The regulation of its expression provides conflicting data. Oestrogen 
stimulation of endometrium appears to produce an up regulation of androgen 
receptor (Fujimoto et al. 1995; Adesanya-Famuyiwa et al. 1999; Apparao et al. 2002) 
while progestogens produce a down regulation (Iwai et al. 1995; Apparao et al. 
2002). Further research is therefore required to elucidate such mechanisms and 
provide clarity in this area. A more detailed overview of the published literature 
regarding androgen receptor expression and regulation can be found in Chapter 1.7.2.
Sex steroids play an important role in the regulation of endometrial function. 
To play such a role there must be a mechanism for their action and this may be direct 
or indirect. In the case of androgens and endometrium, the presence of the AR would 
be vital to the direct action of androgen receptor ligands such as testosterone and 
dihydrotestosterone. Indirect mechanisms such as enzymatic conversion to a more or 
less biologically active form or even to an alternate sex steroid represent indirect 
mechanisms for androgen action. Indirect mechanisms may occur as paracrine, 
autocrine or intracrine processes. Intracrine mechanisms have been established in 
other tissue systems and appear to be important areas for enzymatic action. An 
intracrine mechanism allows each target cell the autonomous control over its own 
sex steroid requirements. While the biological role of androgens and AR remains to 
be determined, data have been published that examine their possible role in 
endometrial function.
A fundamental role of the endometrium is the provision of a receptive 
endometrium for conceptus implantation, allowing progression to a viable 
pregnancy. Upon establishment of a viable pregnancy, the endometrium will 
continue to play a role in its maintenance under the influence of sex steroids. If a 
conceptus is not established then menstruation will occur. Elevated serum androgen 
levels are associated with recurrent miscarriage (Okon et al. 1998) and raised
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androgen levels are a feature of polycystic ovarian syndrome (PCOS), a condition 
associated with subfertility. The role that androgens may play in the pathogenesis of 
subfertility or miscarriage is not yet known but its effect on factors associated with 
poor endometrial receptivity have been studied.
Further clinical evidence of the effect that androgens have upon endometrial 
function is available by observing the actions that phannacological agents used in 
gynaecology have upon the endometrium. Many pharmacological agents used in 
gynaecology such as, progestogens and danazol, are known to bind to the AR 
(Punnonen et al. 1982; Hoppen et al. 1987; Kumar et al. 2000).
In-vitro cell cultures where progestogens and androgens have been added 
were shown to inliibit endometrial proliferation (Neulen et al. 1987). Additional 
studies have also revealed that androgenic progestogens can induce endometrial 
atrophy in both eutopic endometrium (Floyd 1980; Jeppsson et al. 1984; Rose et al. 
1988; Fedele et al. 1995) and the ectopic endometrium of endometriosis (Chimbira et 
al. 1980). Paradoxically, it also known that treatment with the anti-progestgens (such 
as mifepristone, RU486) will also induce endometrial atrophy (Batista et al. 1992; 
Cameron et al. 1996).
Atrophic endometrial changes were also reported by Miller et al. who studied 
an interesting group of 32 young preoperative transsexual females receiving long 
term androgen therapy. The histopathology of this group of patients revealed 
endometrial atrophy (Miller et al. 1986). Chada et al. also investigated testosterone 
treated female transsexual patients, specifically looking at AR expression, and found 
AR expression to be increased but failed to comment upon the finding of endometrial 
atrophy (Chada et al. 1994).
Another pharmacological agent that induces atrophy is danazol, also an 
androgenic drug used in the management of menorrhagia, endometriosis and 
endometrial hyperplasia (Sedati et al. 1992). As it is an effective agent in inducing 
endometrial atrophy, it is also now employed in the pre-operative thinning of the 
endometrium prior to endometrial ablation treatment for menonhagia. It has been 
shown to be as effective as gonadotrophin down regulation with gonadotrophin 
releasing honnone agonists (Sowter et al. 2000). A similar ability to induce 
endometrial atrophy is seen with the use of the commonly used androgenic 
progestogens, norethisterone and levonorgestrel, both of which are used in the
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management of menorrhagia and endometriosis due to their ability to induce 
endometrial atrophy.
Medroxy-Progesterone Acetate (MPA), another androgenic progestogen, has 
been utilised in the management and palliation of endocrine responsive endometrial 
carcinoma (Quinn 1999; Thigpen et al. 1999). Their use has resulted in improved 
progression free survival.
While AR has been shown to be expressed in endometrial carcinoma (Prodi 
et al. 1980; Ito et al. 2002) it is not known if androgens play a direct role by binding 
to the AR. Data could also support indirect androgen effects following aromatisation 
to 0 estrogens. Aromatase has been shown to be expressed in endometrial 
adenocarcinoma (Tseng et al. 1984; Yamamoto et al. 1993; Sasano et al. 1996) with 
abundant precursor for conversion being available within the serum and the post 
menopausal ovary (Jongen et al. 2002). hi addition, high levels of androgens have 
been detected in the utero-ovarian vein and the ovary itself has been shown to have 
an increased capacity for the production of androgens with significantly higher levels 
associated with endometrial adenocarcinoma (Bremond et al. 1982; Nagamani et al. 
1986; Nagamani et al. 1992).
In summary, there is no clear consensus regarding the expression or 
regulation of the androgen receptor in human endometrium. The obseiwation that 
expression is decreased in the late secretory phase at the time of progesterone 
dominance may suggest a role for progesterone in the regulation of endometrial AR 
expression. Additional observations from research into clinical conditions such as 
polycystic ovarian syndrome suggest that there may be important direct and indirect 
roles for androgens. This is reinforced by observations from studies that have 
employed pharmacological agents that have a binding affinity for the androgen 
receptor.
In this Chapter, I aim to add clarity to the expression of the androgen receptor 
at the messenger RNA and protein levels. I will also explore the possible 
mechanisms for endogenous regulation of AR by studying the effect that 
antiprogestogens have on endometrial AR expression when administered in the 
secretory phase.
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4.2 Material and Methods
Material and Methods have been described in Chapter 3. Details that follow 
summarise pertinent material and methods for this area of the study.
4.2.1 Tissue Collection
The patient group for AR immunohistochemistry consisted of fertile women (n= 32) 
with regular menstrual cycles lasting between 25 and 35 days who had not been 
using hormonal preparations for the preceding 3 months. Endometrial tissue included 
samples collected from women during the proliferative phase (n=15), early secretory 
(n=5), mid secretory (n=5) and late secretory phase (n=7) of the menstrual cycle. In 
this group all samples were hill thickness biopsies of the uterus. The stage of the 
menstrual cycle was consistent with the patients reported last menstmal period and 
was confirmed by histological dating, according to the criteria of Noyes et al (Noyes 
et al. 1950). Furthermore, serum samples collected at the time of endometrial tissue 
collection for deteniiination of circulating oestradiol and progesterone concentrations 
by RIA were consistent with the designated cycle stage and a significant decline in 
progesterone concentrations was apparent between biopsies taken in the mid and late 
secretory phase of the cycle, see chapter 3.1.
The patient group for AR real-time quantitative RT-PCR similarly included 
women with regular menstrual cycles lasting between 25 and 35 days who had not 
been using hormonal preparations for the preceding 3 months. Samples were dated 
according to their last menstrual period and the criteria of Noyes et al (Noyes et al. 
1950). Endometrial samples from all stages of the menstrual cycle samples were 
divided into proliferative (n=12) and secretory (n=15) phases with further 
classification of samples as eaiiy-(n=4), mid-(n=3), and late-proliferative (n=5) and 
early-(n=5), mid-(n=5), and late-secretory (n=5) phases.
Some samples were also collected in Tissue Tek II OCT (Van Waters and 
Rogers International, South Plainfield, NJ). The samples collected in Tissue Tek 
were immersed in a 10% sucrose PBS solution for 15 minutes then microwave 
stabilised prior to freezing in Tissue Tek solution with liquid nitrogen to -70 ^ C in 
keeping with the protocol devised by Slayden et al. (Slayden et ai. 1995). Samples 
were stored at -80 °C and when required were cryo-sectioned to 10 micron thickness 
and shipped on dry ice to the Oregon National Primate Research Centre (ONPRC)
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for ill-situ hybridisation studies of AR. (performed by collaborators Professor R.M. 
Brenner and Dr Ov.D. Slayden)
Archived paraffin embedded sections from two additional patient groups 
were also available for analysis hom  previous studies performed within Professor 
Critchleys’ department (Cameron et al. 1996; Cameron et al. 1997).
The first of these two groups consisted of six healthy women with regular 
menstrual cycles (25-35 days). The effects of daily low-dose RU 486 on endometrial 
maturation and proliferation have already been described in this group of women 
(Cameron et al. 1996). No subject had used hormonal contraception in the preceding 
3 months. The subjects were studied in a control and a treatment cycle. Two placebo 
capsules were taken daily from the onset of menses of the first cycle (control). These 
were then replaced with identical capsules of RU 486 (two 1 mg capsules), 
commencing on the first day of menses of the second (treatment) cycle and daily for 
30 days. Endometrial biopsies were collected with a Pipelle endometrial sampling 
device (Prodimed, Neuilly-en-Thelle, France) in the control cycle, 7-11 days after 
the plasma LH surge and on the corresponding day of treatment with RU486 (days 
19-28). In the previous report on samples obtained from these women (Cameron et 
al. 1996) it was noted that RU 486 treatment suppressed mitotic activity in the 
endometrial glands and elevated ER and progestin receptor levels. The AR was not 
studied. Paraffin embedded tissue from these studies were available for the current 
work.
The second group consisted of an additional 10 healthy women with regular 
menses (25-35 days), all o f whom had participated in a study evaluating the effects 
of postovulatory administration of anti-progestogens on the endometrium (Cameron 
et al. 1997). Again, no subject had used hormonal contraception in the preceding 3 
months. Archival endometrial biopsies from this group of women were available for 
evaluation of AR localisation. Each subject had been studied over a control cycle and 
a treatment cycle. In the treatment cycle, the woman received 200 mg oral RU 486 
on the second day after the onset of the LH surge in urine (LH + 2). Endometrial 
biopsies were collected with a pipelle endometrial sampler, either 4 or 6 days after 
the LH surge in the control cycle and on the corresponding day of the treatment 
cycle, that is, 2 or 4 days after oral administration of RU486.
128
4.2.2 Androgen Receptor Immunohistochemistry.
5 micron paraffin sections were de-waxed and re-hydrated as in the general protocol 
(see Chapter 3.2.1). Following the washing steps detailed in the general protocol a 
pressure cooker 0.0IM sodium citrate antigen retrieval step was included. The 
blocking steps included noiinal horse serum as the 20 minute non-immune blocking 
step in a humidified chamber. The antibody raised against the AR was aF39.4 (IgGi; 
Biogenex Laboratories, Inc., San Ramon, CA, USA). Tissue sections were incubated 
overnight at 4°C in the humidified chamber with 50 pi of aF39.4 diluted 1:480 in 
PBS/Bovine Serum Albumin (BSA). The primary antibody was substituted with 
equimolar concentration of mouse immunoglobulin (IgG) in negative control 
sections. After the primary antibody incubation, sections were washed between each 
stage for 10 minutes with PBS/Tween buffer solution. Sections were incubated with 
horse anti-mouse biotinylated secondary antibody made in nomial horse serum to 
incorporate a second blocking step. The final incubation was performed using the 
ABC-Elite detection system (Vectastain, Vector Laboratories, Inc., Peterborough, 
UK). DAB (DAKO Liquid, DAKO Corporation, California, USA) was then added to 
the sections allowing visualisation of the stain. Sections were counterstained with 
Harris’ haemotoxylin, dehydrated in ascending grades of alcohol and mounted from 
xylene in Pertex. (See Chapter 3.2.2)
4.2.3 Androgen Receptor In-Situ Hybridisation.
AR in-situ hybridisation was generously performed by Dr Ov Slayden from the 
Oregon National Primate Research Centre whilst collaborating on research into 
expression of AR protein and messenger RNA in human and macaque endometrium. 
The following is a summary of the material and method for the in-situ hybridisation 
(ISH) performed by Dr Slayden in human and macaque endometrium (Slayden et al. 
2001).
ISH of 10 micron frozen sections of human endometrium was conducted with 
a riboprobe labeled with [35SJUTP (NEN Life Science Products) derived from a 
rhesus monkey-specific 330-bp AR complementary DNA (cDNA) (GenBank 
accession number AF092930). The nucleotide sequence of this AR cDNA has 99% 
homology with the corresponding AR human sequence (Abdelgadir et al. 1999). 
Frozen sections of endometrium were mounted on SuperFrost Plus slides (Fisher
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Scientific) and fixed in 4% parafomialdehyde in PBS for 20 min at 4°C. The tissue 
sections were rinsed in 2x SSC (standard saline citrate), then acetylated with 0.25% 
acetic anhydride in 0.1 mol/L tri-ethanolamine (pH 8.0) for 10 min. Slides were then 
rinsed in 2x SSC, dehydrated tlirough an ascending series of alcohols, and air-dried. 
At this point at least one slide per tissue group was treated with ribonuclease A 
[RNase A; 20 ing/mL, 0.5 mol/L NaCl, 0.01 mol/L Tris, and 1 mmol/L 
ethylenediamine tetraacetate (EDTA), pH 8.0] as a negative control. The slides were 
prehybridized for 1 h at 42 C in 10 mmol/L dithiotlmeitol, 0.3 mol/L NaCl, 20 
mmol/L Tris (pH 8.0), 5 mmol/L EDTA, 1 3 Denhardt’s solution, 10% dextran 
sulfate, and 50% fonnamide. Sections were then incubated at 55°C overnight in the 
same solution containing the appropriate concentrations of the sense and antisense 
probes (5 million cpm/mL). The most appropriate concentrations of labeled probes 
were empirically determined by serial dilution trials. RNase-treated sections were 
incubated with the antisense probe. After treatment with RNase A-containing buffer 
(20 ing/mL; 0.5 mol/L NaCl, 0.01 mol/L Tris, and 1 mmol/L EDTA, pH 8.0) at 37°C 
for 30 min to inactivate nonhybridized probe, the slides were rinsed in a descending 
series of SSC (2, 1, and 0.5 x) and then incubated in 0.1 x SSC at 65°C (high 
stringency) for 30 min. Sections were dehydrated in an ascending series of alcohol 
dilutions, vacuum-dried, coated with NTB2 autoradio-graphic emulsion (Eastman 
Kodak Co., Rochester, NY), stored at 4°C for 2 weeks, developed in D-19 (Eastman 
Kodak Co.), lightly counterstained with haematoxylin, dehydrated in an ascending 
series of alcohol dilutions, cleared with xylene, and coverslipped with Permount 
(Fisher Scientific). Sense- and RNase-treated controls had no specific signals.
Silver grains were counted over stroma and glandular epithelium in sections 
hybridized with radiolabeled probe. The counts were made with Optimas (Media 
Cybernetics, Silver Spring, MD) on images captured at x 250 original magnification. 
In RNase-treated slides, regardless of honnone treatment or state, grains over the 
tissues were identical to those over the glass slide. Therefore, a region of the slide 
away from the section was counted as background, and these counts were subtracted 
from each epithelial and stromal field counted. The abundance of silver grains in the 
field was expressed as the number of silver grains per nucleus (stromal cell and 
glandular cell, respectively). These counts were then expressed as a percentage of the 
maximum signal in all the sections analyzed.
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Statistical analysis was performed using one way analysis of variance with 
Fishers’ protected least significant difference post test (SPSS 11.0). A p value <0.05 
was considered significant.
4.2.4 Temporal expression of androgen receptor messenger RNA in 
endometrium during the menstrual cycle.
Real-Time quantitative RT-PCR was used to measure the levels of Androgen 
Receptor in menstrual cycle cDNA samples. Frozen samples of endometrium stored 
at -80°C were first homogenised, and then total RNA was extracted using the 
commercially available product Trizol (Invitrogen Life technologies Ltd, Paisley, 
UK). RNA extraction, quantitation and reverse transcription methods have been 
detailed in Chapter 3. (See Chapters 3.3.1; 3.3.2; 3.3.3)
Menstrual cycle samples were divided into proliferative (n=12) and secretory 
(n=15) phases with further classification of samples as early-(n=4), mid-(n=3), and 
late-proliferative (n=5) and early-(n=5), mid-(n=5), and late-secretory (n=5) phases.
AR primers and probe were designed using the applied biosystems primer 
express program. A reaction mixture was made containing Stratagene Taqman 
buffer, MgCh (5.5mmol/l), Sure Start Taq DNA polymerase (0.025 lU/pl; 
Stratagene, Amsterdam, Netherlands), dATP (200 pmol/l), dCTP (200 p.mol/1), 
dGTP (200 pmol/1), dUTP (200 pmol/1), AR forward and reverse primers 
(300nmol/l; Biosource, Nivelles, Belgium), and AR probe (200mnol/l; Biosource, 
Nivelles, Belgium). Additionally specific primers and probe for ribosomal IBS were 
also added at 50mnol/l (Perkin-Elmer; Applied biosystems, Warrington, UK).
The mixture was then aliquoted into separate tubes for each cDNA sample. 
An amount of 2.5 p 1/rep lie ate of 1: 2.5 dilution cDNA was added to each tube. After 
mixing, 23pi of each sample were added to the wells on a PCR reaction plate with 
each sample being added and analysed in triplicate. Wells were sealed with optical 
caps and the PCR reaction run on the ABI prism 7700 using standard conditions.
Statistical analysis was perfonned using one way analysis of variance with 
Fishers’ protected least significant difference post test (SPSS 11.0). A p value <0.05 
was considered significant.
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4.3 Results
4.3.1 ïmmunohistochemical localisation of AR in human endometrium.
Menstrual cycle samples were divided into proliferative phase (n=15), early secretory 
phase (n=5), mid secretory phase (n=5), and late secretory phase (n=7). 
Immunolocalisation of the AR revealed a predominantly endometrial stromal 
distribution with no (or barely detectable) staining in the glands (Figure. 4.1).
To facilitate objective image analysis the sections were digitalised and treated 
as described previously in Chapter 3.2.5. This provided a mean percentage positive 
result for the expression of AR in the stromal and glandular compartments of the 
endometrium. Spatial variation in expression was determined by separate analysis of 
the functional and basal layers of the endometrium. Temporal analysis was assessed 
by comparison of the functional and basal layers across the menstrual cycle stages.
The spatial distribution of the AR was similar in the functional and basal 
layers throughout the menstrual cycle with stromal imniunoreactivity being the 
predominant feature. Significant temporal variation in the expression of the AR was 
noted.
The abundance of AR-positive cells was similar in the functional and basal 
stroma throughout the entire proliferative, early secretory and mid secretory phases 
of the cycle, but there was a clear decrease in immunostaining in the late secretory 
phase. This decrease was particularly marked in the functional layer but was noted in 
both layers. Quantitation of the frequency of AR-positive cells showed that the 
decrease in the late secretory phase was highly significant (Figure. 4.2).
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Figure 4.2
Quantification of AR positive cells in human endometrial Stroma. Data are expressed 
as mean (±SEM) percentage o f cells staining positive for AR during the menstrual 
cycle (P, Proliferative; ES, early secretory; MS, mid secretory; LS, late secretory). 
The percentage of AR immunoreactive stromal cells was significantly lower 
(P<0.05) during the late secretory phase compared with other phases of the cycle in 
both the functional and basal layers.
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4.3.2 In-Situ hybridisation of AR mRNA in human endometrium.
To assess if human endometrial AR mRNA expression was consistent with AR 
protein expression, in-situ hybridisation (ISH) was performed in addition to 
quantitative RT-PCR. ISH of AR mRNA in human endometrium aimed to determine 
whether the same cells that expressed the AR protein also expressed AR mRNA and 
ascertain if a similar decline in AR mRNA is noted in the late secretory phase.
A representative sample from the early proliferative phase is depicted at low 
magnification with bright field illumination (Figure 4.3), dark field illumination 
(Figure 4.3) and at high magnification bright field (Figure 4.3). These images are 
consistent with the immunohistochemistry (IHC) data and show that AR mRNA was 
predominantly localised in the endometrial stroma and not the glandular epithelium. 
As with IHC, ISH of late secretory phase endometrium showed a decline in the 
intensity of the stromal cell signal in the late secretory phase (Slayden et al. 2001).
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4.3.3 Temporal expression of AR mRNA with quantitative RT-PCR.
The menstrual cycle samples were divided into proliferative (n=12) and secretory 
(n=15) phases with further classification of samples as early-(n=4), mid-(n=3), and 
late-proliferative (n=5) and early-(n=5), mid-(n=5), and late-secretory (n=5) phases.
Significantly higher levels of AR mRNA were observed in the early and mid 
proliferative phase endometrial tissue samples compared to the remainder of the 
menstrual cycle stages. From the mid proliferative phase of the menstrual cycle there 
is a progressive decline in the relative expression of AR mRNA (Figure 4.4).
The reduced expression of AR protein occurs in the late secretory phase 
human endometrium and this is supported from the findings of ISH and quantitative 
RT-PCR.
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Figure 4.4
Quantitative evaluation of AR mRNA in endometrium across the stages of the 
menstrual cycle. All endometrial tissue samples were compared to an internal 
control (comparator) obtained during the early proliferative stage of the menstrual 
cycle. AR mRNA levels were high in the early and mid proliferative samples but fell 
significantly in samples taken from the late proliferative and early to late secretory 
samples (p<0.01). EP-early proliferative, MP-mid proliferative, LP-late proliferative, 
ES-early secretory, MS-mid secretory, LS-late secretory.
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4,3.4 AR Localisation in Anti-Progestogen Treated Endometrium
The immunohistochemical assessment of endometrial samples from six control 
patients and six women treated with 2 mg/ day RU 486 for 30 days for AR 
immunoreactivity was performed as described in Chapter 3.2.
hi the control specimens there was essentially no immunoreactivity in the 
glandular or surface epithelium, but there was distinct immunostaining of the stroma 
in keeping with the findings detailed previously (Figure 4.5). After 30 days of RU 
486, there were distinct and notable increases in the AR immunostaining of the 
glands and surface epithelium plus some enhancement of stromal AR 
immunostaining.
Furthermore, we evaluated the IHC preparations from five placebo controls 
and five patients treated with a single dose of 200 mg RU 486 on day LH + 2 and 
sampled on days LH + 4 and LH + 6. The controls, who were sampled on days LH + 
4 and LH + 6, had essentially no AR staining in the glands or surface epithelium, but 
had definite stromal AR immunostaining (Figure 4.5). Figure 4.5 is representative of 
the controls from both the 2-mg and the 200-mg studies. On both days LH + 4 and 
LH + 6 after the 200 mg RU 486 dose there were clear increases in glandular and 
surface epithelial immunostaining and some increase in stromal AR immunostaining 
(Figure 4.5).
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Figure 4.5
ïmmunohistochemical localisation of AR in anti-progestogen treated endometrium. 
The findings shown in the photomicrographs are representative of the 2mg and 
200mg studies. Images A and C represent the control endometrial samples taken on 
days LH+4 and LH+6 respectively. Images B and D represent the treatment groups 
on days LH+4 and LH+6 respectively following administration of 200mg of RU486 
on day LH+2 (Image D inset is negative control). AR is demonstrated in the stromal 
cells of both the treatment and control groups. When compared to the control groups, 
treatment with RU486 increases AR immunoreactivity in the endometrial glandular 
and surface epithelial cells. Scale bar represents 50 pm.
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4.4 Discussion
The assessment of the biological role of androgens in endometrial function has been 
hindered by a lack of consistent findings from published data. To generate a 
hypothesis for their role it was necessary to undertake descriptive studies to provide a 
reliable platfomi for further research. This study determined that AR is expressed in 
the endometrial stromal compartment with down regulation of AR protein and 
messenger RNA in the progesterone dominated late secretory phase. Furthermore, 
treatment of endometrium with the anti-progestogen RU486 revealed up-regulation 
of AR in the stromal, glandular and siuTace epithelial compartments. These latter 
findings suggest a role for progesterone in the regulation of AR
The experiments performed on human endometrium were canied out in 
collaboration with colleagues at the Oregon National Primate Research Centre. Our 
collaborators studied nonhuman primates, Rliesus Macaques, to investigate the role 
of androgens in macaque endometrium (Slayden et al. 2001). The antibody utilised 
in both human and nonliuman primate tissues was the monoclonal antibody F39.4 
and the in situ hybridisation protocols employed were identical. In keeping with the 
present results from human endometrium, Macaque endometrial stromal cells were 
the predominant cell population expressing AR. In addition, the studies on the 
macaque endometrium suggested a role for progesterone in the regulation of 
endometrial AR expression. Using tliree independent technical approaches (binding 
assays, hnmunohistochemistry, and In-situ hybridisation) it was demonstrated in 
ovariectomised macaques that expression of AR protein and message was minimal 
and were increased significantly following 28 days of oestradiol treatment. Addition 
of progesterone for the last 14 days inliibited this increase. This finding in the 
macaque is analogous to human endometrial tissue.
Human endometrial immunohistochemical sections were analysed using 
objective image analysis to determine the expression of AR protein in stromal cells. 
High levels of AR protein in the endometrium biopsied from the oestrogen 
dominated proliferative phase were demonstrated. In-situ hybridisation confirmed 
niRNA localisation to the stromal compartment. Quantitative real time RT-PCR 
revealed temporal down regulation of niRNA expression in the secretory phase. AR 
protein was also significantly down regulated in the progesterone dominated
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secretory phase. Overall these cuneiit findings are most similar to the most recently 
published studies by Mertens et al. (Meitens et al. 2001) for human endometrium and 
Adesanya et al. (Adesanya-Famuyiwa et al. 1999) for rhesus Macaques.
In human endometrium, the use of full thickness endometrial biopsies 
maintained architectural integrity allowing a spatial and temporal description of the 
AR in all cellular compartments. The findings were consistent between human and 
nonhuman primate specimens unlike previously published studies on the androgen 
receptor, which lacked a consistency in their observations. The in-situ hybridisation 
study also provided novel data in human endometrium, as no studies have previously 
localised AR mRNA in human endometrium. The use of full thickness cryosections 
again allowed accurate spatial description of AR mRNA expression. The use of 
Taqman probes permitted the relative quantitation of AR mRNA expression to 
determine variances in AR mRNA expression through the menstrual cycle, another 
novel finding in this study.
The nonliuman primate studies were able to create animal models that 
exposed the endometrium to oestradiol alone then added in progesterone and/or 
RU486 for subsequent cycles to examine the effect of the single or combined sex 
steroid effect upon nonhuman primate endometrial AR expression. Such experiments 
were not feasible in human patients. The animal models simulated the human in-vivo 
situation studied. However, both human and nonliuman endometrium displayed 
consistent findings, namely: down regulation of AR in a progesterone dominated 
environment and up-regulation of AR following treatment with an antiprogestogen 
(RU486). These data suggest a role for progesterone in the regulation of endometrial 
AR expression. Indeed it has already been demonstrated in nonliuman primate 
endometrium that antiprogestogen treatment will up-regulate other sex steroid 
receptors such as oestrogen (ER) and progesterone receptor (PR) (Neulen et al. 1990; 
Slayden et al. 1994; Slayden et al. 1998). The expression of ER and PR are under 
dual control of oestrogen and progesterone and it would appear that a similar 
mechanism might exist for the regulation of AR.
The pattern of AR expression in human endometrium would suggest that any 
action of androgens would be predominantly in the proliferative and peri-ovulatory 
phases of the menstmal cycle. Endometrial tissue sections exhibit no substantial 
ininiunoreactivity in the glandular, endothelial or perivascular areas, as stromal
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expression of AR predominates. This suggests that any genomic action of androgens 
would have to be mediated via the endometrial stromal cells. While the endogenous 
action of androgens remains to be elucidated, a common androgenic action appears 
to be endometrial atrophy. The data presented suggests a role for progesterone in the 
regulation of AR and allows a hypothesis to be formulated that may explain the 
mechanism of androgen/antiprogestogen endometrial atrophy.
Antiprogestogen treatment up-regulates AR, ER and PR in human 
endometrium (Cameron et al. 1996; Slayden et al. 2001). The underlying mechanism 
for this action may paradoxically be related to an enlianced action of oestradiol (E2) 
at the molecular level. Animal studies on mice and rabbits indicate that unoccupied 
PR (in the presence of E2 and absence of P) can down-modulate the effects of E2. 
Lydon et al. studied the action of E2 on the uterus and oviducts of wild type and PR 
knockout mice (Lydon et al. 1995). E2 produeed hyperplasia in the uterus and 
oviducts of the PR loiockout mice but in the wild type mice a far less dramatic effect 
was noted. This suggests that unoccupied PR can have a “braking” effect on E2 
action. A similar role for unoccupied PR has also been described in rabbit 
endometrium (Chwalisz et al. 1991) and brain (Chappell et al. 2000). Anti­
progesterone treatment effectively occupies PR and removes it from play; therefore, 
any braking effect of PR on E2 action would effectively be removed. Accordingly, 
the action of E2 at the molecular level would be enlianced resulting in elevated levels 
of ER, PR and AR. As such, the increased expression of AR may play a role in the 
mechanism of endometrial atrophy.
Increased endometrial AR could lead to increased binding of endometrial 
androgens, which may antagonise the effect of oestrogens on endometrial growth. 
Testosterone and danazol have been shown to inhibit endometrial cell proliferation in 
tissue cultures that contained phenol red in sufficient concentrations to provide an 
oestrogenic stimulus (Rose et al. 1988). The authors suggest that the anti­
proliferative effects of danazol may involve a direct anti-oestrogenic effect. A further 
example of the ability of danazol to inhibit endometrial proliferation is demonstrated 
in patients suffering from endometrial hyperplasia who were treated with danazol. 
The changes of hyperplasia were reversed in 97% of patients (Bulletti et al. 1987). 
More recently longitudinal evaluation of the endometrium of patients on long term
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danazol with light and electron microscopy has again shown its ability to induce 
endometrial atrophy (Fedele et al. 1995).
Androstenedione has also been shown to inhibit human endometrial cell 
growth and secretory activity in vitro (Tuckemian et al. 2000), and high plasma 
androgen levels have been associated with adverse reproductive outcome, including 
recurrent miscarriage (Tulppala et al. 1993; Okon et al. 1998; Bus sen et al. 1999; 
Cermik et al. 2003). Okon et al showed that hyperandrogenism con elated highly 
with the increased endometrial production of glycodelin, a protein correlated with 
endometrial dysfunction. Their explanation presumed that this was due to androgen 
antagonism of the ability of oestrogen to prime the endometrium during the 
proliferative phase. Brenner et ah, (personal communication from our collaboration) 
have preliminary data from studies on ovariectomised macaques to support the anti- 
oestrogenic effect of androgens in the endometrium. Systemic treatment with 
dihydrotestosterone blocked the stimulatory effect of E2 on ER and PR levels, 
oviductal ciliogenesis and endometrial mitosis (Hirst et al. 1992). The above findings 
give credibility to the possibility that elevated AR may mediate the anti-oestrogenic 
effect of androgens in the endometrium during antiprogestogen treatment.
A paradoxical observation to this hypothesis is that the risk of endometrial 
hyperplasia and invasive endometrial adenocarcinoma are increased in patients 
affected by PCOS. PCOS is a complicated metabolic disorder that results in elevated 
serum androgen, oestrogen and insulin levels. If, as suggested above, androgens 
exhibit anti-oestrogenic activity in the endometrium and PR is unoccupied then there 
should theoretically be mechanisms in-vivo to prevent endometrial proliferation. In- 
vivo this does not appear to be the case as proliferation and hypeiplasia still occur. 
However, the endometrial endocrine phenotype is different from that of patients 
without PCOS. The elevated insulin levels associated with PCOS have been shown 
to induce aromatase activity in stroma and glands of endometrium whereas normally 
endometrium has no such capacity for intracrine synthesis of oestrogens (Randolph 
et al. 1987). Therefore, in PCOS the elevated free androgens may be converted to 
active oestrogen metabolites in both the endometriiun and peripheral aromatase 
containing tissues, further driving endometrial proliferation. Oestrogenic stimulation 
drives cell proliferation and by the increase in the number of cell divisions the risk of 
random DNA replication errors (activation of oncogenes, inactivation of tumour-
149
suppression genes) inereases. Depending on the kind of genetic damage a malignant 
phenotype may arise with progi'essive growth under the influence of oestrogens 
(Jongen et al. 2002). Thus, oestrogens act as tumour promoters but not as 
carcinogens. The action of oestrogen would then be augmented by the ability of 
endometrial cancers to produce aromatase within the tumour (Bulun et al. 1994; 
Watanabe et al. 1995). The above provides a mechanism for the indirect participation 
of androgens in endometrial hyperplasia/adenocarcinoma.
An interrelation may exist between ovarian morphology, local androgen 
production and hyperplastic and malignant diseases of the endometrium. It has been 
shown that the testosterone levels in the utero-ovarian vein blood samples from 
women with endometrial carcinoma were significantly elevated as compared with the 
utero-ovarian vein levels from women without endometrial earcinoma, without 
significant increases in the peripheral levels of these androgens (Bremond et al. 
1982). hr PCOS, ovarian stromal hyperplasia with increased ovarian androgen 
production is noted and rather than supplying precursor for further metabolism this 
may directly stimulate the AR in endometrium to produce malignant change 
(Hackenberg et al. 1996).
The paradoxical association of AR with endometrial atrophy and endometrial 
hyperplasia/adenocarcinoma remains to be resolved with further study. Indeed the 
biological role of AR in endometrial function requires attention from future research.
In conclusion, the data presented here provide a consistent description of the 
temporal and spatial expression of AR in human endometrium at the protein and 
mRNA levels Evidence is also provided to support a role for progesterone in the 
regulation of endometrial AR expression. Additionally a mechanism for the anti­
progesterone induced endometrial atrophy with reference to progesterone regulation 
of AR is also discussed.
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Chapter 5
Levonorgestrel Regulation of 
Androgen Receptor (AR) and 
17|3 hydroxysteroid dehydrogenase 
type 2 (17(3-HSD2) Expression in 
Human Endometrium.
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5.1 Introduction
Levonorgestrel (LNG) is a potent progestogen, which has a binding affinity for the 
androgen receptor, and is a common constituent of contraceptive preparations. The 
levonorgestrel-releasing intrauterine system (LNG ÏUS; Schering HC, West Sussex, 
UK) releases 20 micro grams LNG locally to the endometrium over 24 hours 
(Luukkainen et al. 1990). Patient acceptability is high but many patients will 
discontinue therapy due to the adverse effect of breakthrough bleeding (BTB) 
(Anderson 1992; Findlay 1996). The mechanism responsible for BTB remains poorly 
understood but is likely to involve angiogenic factors, matrix metalloproteinase 
activation, and altered haemostatic factors that result in increased endometrial vessel 
fragility (Hickey et al. 2000). Such a pathogenesis may be directly related to the high 
dose of local LNG. Alternatively, indirect actions of LNG may be responsible, such 
as its influence upon endometrial sex steroid receptor expression, or ligand 
availability in the endometrium.
Sex steroid ligands play a pivotal role in the control of uterine function by 
binding to their respective receptors (See Chapters 1.7 and 4.1). Briefly, AR has been 
spatially localised to human endometrial stroma with up regulation in the oestrogen- 
dominated proliferative phase followed by down regulation in the late secretory 
phase (Mertens et al. 2001; Slayden et al. 2001). ER and PR are also up-regulated in 
both glandular and stromal tissue in the proliferative phase. However, in the 
secretory phase a down-regulation of ER is noted in both glands and stroma. PR is 
also down regulated in the glands but expression persists in stromal tissues (Garcia et 
ai. 1988; Lessey et al. 1988; Snijders et al. 1992; Critchley et al. 1993). The 
progesterone receptor subtype that persists in the stroma is predominantly the PRa 
isoform (Wang et al. 1998; Brosens et al. 1999).
LNG, delivered locally by the LNG lUS, is known to down regulate ER and 
PR expression in the human endometrium (Critchley et al. 1998). This alteration in 
sex steroid receptor expression may affect endometrial cytokine release which in turn 
may contribute to the pathogenesis of breakthrough bleeding (BTB) (Jones et al. 
2000). The cellular and molecular expression of the androgen receptor in 
endometrium exposed to high dose intra-uterine levonorgestrel has not been
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previously reported and AR may play an important role in endometrial physiology 
(Slayden et ah 2001).
In reproductive tissues, the local actions of sex steroids are modulated by 
hydroxysteroid dehydrogenases (HSDs). The various dehydrogenases are multi-gene 
families. The human 17f3-HSD family has six known members, each being a separate 
gene from a different chromosome with distinct properties in terms of substrate and 
redox direction. The type 2 isoform (17j3-HSD2) has a major role in the inactivation 
of oestradiol to oestrone. 17p-HSD2 is also the enzyme responsible for converting 
androgens to less potent forms while also activating progesterone. The 17p-HSD2 
isoform is expressed in endometrial glandular epithelium, and is up regulated by 
progesterone (Maentausta et al. 1993). Its activity decreases when progesterone 
coneentrations decline premenstrually or following antiprogestin administration 
(Maentausta et al. 1993; Mustonen et al. 1998). LNG is a potent androgen that binds 
avidly to the AR (Kloosterboer et al. 1988). The availability of other androgenic 
ligands to bind to the AR may be influenced by the availability of the enzyme, 17p- 
HSD2.
In this Chapter, the expression of both AR and 17p-HSD2 in a longitudinal 
study of endometrial samples taken from naturally cycling women and from women 
with a LNG lUS over a twelve month time frame has been studied. The results 
provide new data on the expression patterns of these two molecular components that 
may be relevant to the bleeding patterns reported with intrauterine delivery of 
levonorgestrel.
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5.2 Material and Methods
Material and Methods have been described previously in Chapter 3. Details that 
follow summarise pertinent material and methods for this area of the project. Human 
endometrial samples were obtained from tluee different patient groups.
5.2.1 Tissue Collection
The first group consisted of fertile women (n=24) with regular menstrual cycles 
lasting between 25 and 35 days who had not been using hormonal preparations for 
the preceding 3 months. The tissue samples were a subset of the larger set described 
in 3.1.1 and 3.1.2. Endometrial tissue included samples colleeted from women during 
the proliferative phase (n=6), early secretory (n=6), mid secretory (n=6) and late 
secretory phase (n=6) of the menstrual cycle. In this group all tissue samples were 
full thiclmess endometrial biopsies. The stage of the menstrual cyele was consistent 
with the patients reported last menstrual period and was confirmed by histological 
dating, according to the criteria of Noyes et al (Noyes et al. 1950). Furthermore, 
serum samples collected at the time of endometrial tissue collection for 
determination of circulating oestradiol and progesterone concentrations by RIA were 
consistent with the designated cycle stage. A significant decline in progesterone 
concentrations was apparent between biopsies taken in the mid and late secretory 
phase of the cycle see chapter 3.1.
The second group consisted of fertile women (n=12) with regular menstrual 
cycles lasting between 25 and 35 days that had not been using hormonal preparations 
for the preceding 6 months. These same samples were also a subset of the larger set 
of tissue samples detailed in Chapters 3.1.2. The patients were scheduled to have a 
LNG lUS inserted for long-term hormonal contraception. All patients undeiivent a 
pre-insertion endometrial biopsy in either the proliferative (n=5) or secretory phase 
(n=5) of the cycle immediately following which a LNG lUS (Mirena, Schering HC, 
UK) was inserted as an outpatient procedure. The stage of the cycle prior to insertion 
of the LNG lUS was detemiined by reference to serum sex steroid concentrations, 
stated date of last menstrual period and histological dating by the criteria of Noyes at 
al. (Noyes et al. 1950). Further endometrial samples were collected l(n=2), 3 (n=5), 
6 (n=5) and 12 months (n=5) following insertion of the LNG lUS.
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The third patient group included women using a LNG lUS for management 
of regular but heavy menstrual loss. Endometrial samples were collected from 
patients with a LNG lUS in-situ for 3 months, 6 months, or greater than 1 year. 
Endometrial tissue samples were frozen immediately upon collection in liquid 
nitrogen and stored at -80°C.
5.2.2 RNA extraction and real time quantitative RT-PCR
Frozen samples of endometrium stored at -80°C were first homogenised, and then 
total RNA was extracted using the commercially available product Trizol (Invitrogen 
Life technologies Ltd, Paisley, UK). The methods of extraction, quantification, 
cDNA preparation and quantitative RT-PCR are the same as detailed in Chapters 
3.3.1; 3.3.2; and 3.3.3.
Samples of total RNA to be used for quantification of AR mRNA required 
pre-treatment with RNAse free DNAse (Invitrogen Life technologies Ltd, Paisley, 
UK) as this primer probe preparation did not span an intron. Samples of RNA to be 
used for quantification of 17p-HSD2 mRNA did not require pre-treatment with 
RNAse free DNAse as this primer probe preparation spamied an intron.
Real-time quantitative PCR was perfoiined in an ABI 7700 Sequence 
Detection System (Perkin-Elmer, CA, USA). Oligonucleotide foiward and reverse 
primers and oligonucleotide Taqman probes for AR and 17j3-HSD2 were designed, 
with the use of Primer Express version 1.0 (Perkin-Elmer Applied Biosystems, 
Cheshire, UK), from sequences entered in the GenBanlc database. The sequences for 
the androgen receptor and 17P-HSD2 primers and probe are shown in table 3.2.
Numeric data from the real time quantitative RT-PCR were analysed by one 
way ANOVA, followed by Fisher’s protected least significant difference test.
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5.2.3 AR and 17p-HSD2 Immimohistochemistry
As detailed in Chapters 3.2.2 and 3.2.3 the specificity and properties of the 
antibodies for the immunolocalisation of the AR (F39.4; (Slayden et al. 2001) and 
17p-FISD2 (Mab C2-12; (Moghrabi et al. 1997) have been previously described.
Paraffin sections (5 pm) were dewaxed and rehydrated through a series of 
alcohols then washed in distilled water and O.OIM phosphate-buffered saline (PBS, 
Sigma-Aldrich Ltd. Poole, Dorset, England) The slides were then subjected to 
antigen retrieval by pressure-cooking in O.Olmol/L sodium citrate at pFI 6 for 5 
minutes. After cooling for 20 minutes the slides were washed in PBS. Endogenous 
peroxidase activity was quenched with immersion in 3% hydrogen peroxide (Merck, 
Poole, UK) in distilled water for 10 minutes at room temperature. Non specific 
binding of the antibodies was blocked by incubating the sections for 20-30 minutes at 
room temperature in non immune horse semm (Vectastain, Vector Laboratories, Inc., 
Peterborough, UK).
For localisation of the AR, sections were incubated with the mouse 
monoclonal antibody F39.4 (IgGi; Biogenex Laboratories, Inc., San Ramon, CA, 
USA) overnight at 4*^ C at a 1 ;480 dilution in PBS/BSA gelatin or similarly with a 
control mouse IgGi antibody at a 1:600 dilution. For localisation of 17p-HSD2, 
sections were incubated with the mouse monoclonal Mab C2-12 overnight at 4°C at a 
1:20 dilution in normal horse serum or similarly with a control mouse IgG antibody 
at a 1:400 dilution. Following a wash in PBS with Tween 20, the slides were 
incubated in biotinylated horse anti-mouse secondary antibody (Vectastain, Vector 
Laboratories, Inc., Peterborough, UK.) in normal horse serum for 60 minutes at room 
temperature. They were then reacted with the avidin-biotin peroxidase complex 
(Vectastain Elite) for 60 minutes at room temperature and visualised with the 
substrate and ehromagen 3, 3 ’ -diaminobenzidine (DAKO Liquid, DAKO
Corporation, California, USA).
The immune staining intensity of epitopes in all tissue sections was assessed 
in a semi-quantitative manner on a four point scale: 0 = no imniunostaining, 1 = mild 
immunostaining, 2 = moderate immunostaining and 3 = intense imniunostaining. All 
tissue sections were scored blind by two observers. We had previously validated this 
scoring system in a subset of tissue sections in which immunoreactivity was
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measured with a computerised image analysis system, and a strong correlation 
between quantitative data derived from image analysis and subjective scores by a 
trained observer was obtained (Wang et al. 1998). Semi-quantitative scoring results 
were analysed by a non-parametric method, the Kiaiskall Wallis test, followed by 
Dunn’s multiple post test.
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5.3 Results
5.3.1 Temporal expression of endometrial AR messenger RNA following high
dose intrauterine delivery of levonorgestrel.
The menstrual cycle samples analysed were the same as those in the previous 
Chapter and accordingly the findings are also presented in Chapter 4.2.4 showing 
significantly higher levels of AR mRNA in the early and mid proliferative phase 
endometrial tissue samples compared to the remainder of the menstrual cycle stages.
Endometrial tissue samples from women using a LNG-IUS for 3 months, 6 
months or more than 12 months were studied. Samples treated for gi*eater than 12 
months were analysed together as maximal reduction in blood loss occurs by 12 
months (Andersson et al. 1994), and the period of breakthrough bleeding is confined 
usually to the first 3-6 months after initiation of treatment. To allow comparison with 
the menstrual cycle, samples were statistically compared to an early proliferative 
phase sample as a control.
Comparison revealed a significantly greater production of AR mRNA in the 
proliferative phase when compared to any duration of treatment with the LNG lUS 
(p<0.01) (Figure 5.1). No significant differences were noted between the secretory 
phase and the LNG lUS exposed endometrium.
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Figure 5.1
Quantitative evaluation of AR mRNA in endometrium across the stages of the 
menstrual cycle and following intrauterine delivery of LNG. All endometrial tissue 
samples were compared to an internal control (comparator) obtained during the early 
proliferative stage of the menstrual cycle. AR mRNA levels were high in the early 
and mid proliferative samples but fell significantly in samples taken from the late 
proliferative and early to late secretory samples (p<0.01). Levels of AR mRNA were 
again low in the LNG-IUS treated samples when compared to the proliferative stage 
of the cycle (p<0.01). EP-early proliferative, MP- mid proliferative, LP-latç 
proliferative, ES-early secretory, MS-mid secretory, LS-late secretory.
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5 .3 .2  Temporal expression of 17p-HSD2messenger RNA in endometrium 
through the menstrual cycle and following high dose intrauterine 
delivery of levonorgestrel.
The same samples analysed for AR expression were studied for the expression of 
17p-HSD2 mRNA. The highest levels of 17(3-HSD2 mRNA expression was noted in 
the early proliferative phase, with the levels significantly greater than the other stages 
of the menstrual cycle apart from the late secretory phase (p<0.008)(Figure 5.2).
17(3-F[SD2 mRNA was also detected in endometrium exposed to high dose 
intrauterine LNG. Samples were again analysed after 3, 6 or >12 months in vivo 
treatment with an LNG lUS. Relatively higher levels of 17j3-HSD2 mRNA were 
detected following 3 months treatment with LNG lUS. This was significantly greater 
than levels noted during the menstrual cycle stages and the other LNG lUS treatment 
groups (p<0.01; Figure 5.2).
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Figure 5.2
Quantitative evaluation of 17P-HSD2 mRNA in endometrium across the stages of 
the menstrual cycle and following intrauterine delivery of LNG. All endometrial 
tissue samples were compared to an internal control (comparator) obtained during the 
early proliferative stage of the cycle. 17P-HSD2 mRNA levels were significantly 
higher in the early proliferative phase of the menstrual cycle when compared to the 
mid-late proliferative and the early-mid secretory phase samples (p<0.008). In LNG- 
IUS treated samples relatively higher levels o f 17p-HSD2 mRNA were detected 
following 3 months. This was significantly greater than levels noted during the 
menstrual cycle and the other LNG lUS treated samples (p<0.01). EP-early 
proliferative, MP- mid proliferative, LP-late proliferative, ES-early secretory, MS- 
mid secretory, LS-late secretory.
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5.3.3 AR Immunostaining In Endometrium Exposed To High Dose Intra­
uterine Levonorgestrel.
Presence of LNG lUS resulted in a typically pseudo-decidualised stroma with 
atrophic glands and these histological features were observed in all post insertion 
endometrial biopsies, as previously shown by our laboratory (Critchley et al. 1998). 
Prior to insertion all proliferative phase endometrial tissue samples displayed 
strongly positive nuclear immunoreaetivity for AR in the endometrial stroma with 
minimal glandular nuclear immunoreactivity. As we previously noted AR 
immunoreactivity in secretory phase biopsies was localised to stromal nuclei and was 
clearly decreased compared to the proliferative phase (Figure 5.3).
Intra-uterine delivery of levonorgestrel via a LNG lUS was associated with 
minimal AR immunoreactivity in the stromal compartment with a significantly less 
immunoreactivity by 12 months treatment with a LNG lUS (Figures 5.3; 5.4).
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Figure 5.4.
AR immunoreactivity scores in endometrial stromal compartments throughout the 
menstrual cycle and following high dose intrauterine LNG exposure (1-12 months). 
Box and whisker plots; box represents the 25 '^’ and 75 '^’ percentiles and the heavy bar 
represents the median. Symbols (O) represents outliers. P = proliferative, S = 
secretory.
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5.3.4 17p“HSD2 immunostaining Endometrium Exposed To High Dose Intra­
uterine Levonorgestrel.
In full thickness endometrial biopsies 17p-HSD2 was immunolocalised to the 
cytoplasm of glandular epithelium with no stromal immunoreactivity observed 
(Figure 5.5). Maximal immunoreactivity was noted in the secretory phase during 
which both superficial and basal layers displayed strong immunoreactivity. Basal 
layer immunoreactivity was first evident in the early secretory phase. 
Immunostaining in both the early and mid secretory phase biopsies was significantly 
greater than in the proliferative phase (p<0.05). Superficial layer immunoreactivity 
for 17P-HSD2 was also first evident in the early secretory phase with the mid 
secretory phase biopsies displaying significantly greater levels of immunostaining 
than the proliferative phase (p<0.01). In the late secretory phase following the mid 
secretory peak there was persistent superficial and basal immunoreactivity.
One month after insertion of the LNG lUS there was still detectable 17|3- 
FISD2 immunostaining, and the staining intensity was greater than that normally 
found during the proliferative phase. Thereafter, at three months after insertion there 
was a significant decline in 17p-HSD2 expression compared to the level of 17|3- 
HSD2 immunoreactivity in the secretory phase (p<0.01; Figures 5.5; 5.6). This low 
level of immunoreactivity was maintained in the 12 month biopsy specimens. The 
low degree of immunostaining for 17P-HSD2 between 3 and 12 months post 
insertion was not significantly different from that seen during the proliferative phase 
(Figure 5.5)
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Figure 5.6.
17PHSD2 inimuiioreactivity scores in endometrial glandular compartments of 
superficial endometrium across the menstrual cycle and following LNG lUS 
exposure (1-12 months). Box and whisker plots; boxes represent the 25^ and 75^ ’^ 
percentiles and the heavy bar represents the median. The whiskers represent the 10‘'^  
and 90^ percentile. P = proliferative, S = secretory.
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5.4 Discussion
The mechanism of problematic and unscheduled breaktlii'ough bleeding (BTB) 
experienced by users of long-term progestin only contraception remains poorly 
understood. Consequently there are no reliable therapeutic intervention strategies 
available to overcome this problem and improve patient satisfaction. The intrauterine 
exposure of the endometrium to high doses of LNG results in marked endometrial 
atrophy, inactive glands and a heavily decidualised endometrium. There is a marked 
down-regulation of sex steroid receptors (PR, ER and AR) and there are higher local 
concentrations of prostaglandins in the initial months of LNG RIS exposure 
(Critchley et al. 1998; Jones et al. 2000). Another consistent feature in the 
endometrium of long-term progestin only contraceptive users are the abnormalities 
reported in the structure of endometrial microvessels (Hickey et al. 2000). The 
endometrium of long term progestin users have an associated increase in blood 
vessel fragility that may contribute to the pathogenesis of endometrial breaktlirough 
bleeding. Also, in nomial endometrium, progesterone receptors are absent in the 
endothelium but prominent in the perivascular cells (Koji et al. 1994; Critchley et al. 
2001). LNG is reported to induce changes in vessel fragility that may be mediated 
tlnough perivascular cells rather than the endothelium (Roberts et al. 1992).
The present data demonstrate that endometrium exposed to high dose 
intrauterine delivery of levonorgestrel exhibits a significant decrease in stromal AR 
protein immunoreactivity when compared with control proliferative endometrium. 
This significant down regulation is in keeping with levels exhibited in the secretory 
phase and is maintained for at least 12 months following insertion of the LNG lUS, 
In addition there is a down regulation of AR messenger RNA in LNG lUS exposed 
endometrium which, in this case, is closely reflected by the pattern of expression of 
the AR protein.
AR has been shown to be predominantly expressed in the human endometrial 
stroma with minimal glandular immunoreactivity and down regulated in the late 
secretory phase of the menstrual cycle (Mertens et al. 1996; Mertens et al. 2001; 
Slayden et al. 2001). The mechanism of AR up regulation in the normal cycle is 
thought to be mediated by the action of oestradiol and its down regulation mediated 
by the action of progesterone as shown by the data in Chapter 4 (Slayden et al.
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2001). Chapter 4 also provides evidence that administration of mifepristone resulted 
in an up-regulation of AR in the stromal and glandular nuclei. The suggestion from 
these data was that PR provided a tonic inliibitory control over the ability of ER to up 
regulate AR, but when this PR inhibition was removed by the action of an 
antiprogestogen (RU486, mifepristone) there was an up regulation of AR by the 
action of oestradiol acting tlnough ER. Notably, mifepristone treatment, which 
suppresses bleeding and increases amenorrhea, also increases endometrial AR 
(Brown et al. 2002). By inference, the lowered levels of AR in LNG treated 
endometrium may be linked to the sporadic, breaktlnough bleeding typically seen in 
such patients.
Levonorgestrel binds to both the AR and PR (Kloosterboer et al. 1988; 
Lemus et al. 1992). The role of androgens in the regulation of the AR protein and 
mRNA is not yet known, with some studies suggesting an up regulation in response 
to androgens and others suggesting a down regulation (Chada et al. 1994; Fujimoto 
et al. 1994; Iwai et al. 1995; Apparao et al. 2002). hi situ hybridisation studies in the 
primate uterus suggested that testosterone can synergize with oestradiol to up- 
regulate AR (Adesanya-Famuyiwa et al. 1999). Levonorgestrel has similar 
progestogenic and androgenic activity shown by its relative binding affinity for the 
PR when compared with AR (Kloosterboer et al. 1988). It is therefore unclear as to 
the mechanism of AR down regulation in levonorgestrel exposed endometrium, but it 
could be a consequence of both progestogenic and androgenic action.
The data presented have identified high levels of endometrial 17(3~HSD2 
protein in the first month after insertion of the LNG lUS associated with high levels 
of 17(3“HSD2 mRNA expression in endometrial tissue at the tliree month time point. 
Since 17(3-HSD2 converts oestradiol to the less potent oestrogen, oestrone, the 
consequence is that the endometrial glands are exposed to more oestrone than 
oestradiol during the first tliree months after LNG lUS insertion. Any oestradiol 
dependent products of the glands that may have paracrine actions tliroughoiit the 
endometrium would thus be suppressed or perturbed at this time. It is during the first 
months after LNG lUS insertion that the complaint of breaktlirough and unscheduled 
bleeding is most frequent. We therefore propose that the unscheduled breakthrougli 
bleeding experienced by women at this time may be due in part to an intracellular 
“oestrogen deficiency” that either directly or indirectly leads to vascular fragility.
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17P-HSD2 protein expression thereafter is significantly reduced following three 
months treatment, coincident with the onset in improvement in menstmal bleeding 
patterns. However, the decline in 17p-HSD2 mRNA expression appears to be 
staggered, as these mRNA levels do not become undetectable until 6 months of LNG 
lUS treatment.
In human endometrium, steroidal regulation of receptor action is dependent 
upon ligand availability. The 17(3 hydroxysteroid dehydrogenase family is a large 
family, so far comprising 8 members of which 6 human isofomis have been 
characterized. Its primary role is the inactivation of oestradiol to oestrone and 
testosterone to androstenedione but in addition it also converts the inactive 
2Oadihydroprogesterone to active progesterone (Peltoketo et al. 1999; Labile et al. 
2000). The observations in the present study are consistent with those of previous 
publications showing an up regulation of 17[3-HSD2 in the progesterone dominated 
secretory phase (Casey et al. 1994). With intrauterine delivery of levonorgestrel, we 
found an increase in the expression of 17p-HSD2 protein when compared with the 
proliferative phase of the menstrual cycle followed by a down regulation of the 17(3- 
HSD2 protein in glandular epithelium after 3 months treatment that was maintained 
up to the 12 month time point. A significant up regulation of the 17(3-HSD2 mRNA 
in the initial 3 months was also noted followed by a down regulation in patients 
treated for longer than 6 months. This is consistent with the down regulation of the 
PR receptor over this same time frame (Critchley et al. 1998).
Of interest, the decline in 17(3-HSD2 mRNA expression appears to be 
staggered from that of the protein with a decrease in protein expression being noted 
prior to mRNA decline. This may be due to enhanced stability of 17(3-HSD2 mRNA 
possibly resulting in a persistence of the mRNA for long periods without translation 
into protein. It has been shown that mRNA can be stable for days at a time and this 
may be regulated in some cases by sex steroids (Day et al. 1998; Staton et al. 2000). 
Analysis of 17[3-HSD2 mRNA through the menstrual cycle also shows a lack of 
coiTclation with protein expression with higher levels of RNA noted following 
increased protein expression with highest levels of mRNA noted in the early 
proliferative phase when no protein expression is noted. A similar pattern of 17(3- 
HSD2 mRNA expression is seen in the data reported by Casey et al. (1994); 
Mustonen et a l, (1998) and Kitawaki et al., (2000). Northern blot analysis revealed
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17P-HSD2 mRNA in the early proliferative phase (Casey et al. 1994) and Kitawaki 
et al found comparable levels of 17(3-HSD2 mRNA in proliferative and secretory 
phase tissue specimens (Kitawaki et al. 2000). Quantitative analysis of 17p-HSD2 
mRNA in human endometrium reported by Mustonen et a l, also revealed a lack of 
correlation with protein levels, higher levels of mRNA expression occurring in the 
late secretory phase following the serum progesterone peak and previously noted mid 
secretory increase in protein expression (Mustonen et al. 1998).
Molecular factors reported in endometrium of levonorgestrel users includes 
activation of matrix metalloproteinase’s 1, 3 and 9 to a level consistent with that seen 
in menstrual phase endometrium (Galant et al. 2000; Rodriguez-Manzaneque et al. 
2000; Vincent et al. 2000) in addition to decreased tissue inhibitors of 
metalloproteinases (TIMPs). This may explain the features of focal stromal 
breakdown and collagen lysis noted in endometrium from users of Norplant, sub- 
deiinal LNG delivery (Galant et al. 2000). Other factors reported that relate to vessel 
fragility include a decrease in endometrial perivascular alpha smooth muscle actin in 
Norplant users (Rogers et al. 2000) and decreased endothelial cell proliferation 
(Goodger et al. 1994; Rodriguez-Manzaneque et al. 2000; Hague et al. 2002). 
Haemostatic factors may also play an important role as a decrease in tissue factor 
protein and mRNA has been reported in levonorgestrel exposed endometrium (Runic 
et al. 1997). The aforementioned factors all suggest a disruption in the mechanisms 
that control vessel growth and haemostasis.
In summarv. exposure of the endometrium to high dose intrauterine LNG 
results in decidualisation and atrophy. Breaktlnough bleeding problems with this 
method of long-term progestin delivery are maximal during the first few months 
following insertion of an LNG lUS. The data presented demonstrated that during this 
period after LNG lUS insertion, the steroid metabolising enzyme 17(3-HSD2 is 
elevated and steroid receptors, including AR, are suppressed. As a consequence, 
intracellular levels of the less potent oestrogen, oestrone are raised and the more 
potent oestrogen, oestradiol lowered. Problematic breaktlnough bleeding usually 
improves after 3-6 months of LNG lUS usage. At this time, these studies have shown 
that levels of 17p-HSD2 protein are low and thus intracellular concentrations of 
oestradiol would be raised and oestrone lowered. The levels of both AR mRNA and 
protein remain suppressed. There remains no doubt that the mechanisms underlying
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the breaktlirough bleeding associated with use of LNG lUS and indeed other long­
term progestin only methods of contraception are complex. Hopefully, data such as 
presented here will contribute further to our understanding of local progestin action 
and how this relates to BTB in human endometrium.
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Chapter 6
Endometrial Intracrinology: 
Studies of Normal Endometrium and 
Endometrium Exposed to 
Intra-Uterine Levonorgestrel
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6.1 Introduction
Humans possess a sophisticated endocrine system where the bioavailability of active 
sex steroids depends upon not only on the concentrations in the peripheral 
circulation, but to a large extent sex steroid synthesis within peripheral target tissue 
cells (Labrie et al. 2000). This process is termed “intracrinology” and it essentially 
allows peripheral target tissues to have control over sex steroid formation and 
metabolism according to the requirements of the target tissue (Labrie 1991). The 
ligand that is available to bind to the sex steroid receptors in a given target tissue will 
depend upon the enzymes present in the tissue.
Ligand formation is dependent upon a precursor substrate and the adrenal 
gland is such a source. Circulating dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone-sulphate (DHEA-S) provide the high levels of substrate 
required for conversion into potent androgens and oestrogens in peripheral tissues. 
The role of adrenal DHEA in androgen fomiation was discovered in patients being 
treated for prostatic carcinoma. As this is an androgen-responsive cancer, treatment 
involved medical (GnRH agonists) or surgical castration to reduce serum 
testosterone (T) levels by 90-95% (Labrie et al. 2000). However, it was noted that 
when compared to normal prostate tissue, prostate tissue removed from castrated 
patients still contained 50% dihydrotestosterone (DHT). This suggested another 
source of adrenal androgen fonnation (Labrie et al. 1996). This observation led to the 
introduction of combined androgen and 5a-reductase blockade that was the first 
intervention shown to prolong life in prostate cancer (Prostate cancer triallist 
collaborative group2000).
A number of enzymes are involved in the metabolism of sex steroids as 
discussed in the literature review (see Chapter 1.4). The enzymes studied here are 
important in the formation and metabolism of androgens. They include 3p- 
hydroxysteroid dehydrogenase (3(3-HSD) types 1 and 2; 17^-hydroxysteroid 
dehydrogenase (17(3-HSD) types 1, 2, and 5; 5a-reductase (5AR) types 1 and 2; and 
aromatase.
Knowledge of peripheral target tissue enzyme expression is important as it 
has already been shown, as with prostate cancer, that therapeutic interventions can be
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developed to manipulate local endocrine environments. Such knowledge may 
progress the fields of menstrual disorders, contraception and endocrine related 
cancers.
Further examples of clinical inteiwentions to manipulate enzyme function in 
target tissues are seen in breast cancer and endometriosis, hi breast cancer, aromatase 
inhibitors may be used to prevent oestrogen formation, while selective oestrogen 
receptor modulators are used to inhibit binding of active oestrogens. Aiomatase 
inhibitors are now also being explored for their use in benign conditions such as 
endometriosis (Bulun et al. 2000). While endometriotic tissue is histologically akin 
to endometrium, it has been shown to have a different intracrine system (Bulun et al. 
1994; Noble et al. 1996; Noble et al. 1997), containing aromatase and 17(3-HSD1 
whilst lacking expression of 17p-HSD2. This combination favours production of 
oestradiol driving the persistence of endometriosis that produces pain and pelvic 
scarring in patients.
Peripheral sex steroid metabolism is complex with physiological and 
pathological variations in enzyme expression and tissue specific isoforms utilising 
various steroid substrates. Within endometrium further complexity is added as, under 
the control of the menstrual cycle, endometrium regenerates in a 28 day cycle. This 
has the potential to lead to temporal and spatial variations in endometrial receptor 
and enzyme expression. Little is known regarding endometrial enzyme expression 
and what has been published to date is summarised below.
3f3-HSD has two highly homologous isoforms, 1 and 2, that are important in 
the formation of sex steroids from precursors as seen in figure 1.4 (Lachance et al. 
1991; Labrie et al. 1992). The tissue expression of the isoforms varies, type 1 being 
present mainly in the placenta, liver, kidney and skin (Mason et al. 1997). Type 2 is 
expressed principally in the gonads and adrenals (Mason et al. 1997). The function of 
type 2 is consistent with its tissue of expression namely steroidogenesis. However the 
exact function of type 1 is less certain but it appears to be responsible for the 
formation and/or degradation of 5a-androstanes and 5a-pregnanes such as 5 a- 
dihydrotestosterone and 5a-dihydroprogesterone respectively (Mason et al. 1997). 
3P-HSD activity has been demonstrated in the endometrium of human (Tang et al. 
1993) and rhesus macaque endometrium (Martel et al. 1994). Tang et al suggested 
that expression might even be progesterone regulated as an increase in enzyme
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expression was demonstrated following culture of endometrium with 
medroxyprogesterone acetate. The most recent paper by Rliee et al has demonstrated 
expression of the enzyme in the endometrial glandular epithelium with higher 
expression in the secretory phase than the proliferative phase (Rliee et al. 2003). The 
paper also demonstrated the expression of the enzyme in human endometrium at the 
molecular level using RT-PCR. They did not report the temporal or spatial variation 
in expression of the enzyme at either the molecular or the protein level.
To form active androgens and oestrogens the steroid product of 3f3-HSD will 
require the presence of 1713-hydroxysteroid dehydrogenase(s). This is a multigene 
family discussed previously in Chapter 5. There is little homology (usually in the 
region of 20%) between members of this family (Labrie et al. 1997). The enzymes in 
this family are unidirectional within intact cells either reducing sex steroids to active 
forms or oxidising to inactive forms. The expression of 17p-HSD2 in secretory phase 
endometrial glandular epithelium at the protein and messenger RNA level has been 
discussed in Chapter 5. 17|3-HSD2 is responsible for the inactivation of oestrogens 
and androgens as well as the 20a-dehydrogenation of inactive 20a- 
dihydroprogesterone to active progesterone. 17P-HSD1 is responsible for the 
conversion of oestrone to the active oestradiol (Bartlett et al. 1991). The publications 
to date have failed to establish occunence of 17p-HSDl enzyme or its messenger 
RNA in endometrium.
Active androgens in the male are formed mainly within the testis under the 
control of 17p-HSD3, an enzyme that in humans is functional mainly within the male 
(Geissler et al. 1994). The enzyme may be subject to mutations, with the affected 
male individuals suffering male pseudohennaphroditism. To date no females with 
similar mutations have been shown to suffer an equivalent condition (Mendonca et 
al. 1999). As the ovary is the main source of serum androgens in the female, studies 
were carried out to localise 17(3-HSD3 in the ovary but it was not found (Zhang et al. 
1996). However, 17p-HSD3 shares the same substrate specificities as 17f3-HSD5, 
catalysing the conversion of androstenedione to testosterone (Penning 1997), and 
17p-HSD5 has been localised in the ovary (Luu-The et al. 2001). It would therefore 
appear that 17p-HSD5 is the hydroxysteroid dehydrogenase responsible for androgen 
production in the female. However, in the male, 17p-HSD5 is also present in 
peripheral target tissues such as the prostate. In this tissue its role is thought to be a
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combination of androgen formation and progesterone inactivation, via its 20a- 
hydroxysteroid dehydrogenase (20a-HSD) activity, protecting the prostate from the 
action of progesterone (Diifort et al. 1999). In the female 17[3-HSD5 has now been 
localised to the ovary, breast and uterus (Pelletier et al. 1999). Uterine 17p-HSD5 
was localised to the glandular and surface epithelium, however, the stage of the cycle 
in which it was detected was not stated (Pelletier et al. 1999). As androgen receptors 
are expressed largely in the endometrial stroma it may be that local androgen 
production via 17p-HSD5 produces a paracrine effect in the stroma. Another possible 
role may relate to its 20a-HSD activity, inactivating progesterone. To elucidate its 
role, more details regarding the immunolocalisation of 17p-HSD5 in endometrium 
through the menstrual cycle would be required.
Endometrial production of androgens may however require further 
metabolism to the more biologically active androgen dihydrotestosterone or even to 
an alternate sex steroid such as oestradiol before eliciting a response. The enzymes 
responsible for testosterone conversion to oestradiol and dihydrotestosterone are 
aromatase and 5a-reductase respectively.
Aromatase is not expressed in disease-free human endometrium (Bulun et al.
1993) but has been shown to be expressed in benign and malignant pathological 
conditions involving the uterus such as endometrial cancer (Bulun et al. 1994; 
Sasano et al. 1999), uterine leiomyoma (Bulun et al. 1994), and endometriosis 
(Noble et al. 1996; Kitawaki et al. 1997). Due to the expression of aromatase in these 
pathological conditions, the clinical use of aromatase inhibitors has been the subject 
of research, in particular their role in endometriosis and endometrial cancer. 
Endometrial cancer has been shown to be responsive to aromatase inliibitor 
treatment. This was demonstrated in short term in-vivo studies where treatment with 
Letrozole, an aromatase inhibitor, for two weeks prior to theatre produced some 
positive clinical changes (Berstein et al. 2002). Berstein et al. now propose longer 
term randomized trials to assess the effectiveness of aromatase in endometrial cancer 
(Berstein et al. 2002). Endometriosis has also been successfully treated with 
aromatase inhibitors (Takayama et al. 1998). The modulation of aromatase activity in 
ectopic and eutopic endometrium of endometriosis may even be crucial to its 
treatment. A recent study indicated that commonly used treatments such danazol or 
GnRH analogues will reduce aromatase expression and therefore oestradiol
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production (Ishihara et al. 2003). Therefore, while aromatase inhibitors may be an 
attractive therapeutic option in a condition that is difficult to treat, large scale 
randomized trials will be required to assess the effectiveness and adverse effect 
profile of aromatase inhibitors (Bulun et al. 2000).
5a-reductase is present as two isoenzymes, types 1 and 2 (Russell et al.
1994), and is responsible for the activation of androgens and the inactivation of 
progesterone (Fisher et al. 1978). The presence of 5a-reductase in human 
endometrium was first raised by Rose et al. where endometrium cultured with 
testosterone was shown to produce significant quantities of 5a-dihydrotestosterone 
(Rose et al. 1978). In general, type 1 is a catabolic agent favouring progesterone 
(Andersson et al. 1990) as a substrate and is highly expressed in the liver 
(Mahendroo et al. 1999). The finding that males deficient in type 2 are still able to 
convert exogenous testosterone to dihydrotestosterone would suggest that the type 1 
enzyme does have at least some type 2 like activity. Type 2 is an anabolic enzyme 
expressed mainly in androgenic target tissues and favours testosterone as a substrate 
(Normington et al. 1992).
In the male 5a-reductase type 2 deficiency will result in male 
pseudohermaphroditism where a genotypic male has female external genitalia and 
male internal genitalia (Wilson et al. 1993). Females have been identified with 5a- 
reductase type 2 deficiency in families where male members are also affected by this 
condition (Wilson et al. 1993; Katz et al. 1995). Delayed menarche was 
demonstrated in this group but no other clinical symptoms or signs were discovered 
that would suggest 5a-reductase type 2 played an essential role in female endocrine 
physiology. Neither has a role for 5a-reductase type 1 been elucidated in human 
females. However, female knockout mouse models suggest an important 
reproductive role for 5a-reductase type 1.
In the female mouse, 5a-reductase type 1 is localised to the uterus, placenta 
and cervix. When absent, the mice are less likely to deliver their young at term and 
have smaller litter sizes (Mahendroo et al. 1997). Initial fertilisation and implantation 
occurs but at the time of the expected androgen surge from the placenta fetal demise 
appears to occur with a 2-4 fold elevation in serum oestradiol levels noted 
(Mahendroo et al. 1997). It would therefore seem that aromatisation of androgens to 
oestrogen occurs leading in some way to fetal demise. This suggests an important
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catabolic role for 5a-rediictase type 1. In the fetuses that do sui-vive 70% fail to 
labour and steroid levels are normal apart from low levels of a 5a reduced 
metabolite, 5a-androstane-3a,17P-diol. If exogenous 5a-reduced metabolites are 
administered then no parturition defect occurs (Mahendroo et al. 1996). Finally it 
would also appear that a failure of cervical ripening is also noted in type 1 deficient 
mice suggesting that the presence of 5a-reductase type 1 is also important for 
cervical ripening (Mahendroo et al. 1999). It is suggested by Mahendroo et al. that 
the failure of progesterone catabolism leads to this failure in cervical ripening.
While detailed mouse models exist, there are to date few studies examining 
the localisation and regulation of the 5a-reductase isoenzymes in human uterine 
tissues to determine if a similar role for 5a-reductase exists in human females. The 
only study to examine 5a-reductase expression in female reproductive tissues was 
published recently by Ito et al. (Ito et al. 2002). They described the 
immunolocalisation of 5a-reductase type 1 and 5a-reductase type 2 in the glandular 
epithelium of the endometrium with no temporal variation. Their sample numbers 
were small which may have precluded significant differences. In addition to normal 
endometrium, they examined 44 cases of endometrial carcinoma and determined that 
5a-reductase was expressed in 80% of specimens. This would appear to confimi that 
5a-reductase is present in noimal cycling endometrium but the paper does not 
provide answers as to the role of 5aR in normal or malignant endometrium.
There are thus a number of enzymes that are important in the formation and 
degradation of sex steroids in peripheral tissues. The degree of expression of 
enzymes and the availability of substrate will therefore detemiine the ligand 
available to exert a specific function. This knowledge will allow the refinement of 
pharmacological agents to target a specific tissue or condition, such as the use of 
aromatase inliibitors to treat endometriosis. As discussed in Chapter 5 a consequence 
of LNG lUS treatment is the alteration in 17P-HSD2 expression in the endometrium 
leading to intracellular levels oestrone being raised and intracellular levels of 
oestradiol lowered. We hypothesise that this alteration in the intracrine environment 
may be important in the pathogenesis of breaktlirough bleeding (BTB). Further 
examination of the enzymes that compose the intracrine environment in normal 
cycling endometrium and endometrium exposed to intrauterine delivery of 
levonorgestrel will aid to complement our current laiowledge and understanding of
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the processes that may contribute to BTB. Such knowledge may direct future 
research to be focused upon manipulation of enzyme expression as a mechanism for 
preventing BTB.
This Chapter therefore explores the expression of the above enzymes in 
human endometrium across the normal menstrual cycle and in patients where the 
endometrium has been exposed to high dose local levonorgestrel via the LNG-IUS. 
Where antibodies are available, the protein is examined but otherwise real time 
quantitative RT-PCR is used to assess temporal variation in enzyme mRNA 
expression.
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6.2 Materials and Methods
Material and Methods have been described previously in Chapter 3. Details that 
follow summarise pertinent material and methods for this area of the research. 
Human endometrial samples were obtained from two different patient groups.
6.2.1 Tissue coUeetion
The samples that were to be analysed for temporal expression of mRNA consisted of 
endometrium from fertile women (n= 30) with regular menstrual cycles lasting 
between 25 and 35 days who had not been using hormonal preparations for the 
preceding 3 months. The samples were a subset of those collected, and is detailed in 
Chapter 3. Endometrial tissue included samples collected from women during the 
early proliferative phase (n=5), mid proliferative phase (n=5), late proliferative phase 
(n=5), early secretory (n=5), mid secretory (n=5) and late secretory phase (n=5) of 
the menstrual cycle. The stage of the menstrual cycle was consistent with the patients 
reported last menstrual period and was confinned by histological dating, according to 
the criteria of Noyes et al (Noyes et al. 1950). Furthermore, serum samples collected 
at the time of endometrial tissue collection for determination of circulating oestradiol 
and progesterone concentrations by RIA were consistent with the designated cycle 
stage and a significant decline in progesterone concentrations was apparent between 
biopsies taken in the mid and late secretory phase of the cycle. The samples were 
stored at -80°C following collection and were processed to extract RNA as described 
in previous Chapters (See Chapters 3.3.1; 3.3.2; 3.3.3).
The other main patient group studied in this Chapter included women 
attending a menstrual problems clinic for treatment of dysfunctional uterine bleeding 
with the LNG XUS. Endometrial samples were collected from patients attending the 
clinic with an LNG lUS in-utero for 3 months (n=6), 6 months (n==3), or greater than 
1 year (n=4). Samples were frozen immediately upon collection in liquid nitrogen 
and stored at -80°C with subsequent RNA extraction as previously described (See 
Chapters 3.3.1; 3.3.2; 3.3.3).
Previous studies have failed to show the expression of aromatase in the 
endometrium of patients who have a normal menstrual cycle and no uterine disease. 
To confirm this finding a random selection of endometrial samples from across the
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menstmal cycle were subjected to aromatase immunohistochemistry. The samples 
were a subset of full thickness endometrial biopsies as described in Chapter 3.1.1.
6.2.2 Aromatase Immuiiohistochemistry
As detailed in Chapter 3.2.4 the specificity and properties of the antibody for the 
immunolocalisation of aromatase have been previously described (Turner et al.
2002). This antibody was a gift from Dr P Saunders (MRC, Human Reproductive 
Sciences Unit, Edinburgh).
Paraffin sections (5 pm) were dewaxed and rehydrated tlnough a series of 
alcohols then washed in distilled water. Tris buffered saline (TBS) was used for all 
washes and no antigen retrieval step was required. Positive and negative controls 
were included for human coipus luteum and human placenta. A first non-immune 
block was perfonned with noiinal rabbit semm diluted in TBS/BSA (Diagnostics 
Scotland, Edinburgh, Midlothian, UK) for 30 minutes at room temperature. Primary 
antibody incubation was at a 1:50 dilution overnight at 4°C. Rabbit anti-mouse 
biotinylated secondary antibody was employed diluted with normal rabbit serum to 
provide a second non-immune block with secondary antibody incubation as above 
with incubation at room temperature for 60 minutes. The ABC complex used was 
ABC-HRP and this incubation step was also at room temperature for 45 minutes. 
Visualisation employed the clrromagen 3, 3’-diaminobenzidine (DAKO Liquid, 
DAKO Coiporation, California, USA). Results from immunohistochemistry were 
descriptive in nature.
6.2.3 RNA extraction and real time quantitative RT-PCR
Frozen samples of endometrium stored at -80°C were first homogenised, and then 
total RNA was extracted using the commercially available product Trizol (Invitrogen 
Life teclmologies Ltd, Paisley, UK). The methods of extraction, quantification, 
cDNA preparation and quantitative RT-PCR are the same as detailed in Chapter 3.3. 
All samples were pre treated with RNAse free DNAse (Invitrogen Life technologies 
Ltd, Paisley, UK).
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Real-time quantitative PCR was performed in an ABI 7700 Sequence 
Detection System (Perkin-Elmer, CA, USA). Oligonucleotide forward and reverse 
primers and oligonucleotide Taqman probes for 3(3-HSD types 1 and 2, 17|3-HSD 5, 
and 5a-reductase types 1 and 2 were designed, with the use of Primer Express 
version 1.0 (Perkin-Elmer Applied Bio systems, Cheshire, UK), from sequences 
entered in the GenBank database. The sequences for the primers and probes above 
are detailed in table 3.2. Numeric data from the real time quantitative RT-PCR were 
analysed by one way ANOVA, followed by Fisher’s protected least significant 
difference test.
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6.3 Results
6.3.1 Aromatase Immunohistochemistry
The positive eontrols for the aromatase immunohistochemistry were human placenta 
and corpus luteum. hnmunoreactivity was noted in human placental 
syncytiotrophoblast and in the human granulosa lutein cells as would be anticipated 
(Figure 6.1). The samples of human endometrium did not however show any 
evidence of positive immunoreactivity (Figure 6.1). Using this new monoclonal 
antibody we have therefore confirmed the findings of other investigators. As the 
protein was not expressed in human endometrium no primers or probes were used to 
look at the expression of aromatase mRNA in human endometrium.
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Figure 6.1
Immunohistochemical localisation of Aromatase in human placenta, human corpus 
luteum, and human endometrium, (x 20 magnification, except corpus luteum 
images). (A) Human Placenta -  immunoreactivity noted in syncytiotrophoblast. (B) 
Human Placenta -  negative control. (C) Human Corpus Luteum (xlO magnification) 
-  immunoreactivity in granulosa lutein region (GL) and absent immunoreactivity in 
the theca lutein region (TL). As anticipated, aromatase immunoreactivity was in the 
granulosa cells region as it expresses aromatase whereas theca cells do not. (D) 
Human Corpus Luteum (xlO magnification) -  negative control. (E) Absent 
immunoreactivity for aromatase in secretory endometrium (negative control inset). 
(F) Absent immunoreactivity for aromatase in proliferative endometrium. Scale bar 
50 pm at X 20 magnification
Reactions Catalysed by Aromatase:
Testosterone -> Oestradiol
Androstenedione -> Oestriol
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6.3.2 Temporal expression of 17p-HSD 5 mRNA lu human endometrium and
following high dose intra uterine delivery of levonorgestrel.
The samples analysed for 17(3-HSD 5 revealed highest expression of the mRNA in 
the mid secretory phase with the fold increase being significantly greater than at any 
other time point in the menstmal cycle (p<0.05; figure 6.2).
Human endometrium that had been exposed to intra-uterine levonorgestrel for 
3, 6 or >12 months in vivo were also analysed and compared to an internal mRNA 
control from the late proliferative phase of the menstrual cycle to calculate the fold 
increase compared with the menstrual cycle. Endometrium exposed to intra-uterine 
LNG expressed 17(3-HSD 5 mRNA at levels significantly less than the mid secretory 
phase but not significantly different from any other menstrual cycle stage (p<0.005; 
figure 6.2).
17f3-HSD 5 has been widely studied in the human prostate but only one 
previous study has localised the enzyme to human endometrial glandular epithelium 
without commenting upon a specific cycle stage. This finding confirms the 
expression of 17|3-HSD 5 at the mRNA level in the endometrium with highest levels 
found in the mid secretory phase. The antibody to corroborate these data was not 
commercially available and could not be sourced.
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Figure 6.2
Quantitative evaluation of 17p-HSD5 mRNA in endometrium across the stages of 
the menstrual cycle and following intrauterine delivery o f LNG. All endometrial 
tissue samples were compared to an internal control (comparator) obtained during the 
early proliferative stage of the cycle.
17p-HSD5 mRNA levels were significantly higher in the mid secretory phase of the 
menstrual cycle when compared to the proliferative phase, the early secretory and 
late secretory phases (p<0.05). In endometrium exposed to intra-uterine 
levonorgestrel, 17p-HSD5 mRNA levels were also significantly lower compared 
with the mid secretory phase (p<0.005) but not significantly different from any other 
menstrual cycle phase. EP, early proliferative; MP, mid proliferative; LP, late 
proliferative; ES, early secretory; MS, mid secretory; LS, late secretory.
Reactions Catalysed by 17p-HSD5:
Androstenedione Testosterone
Progesterone 20a-hydroxyprogesterone
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6.3.3 Temporal expression of 3P-HSD 1 and 2 mRNA in human endometrium
and following high dose intrauterine delivery of levonorgestrel.
There is a high degree of homology between types 1 and 2 3P-HSD. In an attempt to 
provide discrimination in the detection of each subtype, sequences were chosen hom 
the primer express progiam where there was at least one nucleotide sequence 
difference in each of the primers and probe from the alternate subtype. This was 
achieved in both primer probe sets. 3|3-HSD 1 contained 3 nucleotides within the 
forward primer, 2 nucleotides in the reverse primer and 2 nucleotides in the probe 
that did not correspond to 3|3-HSD 2. 3(3-HSD 2 contained 1 nucleotide within the 
forward primer, 3 nucleotides in the reverse primer and 3 nucleotides in the probe 
that did not correspond to 3p-HSD 1.
The samples analysed for 3P-HSD 1 revealed highest expression of the 
mRNA in the peri-menstmal stages with the fold increase in the mid to late secretory 
and early proliferative stages being significantly increased compared to the mid cycle 
late proliferative and early secretory stages (figure 6.3). The early proliferative and 
late secretory stages in particular were highly significant compared to the mid cycle 
stages (p<0.005).
Human endometrium that had been exposed to intra-uterine levonorgestrel for 
3, 6 or >12 months in vivo were then analysed for 3p-HSD 1 and compared to an 
internal mRNA control (comparator) from the late proliferative phase of the 
menstrual cycle. The LNG exposed endometrium expressed 3p-HSD 1 mRNA with 
the fold increase at 3 months being significantly greater than any other menstrual 
cycle stage or treatment duration. Following the initial fold increase in 3p-HSD 1 
expression in the first three months a decline in mRNA expression is noted such that 
by 12 months there is no significant variation in 3p-HSD 1 from the menstrual cycle 
(figure 6.3).
3P“HSD 2 mRNA showed a similar pattern of expression during the 
menstrual eycle to that of 3p-HSD 1 with the fold increase in the peri-menstrual 
stages being significantly greater than the mid cycle stages (figure 6.4). This suggests 
that either the level of discrimination by the Taqman probes between the two 
isoforms may not be sufficient, or that both isofoims follow a similar pattern of 
expression during the menstrual cycle.
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Interestingly the data for 3p-HSD 2 expression in endometrium from women 
using the LNG-IUS for 3, 6 or >12 months in vivo do not follow the same pattern as 
that for 3p-HSD 1. 3P-HSD 2 mRNA expression from 3 months onwards reveals a 
maintained significant fold increase in expression when compared to any menstrual 
stage cycle (figure 6.4).
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Figure 6.3
Quantitative evaluation of 3P-HSD1 mRNA in endometrium across the stages of the 
menstrual cycle and following intrauterine delivery of LNG. All endometrial tissue 
samples were compared to an internal control (comparator) obtained during the late 
secretory stage of the cycle.
3p-HSDl mRNA levels were significantly higher in the mid and late secretory phase 
as well as the early proliferative phase of the menstrual cycle when compared to the 
mid cycle, late proliferative and early secretory phase (p<0.005). In LNG-IUS 
exposed endometrium, 3P-HSD1 mRNA levels at 3 months were significantly higher 
than all menstrual cycle phases and LNG treatment time points (p<0.001). EP, early 
proliferative; MP, mid proliferative; LP, late proliferative; ES, early secretory; MS, 
mid secretory; LS, late secretory.
Reactions Catalysed by 3P-HSD1 :
Androstenediol Testosterone
Dehydroepiandrosterone Androstenedione
17 OH Pregnenolone 17 OH Progesterone
Pregnenolone Progesterone
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Figure 6.4
Quantitative evaluation of 3p-HSD 2 mRNA in endometrium across the stages of the 
menstrual cycle and following intrauterine delivery of LNG. All endometrial tissue 
samples were compared to an internal control (comparator) obtained during the late 
secretory stage of the cycle.
3P"HSD 2 mRNA levels were significantly higher in the mid and late secretory 
phases (p<0.05) as well as the early and mid proliferative phases (p<0.001) of the 
menstrual cycle when compared to the mid cycle, late proliferative and early 
secretory phase. In LNG-IUS treated endometrium, 3p-HSD 2 mRNA levels at 3, 6 
and 12 months were significantly higher than all menstrual cycle phases (p<0.001; 
significance values for 3 months not shown but similar to those for the 6 and 12 
month treatments). EP, early proliferative; MP, mid proliferative; LP, late 
proliferative; ES, early secretory; MS, mid secretory; LS, late secretory.
Reactions Catalysed by 3p-HSD 2:
Androstenediol ->
Dehydroepiandrosterone ”>
17 OH Pregnenolone 
Pregnenolone ->
Testosterone 
Androstenedione 
17 OH Progesterone 
Progesterone
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6.3.4 Temporal expression of 5a-reductase 1 and 2 mRNA in human 
endometrium and following high dose intrauterine delivery of 
levonorgestrel.
There are no reliable antibodies that will discriminate between 5a-reductase types I 
and 2. Attempts were therefore made to determine enzymatic activity in human 
endometrium at various menstrual cycle stages through collaboration with Dr Fouad 
Habib (Reader in Biochemistry and Cell Biology, Department o f Oncology, Western 
General Hospital, Edinburgh, UK) who has published widely on 5a-reductase in 
normal and malignant prostate tissues. The assays developed for prostate tissues 
were not suitable for use in the human endometrial samples that we had collected as 
a greater volume of tissue was required.
The sequences to detect the mRNA of both Sa-reductase types 1 and 2 
spanned an intron to preclude amplification of genomic DNA and all cDNA samples 
were prepared with DNAse pre-treatment.
The samples analysed for 5a-reductase type 1 revealed highest expression of 
the mRNA in the late proliferative stage with the fold increase being significantly 
greater than in the early proliferative and mid secretory stages with a trend towards 
being significantly greater than the late secretory stage (p<0.05;figure 6,5).
Endometrium treated with the LNG-IUS for 3, 6 or >12 months in vivo 
revealed 5a-reductase type 1 mRNA expression at levels no different from the 
majority of the menstrual cycle stages with the late proliferative stage still expressing 
the highest level of 5a-reductase type 1 (figure 6.5).
5a-reductase type 2 exhibited an expression pattern similar to that of Sp-HSD 
1 and 2 with significantly greater fold increases in the peri-menstrual stages when 
compared to the mid cycle stages, the late proliferative in particular (figure 6.6).
Endometrium from women with the LNG-IUS for 3, 6 or >12 months 
produced significantly lower levels of 5a-reductase type 2 mRNA expression when 
compared to the peri-menstrual stages of the menstrual cycle but no different from 
the mid cycle stages (figure 6.6).
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Figure 6.5
Quantitative evaluation of 5-alpha reduetase 1 mRNA in endometrium across the 
stages of the menstrual cycle and following intrauterine delivery of LNG. All 
endometrial tissue samples were compared to an internal control (comparator) 
obtained during the late secretory stage of the cycle.
5-alpha reductase 1 mRNA levels were significantly higher in the late proliferative 
phase (p<0.05) of the menstrual cycle when compared to all other menstrual cycle 
phases except the mid proliferative phase. In LNG-IUS treated endometrium, 5- 
alpha reduetase 1 mRNA levels at 3, 6 and 12 months were significantly lower than 
the late proliferative phase (p<0.01). EP, early proliferative; MP, mid proliferative; 
LP, late proliferative; ES, early secretory; MS, mid secretory; LS, late secretory.
Reactions Catalysed by 5-alpha reductase 1 :
Progesterone 5a-pregnandione
Testosterone Dihydrotestosterone
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Figure 6.6
Quantitative evaluation of 5-alpha reduetase 2 mRNA in endometrium across the 
stages of the menstrual cycle and follov^ing intrauterine delivery of LNG. All 
endometrial tissue samples were compared to an internal control (comparator) 
obtained during the mid secretory stage of the cycle.
5-alpha reductase 2 mRNA levels were significantly higher in the early proliferative 
phase (p<0.01) of the menstrual cycle when compared to all other menstrual eycle 
phases except the late secretory phase. The late secretory was also significantly 
elevated compared to the mid and late proliferative phases. In LNG-IUS treated 
endometrium, 5-alpha reductase 2 mRNA levels at 3, 6 and 12 months were 
significantly lower than the late proliferative phase (p<0.01). Furthermore, 
endometrium exposed to LNG for 3 and 12 months expressed significantly lower 
levels o f 5-alpha reduetase 2 mRNA compared to the mid and late secretory phases 
of the menstrual cycle. EP, early proliferative; MP, mid proliferative; LP, late 
proliferative; ES, early secretory.
Reactions Catalysed by 5-alpha reductase 2:
Progesterone
Testosterone
-> 5a-pregnandione
Dihydrotestosterone
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6.4 Discussion
There has not yet been a coordinated analysis of the enzymes that shape the 
intracrine environment of the endometrium. An understanding of the endometrial 
intracrine environment will be important to the field of endometrial biology as it will 
provide further insight to the factors that control the expression of local endometrial 
factors. The potential importance for such infonnation has been demonstrated in 
Chapter 5 where levonorgestrel was shown to manipulate this environment by 
altering the expression of 17p-HSD2, contributing further to our understanding of 
the processes involved in breakthrough bleeding. By extending the range of enzymes 
analysed we have added to the data available helping to further our understanding of 
the intracrine factors that affect the function of endometrium tlnough the menstrual 
cycle and following its exposure to levonorgestrel.
The published data thus far have not supported the presence of aromatase in 
human endometrium (Bulim et al. 1993). The data presented here employed a novel 
monoclonal antibody that has been validated and shown to immunolocalise 
aromatase in primate tissues including human placenta and human ovary (Turner et 
al. 2002). Using this monoclonal antibody, supported by the inclusion of appropriate 
control samples, the current findings support the data previously published, i.e., 
aromatase is not expressed in the endometrium of patients with no concuiTent 
endometrial related pathology. As no aromatase was identified at the protein level, 
and previous studies have also shown this to be true for mRNA expression (Bulun et 
al. 1993), real time Taqman analysis for aromatase mRNA was not conducted. This 
confirmation suggests that any androgenic precursor that may be produced by 
enzymatic conversion of adrenal precursor substrate will not be converted directly to 
an oestrogenic form by aromatisation. Consequently it would not be anticipated that 
aromatase inliibitors would be able to directly manipulate the endometrial intracrine 
environment.
The enzymes responsible early in the steroidogenic pathway for the synthesis 
of mineralocorticoids, glucocorticoids and sex steroids include 3|3-HSD. In humans, 
the principal location of this enzyme is in the adrenal and gonads (Mason 1993). In 
the female, dehydroepiandrostenedione (DHEA) is produced in the adrenal gland 
with serum levels some 100-500 times greater than testosterone and 1000-10000
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times greater than oestradiol (Labrie et al. 2000). The adrenal is also a source of 
pregnenolone, a steroid precursor that 3p-HSD can convert to progesterone. The 
adrenal therefore provides an excellent source of substrate for the production of 
steroids in peripheral target tissue. The presence or absence of 3p-HSD in peripheral 
tissues such as the endometrium will therefore be cmcial to a tissues ability to 
produce steroid hormones from the abundant adrenal substrate.
Rliee et al. report 3|3-HSD glandular epithelial imniunoreactivity in both 
secretory and proliferative phase endometrium. They did not subdivide their samples 
into early, mid or late stages. However, they did note significantly greater 
immunoreactivity in the secretory phase than the proliferative phase where 
immunoreactivity was weak (Rliee et al. 2003). Tang et al. also noted activity of 3(3- 
HSD to be higher in the secretory phase (Tang et al. 1993). The mRNA data 
available in the paper by Rliee et al. also suggests that the 3|3-HSD subtype most 
likely to be present is type 1. The mRNA data presented herein concurs with those of 
Rhee et al with higher levels of mRNA being noted in the mid to late secretory phase 
persisting to the peri-menstrual phase.
Despite being able to identify Taqman probes that were dissimilar, it is not 
possible to state that there is sufficient discrimination that allows definitive 
determination of the 3p-HSD isoform present in the endometrium. In espective of the 
subtype present, both probes exhibit similar variation through the menstrual cycle. 
Having determined that 3(3-HSD is expressed in secretory phase endometrium with 
mRNA levels highest in the peri-menstrual time frame it remains to be determined 
how it is regulated and what function this enzyme may have in human endometrium.
Mason et al. (Mason et al. 1993) reviewed the regulation of 3(3-HSD and 
suggested that its regulation was tissue-specific involving local mechanisms. 3(3- 
HSD mRNA expression is similar to that of 17(3-HSD2 mRNA with expression at its 
highest level in the peri-menstrual phase. Our data suggest that 17(3-HSD2 is up 
regulated by progesterone and Maentausta et al. also suggest that this enzyme is up 
regulated by progesterone (Maentausta et al. 1993). Rliee et al. have hypothesised 
that 3(3-HSD is progesterone-regulated (Rliee et al. 2003). In the decidual samples 
analysed by Rliee et al. an up-regulation of 3(3-HSD was noted, and in the first 
trimester serum progesterone levels are higher than in the non-pregnant state (Rhee 
et al. 2003). Tang et al. also showed that proliferative endometrium exposed to the
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progestin medroxyprogesterone acetate in vitro, up-regulated 3p-HSD (Tang et al. 
1993). The data presented here would also support a role for progesterone in the up- 
regulation of human endometrial 3(3-HSD. In endometrium exposed to high doses of 
intra-uterine levonorgestrel, both primer probe sets revealed an up-regulation of 3(3- 
HSD mRNA following three months treatment. Up regulation of 3(3-HSD 2 favours 
the formation of androgenic ligands. The androgenic ligands produced may in part 
explain the mechanism of endometrial atrophy noted with endometrial exposure to 
high dose intra-uterine LNG-IUS. As described in chapter 4.4, androgens have been 
shown to have an anti-proliferative effect and data from this study has described a 
mechanism for the role of androgens in the atrophic changes associated with anti­
progesterone use.
As previously stated, the function of endometrial 3(3-HSD type 1 is uncertain 
but it has a high affinity for its substrate (Rlieaume et al. 1991) and can convert 
pregnenolone to progesterone, 17-hydroxypregnenolone to 17-hydroxyprogesterone, 
DHEA to 4-androstenedione, and 5-androstene-3(3,17(3-diol to testosterone 
(Lachance et al, 1990). In endometrium, it may be involved with the provision of 
progesterone from pregnenolone and/or the conversion of androstenedione from 
DHEA. Further sex steroid production would depend upon the presence or absence 
of alternative metabolizing enzymes such as 17(3-HSD 5, 5a-reductase or aromatase. 
We have established that aromatase is only expressed in the endometrium of patients 
with concurrent pelvic pathology such as endometriosis or fibroids. 17(3-HSD 5 is 
known, however, to be expressed in human endometrial glandular epithelium with 
the stage of the cycle not having been cun ently determined (Pelletier et al. 1999).
Pelletier et al. used a 17(3-HSD 5 antibody to detect the enzyme in a variety 
of tissues. In the uterus, Pelletier determined that endometrial glandular epithelium of 
the functional and basal layers exhibited positive immunoreactivity (Pelletier et al. 
1999). The enzyme was for a long time misidentified as type 2 3a-hydroxysteroid 
dehydrogenase (3a-HSD) as it is highly labile and it is easily destroyed upon 
homogenisation (Dufort et al, 1999). It has now been shown that in intact cells there 
is unidirectional conversion of androstenedione to testosterone in keeping with its 
17(3-FISD function that is much greater than the 3a-HSD conversion of 
dihydrotestosterone to 5a-androstan-3a,17(3-diol (3a-diol) (Dufort et al. 1999). The 
enzyme is therefore now Imown as 17(3-HSD 5. hi addition to 17(3-HSD and 3a-HSD
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activity the enzyme also possesses 20a~hydroxysteroid dehydrogenase (20a~HSD) 
activity inactivating progesterone to 20a-hydroxyprogesterone. While the enzyme 
does possess multiple roles, the endometrium has been shown by Labrie et a l to 
possess higher androgenic 17(3-HSD activity with the rate of testosterone production 
by the endometrium only surpassed by placenta, liver and testis (Labrie et a l  1997).
Our results confirm the expression of 17p-HSD 5 at the mRNA level with an 
up regulation of expression in the mid secretory phase. As stated previously there is 
no commercially available antibody and we could not otheiwise source an antibody 
that would detect 17(3-HSD 5. In an attempt to see if we could determine the 
expression of the enzyme, via its 3a-HSD activity, we searched the available 
literature but no localisation or endometrial enzyme activity studies have been 
performed. Type 2 3a-HSD mRNA has been demonstrated in the uterus but the cycle 
stage in which it is predominant was not determined.
The role of 17p-HSD 5 in human endometrium has not yet been detennined 
but it is involved in a step that is important for the formation of active sex steroids. 
Its presence in glandular epithelium is consistent with the findings for other 
hydroxysteroid dehydrogenases, 3p-HSD (Rhee et al. 2003) and 17p-HSD 2 (Burton 
et al. 2003). In the case of 3p-HSD mRNA and 17p-HSD mRNA and protein, 
expression has been shown to be maximal in the secretory phase. The same may be 
true for 17P-HSD 5 but as yet we know only that 17p-HSD 5 mRNA expression is 
maximal in the mid-secretory phase and hopefully further data on the 
immunolocalisation of the protein will be forthcoming in future studies. It would 
however be credible that 17P-HSD 5 would also be expressed at the protein level in 
the secretory phase glandular epithelium.
To reiterate, the endometrium has been shown by Labrie et al. to possess 
androgenic 17p-HSD activity as evidenced by testosterone production from 
androstenedione (Labrie et al. 1997). The ability of the endometrium to produce 
active androgens from precursors is also supported by in vitro data from various 
authors (Collins et a l  1969; Rose et al. 1978; Hausknecht et a l 1982) In the in vivo 
situation the expression of 3p-HSD would pennit the production of androstenedione 
from DHEA while the expression of 17p-HSD 5 would pennit the conversion of 
androstenedione to testosterone. Indeed Bomiey et al. showed significant elevations
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in the concentration of endometrial DHEA during the secretory phase (Bonney et al. 
1984). The expression of 17p-HSD 2, which catalyses oestradiol to oestrone and 
testosterone to androstenedione, would be a mechanism for the fine balancing of 
testosterone production should it be required. Puranen et al. suggest that androgenic 
substrate is the best for 17p-HSD 2 when compared to oestrogen and progesterone 
and they hypothesise that a possible function for 17p-HSD 2 in the prostate is to 
protect the tissue from excessive androgen stimulation (Puranen et al. 1999).
A level of complexity is however added with the knowledge that in the 
secretory phase, serum progesterone levels predominate and there are known 
progesterone-regulated events important for secretory differentiation. Therefore, it 
may in fact be that the presence of 3p-HSD (catalysing pregnenolone to 
progesterone), 17p-HSD2 (catalysing 20a-dihydroprogesterone to progesterone) and 
17P-HSD5 (catalysing progesterone to 20a-dihydroprogesterone) are more important 
in balancing progesterone levels in the secretory glandular epithelium. However, 
neither androgens nor progesterone have significant levels of genomic receptors in 
the secretory phase glandular epithelium at the time 3(3-HSD, 17|3-HSD2, and 17(3- 
HSD5 are expressed. The action of the ligands upon genomic sex steroid receptors 
would therefore need to be via a paracrine mechanism as AR and PR are both present 
in the secretory phase stromal cells. To further evaluate the likely ligands present to 
exert an influence upon the endocrine environment we also analysed the endometrial 
samples for the temporal expression of 5a-reductase types 1 and 2.
5a-reductase type 1 is a catabolic enzyme that favours progesterone as a 
substrate (Andersson et al. 1990) and 5a-reductase type 2 is an anabolic enzyme that 
favours dihydrotestosterone production from testosterone (Normington et al. 1992). 
Ito et al. have reported the expression of 5a-reductase types 1 and 2 in glandular 
epithelium of both the proliferative and secretory phases of the menstrual cycle. They 
do however suggest that expression is weak at all phases. Their study also examined 
the expression of 5a-reductase types 1 and 2 in endometrial carcinoma, confirming 
its expression at the protein and mRNA level. They did not however examine 
expression of mRNA from the normal menstrual cycle. In our study we employed 
real time RT-PCR using Taqman probes to identify temporal expression of 5a- 
reductase types 1 and 2 during the menstrual cycle. We determined that 5a-reductase 
type 1 was expressed maximally in the middle of the cycle whereas maximal
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expression of 5a-reductase type 2 was in the peri-menstrual phase. O f note, the 
publication by Ito et al. only included 3 patients in each of the early, mid and late 
proliferative or secretory phases. Their numbers may have been too small to show 
significant differences in expression between the stages of the cycle. It should also be 
noted that the positive controls, liver and prostate, employed in the study by Ito et al. 
express both 5a-reductase types 1 and 2 and are therefore inadequate to demonstrate 
specificity of the antibodies. However, Ito et al. do show expression of both 
reductases in secretory glandular epithelium. This finding of 5a-reductase expression 
in glandular epithelium suggests that the secretory glandular epithelium has the 
ability to function as an intracrine unit controlling ligand availability for paracrine 
activation of the endometrial stromal cells.
As secretory glandular epithelium is now known to express mRNA and 
protein for 3p-HSD, 17p-HSD2, 17p-HSD5, and 5a-reductase types 1 and 2 it has 
the potential to utilise the relatively abundant levels of DHEA that is produced by the 
adrenal glands and circulates at far higher concentrations than semm oestradiol or 
testosterone.
Is the puipose of this intracrine unit to produce active androgens that will 
affect endometrial function to play a role in successful implantation or partake in the 
onset of menstruation? Is the purpose of this enzyme complex to balance 
progesterone expression to allow successful implantation or initiate menstruation 
should implantation fail to occur?
As the AR is expressed in stromal cells any action of androgens produced by 
the glandular epithelium are likely to be mediated in a paracrine manner. Androgens 
have been shown during in vitro and in vivo experiments to have a direct effect upon 
endometrial stromal cells, hi vitro experiments with androgens have shown that they 
can induce prolactin secretion from endometrial stromal cells in culture (Narukawa et 
al. 1994). Furthermore, elevated serum androgens are a principal biochemical feature 
of Polycystic Ovarian Syndrome (PCOS). Data have been published demonstrating 
an association between PCOS and altered expression of factors important for 
maintaining a receptive endometrial environment for implantation.
Apparao et al. demonstrated that PCOS patients down regulate alpha (v) 
betaS integrin (Apparao et al. 2002), a marker that if down regulated suggests 
reduced endometrial receptivity (Lessey et al. 1992). In vivo experiments where
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uterine flushings were obtained from PCOS patients with elevated serum androgens 
levels exhibited reduced levels of glycodelin-A, another factor thought to be 
important for the establislunent of successful conceptus implantation (Okon et al. 
1998; Tuckerman et al. 2000). Furthennore, progesterone concentrations appear 
umelated to glycodelin-A levels (Westergaard et al. 1998).
In vitro and in vivo data are also available to illustrate the decreased 
expression of a further factor believed to be important for endometrial receptivity 
HOXA-10 (Cermik et al. 2003). Testosterone has been reported as the only sex 
steroid that diminished uterine expression of HOXA-10. HOXA-10 expression was 
repressed by in vitro testosterone treatment, an effect that was blocked by flutamide 
(an androgen receptor antagonist), and in PCOS patients the endometrium of the mid 
secretory phase expressed significantly less HOXA-10 mRNA compared to fertile 
controls (Cermik et al. 2003).
Androgens therefore appear to play a role in the control of factors important 
for the formation of a receptive endometrium that will allow successful conceptus 
implantation. While serum androgen levels show little variation thi'ough the 
menstrual cycle the presence of an intracrine unit within the glandular epithelium 
provides a means for local production of androgens that can then be involved in the 
paracrine control of factors such as prolactin, glycodelin-A, and HOXA-10. 
Progesterone is however also known to play a key role in the differentiation of the 
secretory phase endometrium. It may prove to be that the expression of the enzymes 
in this intracrine unit serves to provide regulation of ligand for both the AR and PR.
In Chapter 5 the regulation of metabolising enzymes and AR in endometrium 
exposed to intra-uterine levonorgestrel were explored to provide insight into their 
regulation. Additionally this provided the opportunity to evaluate the role of high 
dose local levonorgestrel, released via the LNG-IUS, upon the significant clinical 
problem associated with LNG-IUS usage, breakthrough bleeding (BTB). We have 
already shown that AR is down regulated with LNG lUS treatment and 17(3-HSD 2 
is up-regulated. These findings generated the hypothesis that disruption of oestradiol 
to 0 estrone ratios in endometrium exposed to intra-uterine levonorgestrel may 
contribute to BTB. In this Chapter we further assessed the local intracrine 
environment in relation to the metabolising enzymes 17(3-HSD 5, 3(3-HSD types 1 
and 2, and 5a-reductase types 1 and 2.
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The only significant alterations in enzyme mRNA expression following 
endometrial exposure to levonorgestrel were the increased expression of 3p-HSD and 
the reduced expression of 5a-reductase2. Type 1 and type 2 3p-HSD show an up- 
regulation in mRNA expression after 3 months treatment with the LNG-IUS. 
Interestingly from then on, at the 6 month and the greater than 12 month follow up 
time points, Sp-HSD type 1 mRNA levels are not significantly different fiom the 
peri-menstrual phase of the cycle levels while 3p-HSD type 2 continues to be 
expressed at a higher level when compared to all stages of the cycle at all time 
points. 5a-reductase type 2 mRNA was significantly lower than the mid and late 
secretory phases in addition to the early proliferative phase.
None of the other metabolising enzymes were expressed at levels that were 
significantly different from the nonnal menstrual cycle. The differential expression 
in the 3P-HSD subtypes perhaps suggests that the objective of designing two Taqman 
probes that would differentiate between the types of 3p-HSD was achieved. This 
would therefore also suggest that both subtypes are expressed at significantly 
elevated levels in the peri-menstrual phase of the cycle. In any event, the levels 
detected by both probes were elevated at the time point associated with the greatest 
incidence of breakthrough bleeding. This would add to the evidence that endometrial 
3p-HSD may be regulated by progesterone to some degi'ee in endometrium. The 
increased levels of 3p-HSD would suggest a tendency towards production of 
progesterone or androstenedione. There are no reports of aromatase activity or 
protein expression in levonorgestrel exposed endometrium and given the lack of 
expression of aromatase in normal endometrium, it would seem unlikely that 
androstenedione is converted to oestrone in levonorgestrel-treated endometrium. 
There are studies suggesting that progesterone and medroxyprogesterone acetate can 
stimulate aromatase activity in endometrial stromal cell cultures but no in vivo data 
exists (Tseng et al. 1986; Huang et al. 1989). Should aromatase be expressed in 
levonorgestrel-treated endometrium this may contribute to the hypothesis generated 
fi'om the finding in the previous Chapter that increased expression of 17p-HSD2 
would favour higher intracellular levels of oestrone to oestradiol. Additionally the 
reduced expression of 5a-reductase type 2 would suggest that any precursors would 
not be likely to be converted to dihydrotestosterone, favouring the formation of 
oestrogens over androgens. These hypotheses would however require further
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substantiation initially with the demonstration of aromatase in endometrium exposed 
to intra-uterine levonorgestrel, and subsequent clarification of 5a-reductase protein 
expression in nonnal endometrium and endometrium exposed to intra-uterine 
levonorgestrel.
In summary, the secretory phase endometrium exhibits steroidogenic 
potential that is greater than the proliferative phase. More specifically, it would 
appear that the secretory phase glandular epithelium represents an ‘intracrine unit’ 
where the expression of key steroidogenic enzymes may play a role in the production 
of active progesterone or androgens from adrenal precursors. Published data do 
suggest that androgen production by secretory phase endometrium is significant 
(Rose et al. 1978; Hausknecht et al. 1982; Labrie et al. 1997). While the precise role 
of androgen production is unlmown, in vitro data suggest that androgens play a role 
in the expression of factors important for the provision of a receptive endometrium 
that will provide a platform for successful implantation. Study of endometrial 
samples from women with the LNG-IUS revealed significant changes in the 
expression of 3(3-HSD and 5a-reductase type 2. At present, the extrapolation of these 
data to provide an understanding as to its relevance for BTB will require further 
study.
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Chapter 7
General Discussion
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7.1 General Discussion
To addresses the hypotheses in this study, it was necessary to provide further 
clarification with respect to the expression of the androgen receptor and sex steroid 
metabolising enzymes in human endometrium. The findings of this study provide 
further clarity in this under researched area and are an important addition to the 
published literature.
Endometrial tissues from patients with regular menstrual cycles were studied 
to determine the spatial and temporal expression of Androgen Receptor (AR) in 
endometrium. Using a monoclonal antibody and objective image analysis, AR was 
localised to endometrial stromal cells with minimal glandular immunoreactivity. A 
decrease in expression of AR was noted in the late secretory phase. This localisation 
and expression pattern is consistent with the localisation of AR mRNA using in-situ 
hybridisation (ISH). Furthennore, temporal analysis of endometrial tissue utilising 
quantitative real time RT-PCR (Q-RT-PCR) confmned a down regulation of AR 
mRNA in the secretory phase.
It was also important to identify the spatial and temporal expression of sex 
steroid metabolising enzymes in endometrium. They will determine ligand 
availability for steroid receptor binding and the net steroid effect on endometrial 
tissue according to their pattern of expression. Immunohistochemical techniques and 
Q-RT-PCR were available to study 17(3-hydroxysteroid dehydrogenase 2 (17(3-HSD 
2). 17P-HSD 2 was localised to secretory glandular epithelium with maximal 
expression in the mid secretory phase. 17P-HSD 2 mRNA revealed a parallel 
temporal expression to the 17P-HSD 2 protein in keeping with published literature. 
Q-RT-PCR also revealed significantly higher 17P-HSD 5 mRNA in mid secretory 
phase endometrium
Additional sex steroid metabolising enzymes were also analysed using Q-RT- 
PCR. No methods for detecting protein from this group of enzymes were available at 
the time of this study. Temporal mRNA analysis demonstrated a significant peri- 
menstrual increase in the expression of both 3p-HSD enzymes and 5aR  2. 5aR  1 
was significantly increased in the late proliferative phase of the cycle. While 
evidence of protein expression was not directly available from this study, published
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data exists supporting the expression of Sp-HSD, 17P-HSD2, 17p-HSD5, and 5a- 
reductase types 1 and 2 in secretory glandular epithelium. This study describes this 
constellation of enzymes as an “intracrine unit”. The expression of these enzymes as 
an intracrine unit in secretory endometrium provides the endometrium with 
autonomous control over the provision of sex steroid ligands.
Having established the pattern of expression of AR and the sex steroid 
metabolising enzymes it remained to establish their role in endometrial physiology 
and pathology. Failure of implantation and recurrent miscarriage are forms of 
endometrial dysfunction that have been noted in conditions that are associated with 
higher serum androgen levels. Where such endometrial dysfunction has been noted, 
genes associated with adverse reproductive outcome have been identified in 
endometrium and have been shown to be androgen regulated. It would therefore 
appear that where the ratio of sex steroids lead to a relative androgen excess, the 
endometrium is adversely affected. The role of locally expressed enzymes in women 
with a normal reproductive history may therefore be, as originally hypothesised, to 
provide a stable ratio of sex steroid ligands in endometrium.
Mid and late proliferative phase endometrium show little temporal variation 
in the expression of enzymes, suggesting there is a relative parity within enzyme 
expression. The secretory phase however exhibits temporal variation in the 
expression of sex steroid metabolising enzymes. High levels of serum oestradiol are 
responsible for the proliferative phase changes but in the secretory phase oestradiol 
does not exert such an influence. Data from this study and others suggests that 
progesterone receptor (PR) has a ‘braking’ effect on oestradiol action in 
endometrium preventing continued endometrial proliferation leading to endometrial 
hyperplasia. In the secretory phase, progesterone action is important for endometrial 
differentiation. Co-incident with the secretory phase elevation in serum progesterone 
levels there is a significant increase in the expression of 17(3-HSD 2. The local 
expression of this enzyme converts local oestradiol and testosterone to the less 
biologically active oestrone and androstenedione respectively while at the same time 
providing a route o f conversion for the less active 20a-dihydroprogesterone to active 
progesterone. At this point in the secretory phase, the endocrine ratio favours 
relatively higher intracellular progesterone and lower intracellular oestradiol and 
testosterone levels. This effectively maximises the opportunity for progesterone to
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play its role in secretory endometrial differentiation. This would also support the data 
available that suggests elevated androgen levels are associated with failure of 
implantation and recuiTent miscarriage as the presence of 17(3-HSD 2 favours a 
minimisation of the effect of androgens upon endometrial function at this time in the 
cycle.
To evaluate the role of progesterone in the regulation of endometrial AR, 
endometrium treated with the anti-progestogen mifepristone (RU486) was also 
studied. This revealed an up regulation of AR in the glandular and surface epithelial 
compartments of mifepristone treated secretory endometrium with additional stromal 
enhancement. This is in keeping with previous data showing oestrogen receptor (ER) 
and PR up regulation in the same tissue. As PR antagonism up regulates AR 
expression it may be that down regulation of AR in the late secretory phase is 
mediated by the elevated serum progesterone levels in the secretory phase. This 
suggests that AR may in part be regulated by progesterone but data regarding AR 
regulation is complex and as yet no firm conclusions can be reached.
Reduced late secretory phase AR expression may, however, be a reflection of 
the dilution in the stromal cell population secondary to the influx of uterine NK 
(uNK) cells in the late secretory phase. Further studies are required to assess the 
localisation of AR in uNIC cells but it is known that uNK do not express ERa or PR.
The study of mifepristone treated endometrium also presented an opportunity 
to explain the mechanism of endometrial atrophy associated with mifepristone 
treatment. Elevated endometrial AR will provide further AR sites for the binding of 
androgenic ligands that would lead to an enliancement of the effect of androgens. As 
detailed in chapter 4.4, androgenic agents have been shown to induce endometrial 
atrophy and androgens have also been shown to have an anti-proliferative effect on 
the endometrium. Therefore, in mifepristone treated endometrium a direct effect of 
enhanced stromal AR activation may be an anti-proliferative effect, inducing 
endometrial atrophy.
Androgenic activity in secretory endometrium is also noted. Temporal 
variations in the perimenstmal late secretory and early proliferative phases reveal an 
up regulation of 3p-HSD and 5aR 2. With both enzymes being expressed at the 
same time and both producing active androgens, this would provide a means for the 
local production of dihydrotestosterone (DHT), a more biologically active androgen
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than testosterone. The proposed mechanism for this would be 
Dehydroepiandrosterone (DHEA) conversion to androstenediol by the action of 17(3- 
HSD5,up regulated in the mid secretory phase, followed by androstenediol 
conversion to testosterone by 3(3-HSD and finally testosterone conversion to DHT 
by 5aR 2. Secretory phase endometrium has previously been shown to possess 
androgen steroidogenic activity (Hausknecht et al. 1982). If such an intracrine 
mechanism for DHT production existed this may be another mechanism to account 
for the late secretory phase AR down regulation. That is to say, if  AR regulation is 
similar to that of the other sex steroids and it is down regulated by its own ligand 
then DHT may be responsible for such down regulation. At present, such statements 
require substantiation with further study and the physiological role of AR and the sex 
steroid metabolising enzymes remains to be elucidated.
The additional patient groups studied were women using the levonorgestrel 
releasing intra-uterine system (LNG-IUS). Patients using such methods of 
contraception may suffer problematic breaktlnough bleeding necessitating 
discontinuation of this treatment. In endometrium exposed to high intra-uterine 
concentrations of levonorgestrel via the LNG-IUS, AR was significantly down 
regulated whereas 17P-PISD 2 was elevated. Since 17(3-HSD2 converts oestradiol to 
the less potent oestrogen, oestrone, the endometrium would have a relatively low 
intracellular concentration of oestradiol, hi such a scenario, oestradiol dependent 
products of the glands, that may have paracrine actions tlu'oughout the endometrium, 
would thus be suppressed or perturbed at this time. Oestrogen deficiency may 
therefore be implicated in the mechanism of breaktln ough bleeding.
A variation in the expression of some of the other sex steroid metabolising 
enzymes is also noted, increased expression of 3P-HSD and reduced expression of 
5aR 2. Neither would be expected to impact upon the intracellular oestradiol 
concentration. However, if as hypothesised, the ratio of sex steroids is important in 
maintaining an endometrial equilibrium the altered expression in both would serve to 
further the imbalance in this ratio with an androgen excess. The mechanism whereby 
such alterations induce breaktlnough bleeding will require further study.
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Ill conclusion, clarification of endometrial AR expression has been an 
addition to the published literature. Important data regarding the expression of sex 
steroid metabolising enzymes in human endometrium have also been detailed. The 
findings of this study will provide a basis to take fomard further research to establish 
what role AR and the androgen steroidogenic activity of secretory endometrium 
plays in endometrial physiology. Novel data are also presented for the temporal 
variation in expression of AR and sex steroid metabolising enzymes in endometrium 
exposed to high dose intra-uterine levonorgestrel. These data also provide an 
important platform to explore further mechanisms and treatments for the clinical 
problem of breaktlirough bleeding.
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7.2 Suggestions for Future Study
Further research is required with respect to the expression and regulation o f androgen 
receptor (AR) and sex steroid metabolising enzymes in human endometrial tissues. 
The purpose of future studies would initially be to provide coiToboration of the data 
presented in this thesis. With coiToboration, future study designs could be taken 
forward to analyse the regulation of AR and sex steroid metabolising enzymes in 
normal human endometrium. However, in addition to examining such factors in 
normal endometrium it will be important to study their expression and regulation in 
dysfunctional endometrium. Dysfunctional endometrium should include 
endometrium from patients with endometriosis, polycystic ovarian disease, recurrent 
miscaiTiage, endometrial hyperplasia and endometrial carcinoma.
Initially I would suggest descriptive studies to provide corroborative data for 
the expression of the mRNA of sex steroid metabolising enzymes using molecular 
techniques such as northern blotting or in-situ hybridisation of normal endometrium. 
There are published data available regarding the expression of several of the sex 
steroid metabolising enzyme proteins in endometrium. However, there is still a need 
for further studies to clarify the expression of other key sex steroid metabolising 
enzymes in normal endometrium at the protein level, as thus far only mRNA data are 
available. Such studies have been hampered by the lack of available antibodies. 
Locally available techniques to study 5-alpha reductase (5aR) with an enzyme 
activity assay and 3-beta hydroxy steroid dehydrogenase (3p-HSD)
immunolocalisation were available. We did not have the required volume of tissue 
that was required for the 5aR assay and there was insufficient time within this study 
to perform the required immunolocalisation experiments for 3(3-HSD. These are 
initial experiments that may be perfoiined to establish further data regarding protein 
expression in endometrium.
Regulation of AR expression in endometrium also requires further study to 
provide clarity. Initially, it will need to be determined if the significant reduction in 
late secretory AR is a true down regulation or a dilution effect of secretory phase 
uterine NK (uNK) cell influx. I would suggest that AR and CD56 co-localisation 
experiments are performed to detennine if the uNK cells expressed AR because
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should they not express AR this would remain a possible explanation for the late 
secretory reduction.
To determine the regulation of AR and sex steroid metabolising enzymes in 
endometrium I feel a combined in-vitro/in-vivo approach would provide important 
data. In-vitro endometrial explant culture would allow treatment of proliferative and 
secretory endometrium with varying doses of sex steroids to assess the dose response 
of AR and enzyme mRNA in the explant cultures. This would provide some insight 
into the regulation of these factors. To assess the complex endocrine enviromnent of 
the endometrium during the menstrual cycle in-vivo analysis would provide the 
closest approximation to the mechanism of regulation.
Recent data by Slayden et al. has shown that AR blockade with Flutamide, a 
pharmacological agent that is metabolised to the AR inliibitor hydroxyflutamide, will 
prevent the atrophic endometrial changes associated with antiprogestin treatment in 
rhesus macaques (Slayden et al. 2003). I would propose the recruitment of patients 
with regular menstrual cycles to undergo timed biopsies in the proliferative phase, 
early secretory, mid secretory and/or late secretory phase of a pre-treatment and 
treatment cycle, where the treatment is daily flutamide. Samples would then be 
analysed with optimised immunohistochemical protocols and Q-RT-PCR. This 
would provide data regarding the effect of AR inhibition on AR, ER, PR, and 
enzyme expression at the protein and mRNA levels.
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Appendix I: Source of General Materials
Tissue Collection Supplier
Neutral Buffered Formalin (NBF) See Appendix: Recipes
Paraformaldehyde (PFA) See Appendix: Recipes
Pipelle Suction Curette Laboratoire CCD, Paris, France.
TP 1050 Tissue Processor Leica Corp., UK.
RNA Extraction Supplier
Trizol Reagent Invitrogen Life Tech, Paisley, UK.
Hand Held Homogeniser 
(PolytronPT 1200B) Kinematica, Switzerland.
Cholorofomi Sigma, Poole, Dorset, UK,
Isoprop ano loi Sigma, Poole, Dorset, UK.
Ethanol (Molecular Biology Grade) BDH Laboratory Supplies, Poole, UK.
RNA Storage Solution Anibion Inc, Austin, Texas, USA.
Phase Lock Gel Tubes Eppendorf, Hamburg, Germany.
Real Time Q-RT-PCR Supplier
DNAse Amplification Kit Invitrogen Life Tech, Paisley, UK.
Taqman Reverse Transcription Reagents AB Applied Biosystems, Cheshire, UK.
Taqman MasterMix Stratagene, Amsterdam, Netherlands.
Ribosomal RNA Control Reagents AB Applied Biosystems, Cheshire, UK.,
Primers / Probe Sets for Sequences Biosource, Nivelles, Belgium
ABI Prism 7700 AB Applied Biosystems
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Iinmunohistochemistry Supplier
Histoclear Nat. Diagnostics, Atlanta, Georgia, USA.
Phosphate Buffered Saline (PBS) See Appendix 2
PBS + Tween 20 See Appendix 2
Tris Buffered Saline (TBS) See Appendix 2
TBS + Tween 20 See Appendix 2
Hydrogen Peroxide Solution 30% BDH Laboratory Supplies, Poole, UK.
Sodium Citrate See Appendix 2
Pressure Cooker Clipso, Tefal, Nottingham, UK.
Avidin/Biotin Blocking Kit Vector Laboratories, Peterborough, UK.
Non hnmune Horse Serum (Vectastain) Vector Laboratories, Peterborough, UK.
Bovine Serum Albumin Sigma, Poole, Dorset, UK.
Biotinylated Horse anti-Mouse Antibody Vector Laboratories, Peterborough, UK.
Avidin Biotin Peroxidase Complex Vector Laboratories, Peterborough, UK.
3,3’ Diaminobenzidine Dako, Cambridge, UK.
Harris Haematoxylin Pioneer Research Chemicals, Colchester, UK.
Xylene BDH Laboratory Supplies, Poole, UK.
Pertex Cellpath Pic, Hemel Hempsted, UK.
Image Aialysis System Improvision inc., Lexington, MA, USA.
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Appendix II: Recipes for Solutions
4% Paraformaldehyde(PFA)
Weight/Volume Chemical Name Supplier
4g Parafomialdehyde Sigma
100ml PBS (see below) Sigma
Heat to 60°C
Store at 4^C and use within 7 days
4% Neutral Buffered Formalin(NBF)
Weight/Volume Chemical Name Supplier
6.5g Na2HP04 BDH
4.5g Na2HPO4.2H20 BDH
100ml 40% formaldehyde BDH
900ml Distilled Water
O.OIM Phosphate Buffered Saline (PBS) pH 7.4
Weight/Volume Chemical Name Supplier
5 Tablets PBS Sigma
1000ml Distilled Water
O.OIM Phosphate Buffered Saline +Tween (PBST) pH 7.4
Weight/Volume Chemical Name Supplier
5 Tablets PBS Sigma
1000ml Distilled Water
8g NaCl BDH
lOOpl Tween 20 Sigma
260
0.5M Tris Buffered Saline (TBS)
Weight/Volume Chemical Name Supplier
60.55g Trizma Base Sigma
700ml Distilled Water
pH to 7.4 and make up to 1000ml with Distilled Water
Dilute 1:10 for working 0.05 Solution and add 8.5g NaCl/litre
0.5M Tris Buffered Saline+ Tween 20(TBST)
Weight/Volume Chemical Name Supplier
60.55g Trizma Base Sigma
700ml Distilled Water
pH to 7.4 and make up to 1000ml with Distilled Water
Dilute 1:10 for working 0.05M Solution and add 8.5g NaCl/litre and
add 100 pl/L Tween 20
O.IM Sodium Citrate
Weight/Volume Chemical Name Supplier
29.41g Tri-Sodium Citrate BDH
o.ig Sodium Azide Sigma
700ml Distilled Water
pH to 6.0 and make up to 1000ml with Distilled Water
Dilute 1:10 for working O.OIM Solution
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Appendix III: Conference Proceedings
1. Burton KA, Hiliier SG, Habib FK, Mason JI, Critchley HOD. Spatial and 
temporal distribution of the androgen receptor in human endometrium. “Fertility 
2000” .Toint Meeting of the British Fertility Society, Society for the Study of 
Fertility; and British Andrology Society. August 2000. Edinburgh. Oral 
Presentation. Journal of Reproduction and Fertility: Abstract series 25: Abstract 
no 113.
2. Burton KA, Hiliier SG, Habib FK, Mason JI, Critchley HOD. Localisation of 17 
beta-hydroxysteroid dehydrogenase type II (17beta-HSD II) in human
endometrium across the menstmal cycle. Oral Presentation, Munro-Kerr 
Society winter meeting. January 2001. Glasgow Royal Infirmary.
1*^  Prize for Best Presentation.
3. Burton KA, Hiliier SG, Habib FK, Mason JI, Critchley HOD. Localisation of 17 
beta-hydroxysteroid dehydrogenase type II (17beta-HSD II) in human
endometrium across the menstrual cycle. Oral Presentation. British Fertility 
Society. April 2001. Belfast. Human Fertility
4. Burton KA, Hiliier SG, Habib FK, Mason JI, Critchley HOD. Modulation of 
Androgen Receptor and 17 beta-hydroxysteroid dehydrogenase 2 in endometrium 
treated with the Levonorgestrel releasing intrauterine system. Poster
Presentation. Blair Bell Society Winter Meeting. London, December 2001
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